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Abstract 
Advances in the treatment of ovarian cancer have had a limited impact on prognosis over 
recent decades. Alternatives to the traditional surgical and chemotherapeutic approach 
are being sought. Many novel therapies relate to a greater understanding of the molecular 
changes which occur during carcinogenesis and the development of targeted therapies to 
exploit these abnormalities. The aim of this thesis was to investigate the prognostic 
significance of markers relating to tumour immunology, angiogenesis and apoptosis, 
through the use of Tissue Microarray Technology. 
339 cases of ovarian cancers diagnosed between 1982 and 1997 were assessed. 
Tumours were analysed immunohistochemically for expression of components of the IFNJ 
(IFNGR1, STAT1, p27, caspase 1), TRAIL (DR4 and DR5) and angiogenic (VEGF) 
pathways. 
Loss of expression of IFNGR1 was an independent predictor of poor prognosis, although 
STAT 1 was not. High levels of cytoplasmic and nuclear p27 expression were associated 
with a reduced survival; cytoplasmic was independently prognostic. Tumours with reduced 
levels of caspase 1 had improved survival. These results suggest that only patients 
expressing IFNGR1 may benefit from IFNJ therapy and provides evidence of 
immunoediting in ovarian cancer. 
DR4 and DR5 did not predict prognosis suggesting that the TRAIL pathway may not be 
significant in ovarian cancer apoptosis with implications for TRAIL-related therapy. 
High levels of VEGF occurred infrequently, being an independent marker of poor 
prognosis. This may identify a group of patients who may preferentially benefit from anti-
angiogenic therapy. 
The thesis illustrates that ovarian cancers are heterogeneous and variations in expression 
of protein markers can predict tumour behaviour and stratify for therapy. Future targeted 
therapies may be selected on the basis of an immunohistochemical profile which predicts 
the pathways that are still functioning. New therapies as they arise should be trialed and 
targeted to tumours expressing the appropriate molecular markers. 
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1 Introduction 
1.1 Ovarian Carcinoma 
1.1.1 Epidemiology 
 
Ovarian cancer is an uncommon disease which, unfortunately, is fatal in the majority of 
cases. The lifetime risk of ovarian cancer is approximately 2% and it is the fourth most 
common cause of cancer-related death in women within the UK, although its incidence 
worldwide is slightly less [1]. In 2005 almost 7000 cases of ovarian cancer were 
diagnosed, and until recently it was the most common gynaecological malignancy. Current 
data illustrates that it is now the second commonest after uterine cancer. The incidence of 
ovarian cancer has remained constant, but there has been an exponential rise in the rates 
of endometrial cancer [2]. The incidence of ovarian cancer appears to be slowly 
increasing with rates of 15 and 17 per 100,000 women in 1975 and 2005 respectively, 
which may simply reflect the proportionally older population in the UK compared with 30 
years ago [2]. Ovarian cancer is predominately a disease of older, postmenopausal 
women. The incidence increases rapidly after the age of 50, with over 85% of ovarian 
cancers occurring above that age [2]. Less than 1% of epithelial ovarian cancers occur 
below the age of 20, with two thirds of the ovarian malignancies in these young patients 
being germ cell tumours [3]. Since germ cell tumours represent less than 5% of ovarian 
cancers and tend to present at an earlier stage, they make minimal impact on incidence 
and mortality rates [4].  
The impact of age in ovarian cancer is not limited to incidence alone, increasing age is 
coupled to decreasing performance status which may limit the extent to which the most 
aggressive treatments can be instituted or sustained. Hence, increasing age and reduced 
performance status have been linked with poor prognosis [5], which is independent of 
other prognostic factors [6]. 
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Worldwide there are almost 200,000 new cases of ovarian cancer annually. Incidence 
rates vary considerably with highest rates in Northern Europe and the USA and lowest 
rates in Africa and Asia. This may reflect the protective effect of higher parity in these 
areas [7]. There is conflicting data from migrant studies pertaining to the impact on risk of 
women moving from areas of contrasting incidence of ovarian cancer. A study of 
immigrants to Israel, from countries with a higher incidence of ovarian cancer, 
demonstrated that the risks were not significantly different to the background population 
[8], although other authors did not find this risk adjustment to occur [9]. These conflicting 
results illustrate the complexity of risk, which includes interactions between racial, cultural 
and socio-economic factors. The Surveillance, Epidemiology and End Results (SEER) 
programme registration data for cases diagnosed in the US over a 7 year period recorded 
an incidence of 17.2 and 11.8 per 100,000 women in Caucasian and non-Caucasian 
women respectively [10]. 
1.1.2 The Hallmarks of Cancer 
 
Dysregulation of a number of pathways, the hallmarks of cancer, are necessary for 
oncogenesis. These include self sufficient growth signalling, insensitivity to inhibitory 
growth signals, evasion of apoptosis, limitless replication potential, sustained 
angiogenesis, tissue invasion and metastasis of tumour (Figure 1.1) [11]. 
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Figure 1.1 Acquired capabilities of cancer. Adapted from Hanahan et al. [11]. 
1.1.2.1  Self sufficiency in growth factor signals 
 
One of the most obvious properties of cancer cells is the capacity for uncontrolled growth. 
Tumour cells¶ independence from normal growth factor (GF) control is in part due to the 
generation of its own GFs. This is in contrast to normal cells which only respond to 
exogenous GFs [11]. There are three molecular strategies by which tumours achieve 
growth autonomy, including alteration in extra cellular growth signals, receptor 
transducers of these signals and alteration of intracellular circuits which translate these 
signals into actions. Two illustrations of tumours secreting and responding to their own 
GFs in a positive feedback loop involve platelet derived growth factor (PDGF) and tumour 
growth factor D [11].  Receptor over-expression may enable tumour cells to be hyper-
responsive to ambient levels of GF. For example, epidermal growth factor 1 (EGFR1) is 
over-expressed in ovarian cancer, with a subsequent negative impact on prognosis [12]. 
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Downstream cytoplasmic circuitry can be altered, resulting in abnormally prolonged 
stimulation of cells following receptor signalling which is often related to the ras pathway. 
The ras pathway involves numerous proteins involved with cell proliferation [11]. 
1.1.2.2  Insensitivity to anti-growth signals 
 
Within normal tissue, multiple anti-proliferative signals operate to maintain cellular 
quiescence. The retinoblastoma protein (pRb) acts as a central coordinator of anti-
proliferative signals. pRb blocks proliferation by sequestering and inactivating transcription 
factors from the E2F group of genes which are involved in cell cycle regulation. These 
control the expression of genes essential for progression from G1 into S phase [13]. 
Disruption of the pRb pathway liberates E2Fs, thus allowing cellular proliferation and 
rendering cells unresponsive to anti-proliferative signals. TGFE represents a widely 
studied anti-proliferative factor, which prevents phosphorylation and subsequent 
inactivation of pRb. TGFE blocks phosphorylation of pRb by stimulation of p15INK4B and 
p21, which block cyclin:CDK complexes which are responsible for pRb phosphorylation 
[14]. Loss of TGFE responsiveness has been demonstrated in tumours via down-
regulation of TGFE receptors [11]. 
1.1.2.3 Evading apoptosis 
 
Apoptotic machinery is present in all cells and is divided into sensors and effectors. The 
sensors include cell surface receptors that bind to survival (e.g. IGF-1, IGF-2 and IL-3) 
and death factors (Fas ligand, TNFD and TRAIL) [11]. Many apoptotic signals converge on 
the mitochondria which produces cytochrome c, a potent catalyst of apoptosis. The 
release of cytochrome c is controlled through the Bcl-2 family of proteins which have 
either pro-apoptotic (Bax) or anti-apoptotic effects (Bcl-2 and Bcl-XL) [11]. The ultimate 
effectors of apoptosis are the caspases which can be stimulated through cytochrome c or 
death receptors. 
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Tumour cells all develop strategies to avoid apoptosis. One of the most common involves 
mutations and ultimately inactivation of p53, which is seen in over 50% of human cancers. 
Physiologically, p53 is a potent coordinator of apoptosis resultant from DNA damage, 
hypoxia and oncogenes hyper-expression [15]. Defects in the TRAIL pathway, the major 
p53 independent pathway for apoptosis, can also occur with disruptions to the TRAIL 
receptor and downstream signalling pathways [16]. In addition, over-activity of anti-
apoptotic pathways can inhibit cell death. For example, the PI3kinase-AKT/PKB pathway 
can be hyper-stimulated through extra-cellular factors such as IGF1/2 and IL-3, 
intracellular factors, for example ras and via loss of pTEN (a tumour suppressor gene) 
[11]. A mechanism that inhibits cell death through fas, involving upregulation of decoy 
death receptors, has been demonstrated in tumour cells [17]. 
1.1.2.4 Limitless replicative potential 
 
Normal cells have a limited number of possible cell divisions before they enter a state of 
senescence. Tumour cells have been shown in vitro to be immortalised with limitless 
replicative potential. This is thought to be in part due to defects in the pRb and p53 tumour 
suppressor systems [18], although effects on telomere maintenance may play a more 
significant role. Telomeres represent the ends of chromosomes, they act as the counting 
device for cell division. Each cell division leads to progressive loss of base pairs from the 
telomere and this erosion eventually leads to loss of protection of the chromosomal DNA. 
This in turn leads to fusion of chromosomal ends producing severe karyotype 
abnormalities resulting in cell death [19]. Telomere maintenance is seen in most cancer 
cells, with the upregulation of telomerase enzymes which add base pairs to the telomere. 
This preservation of the telomere effectively inactivates the cells usual counting 
mechanism for cell division [20]. 
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1.1.2.5 Sustained angiogenesis 
 
7KHR[\JHQDQGQXWULHQWVVXSSOLHGE\D WLVVXH¶VYDVFXODWXUHDUHFUXFLDO IRU FHOO IXQFWLRQ
and survival, necessitating that all cells are within 100Pm of a blood capillary. The process 
by which new vessels form to ensure adequate blood supply to developing tissue, 
angiogenesis, is controlled by stimulatory signals such as vascular endothelial growth 
factor (VEGF) and fibroblast growth factors (FGF). 
The rapid growth of tumours requires a high level of angiogenesis. This has been 
demonstrated to be strongly associated with VEGF, since neutralising antibodies to VEGF 
inhibited tumour angiogenesis in mice models [21]. Tumours appear to activate the 
angiogenic switch through increased expression of VEGF and FGF with reduced 
expression of angiogenesis inhibitors such as thrombospondin-1 [22]. Different tumour 
types may use different strategies to activate the angiogenic switch, which makes the 
development of drugs to inhibit this process potentially challenging. 
1.1.2.6 Tissue invasion and metastasis 
 
The characteristic behaviour of tumour cells, which differs from normal cells, is the ability 
to invade tissue stroma and metastasise. Tumours utilise extra-cellular proteases and 
changes to the physical coupling of cells to achieve this.  
1.1.3 Aetiology 
 
The precise cause of epithelial ovarian cancer remains unclear; however, several factors 
are thought to play a role in its aetiology. 
1.1.3.1 Environmental Factors 
 
The fact that the incidence of ovarian cancer is highest in industrialised regions, such as 
Northern Europe and North America, points to an environmental link to the disease [7]. 
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The exception to this rule is Japan, which in spite of being heavily industrialised has a low 
incidence of ovarian cancer, approximately 3 per 100,000 women. However, a higher rate 
of ovarian cancer is observed in Japanese immigrants in the USA, this risk eventually 
increases to equal that of their white counterparts within 2-3 generations [23]. This 
suggests that the causative carcinogen is likely to be within the immediate local 
environment, such as food. 
Some have suggested that exposure to a chemical carcinogen might occur via 
transmission through the vagina, uterus and fallopian tubes to reach the ovaries. This 
potential route is feasible following studies by Venter et al using radio-nucleotides [24]. 
Whilst a variety of chemicals come into contact with the female genital tract, talc exposure 
is the most extensively studied. Some authors have described an increased risk with talc 
exposure, although they fail to produce a sound rationale for these findings [25]. In 
addition, other workers failed to find a similar association [26]. 
1.1.3.2 Dietary Factors 
 
One of the major dietary differences among people in industrialised compared with non-
industrialised countries is the high intake of meat and animal fat, which has been reported 
to be associated with an increase of ovarian cancer [27].  However, another study failed to 
show any significant effect of fat, protein, fibre or vitamins [28]. Cramer et al suggested 
that galactose may be associated with increased ovarian cancer risk, by inducing ovarian 
damage [29]. Others authors have failed to substantiate these conclusions, finding no 
increased risk with lactose, galactose or lactose intolerance [30]. Occasional reports have 
linked caffeine [31], alcohol [32] and tobacco [33] with an increased risk of ovarian cancer, 
but none have been confirmed by other investigators. 
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1.1.3.3 Reproductive factors 
 
Parity 
The protective effect of parity on ovarian cancer risk is well-documented. A European 
based study suggested a reduced risk in parous women compared with nulliparous, with a 
relative risk (RR) of 0.7. The relative risk was as low as 0.6 in grand multips [34]. A large 
study in the US estimated that the risk may be reduced by as much as 50% in parous 
women. This study also calculated that a 13-19% reduction in ovarian cancer risk 
occurred with each pregnancy [35]. 
Lactation 
A number of studies suggest a modest protective effect from breast feeding. Whittemore 
et al demonstrated a long term reduction of 19% in women who breast fed. This remained 
significant when controlling for the effects of parity [35]. An Italian study suggested the risk 
reduction may be as high as 50% in women who have breast fed for over 12 months [36].  
Infertility 
The effect of infertility on ovarian cancer incidence is a particularly complicated 
relationship to investigate. This is primarily due to a number of confounding factors known 
to exert their own effects on ovarian cancer risk. For example, high parity and prolonged 
use of the oral contractive pill (OCP) are both protective against ovarian cancer, although 
for obvious reasons tend to occur less frequently in women with infertility. In addition, the 
use of medication to treat infertility further clouds the picture. When one considers the 
ovulation and gonadotrophin hypotheses relating to ovarian cancer (discussed later), it is 
clear that ovulation-induction agents which increase levels of gonadotrophin and rates of 
ovulation may increase the risk of ovarian cancer. Therefore, it is not surprising that case 
control studies demonstrated increased rates of ovarian cancer in women with infertility 
[35]. This risk is seen to be especially high with prolonged, multiple fertility treatments [37]. 
In view of the confounding factors mentioned, no convincing data exists to suggest that 
infertility per se is an independent risk factor for ovarian cancer.  
 9 
1.1.3.4 Hormonal factors 
 
A few case control studies have postulated that a late menopause is associated with an 
increase risk of ovarian cancer [38]. However, this data was not supported by a large 
cohort study [39], or a meta-analysis of six similar case control studies [40]. 
Early meta-analysis studies presented contradictory findings with regard to the impact of 
hormone replacement therapy (HRT). Some suggested that risk was increased [41], whilst 
others argued to the contrary [42]. Data from a large prospective cohort study has 
provided more robust evidence, and suggests that a slight increase in the incidence of 
ovarian cancer is seen with HRT (RR 1.2). This risk was substantially greater if HRT was 
used for over 10 years (RR 2.2). The risk was thought to be lower if combined 
preparations with progesterone were used [43]. However, the results of such studies may 
be academic following the :RPHQ¶V+HDOWK,QLWLDWLYHWHI) study which concluded that a 
significant increase in the risk of breast cancer, pulmonary emboli, stroke and ischaemic 
heart disease existed with HRT. In the light of this report the use of HRT has reduced 
dramatically, especially long term use. Therefore, any potential effects of HRT on ovarian 
cancer incidence are likely to be minimal [44].  
A large number of studies have illustrated the protective effects of the OCP on ovarian 
cancer risk. In the Oxford Family Planning Association study, the use of the OCP was 
associated with a 60% reduction in risk [45]. There was a trend towards increased 
protection the longer the OCP was used, and this has been supported by findings from a 
similar study [46].  
1.1.3.5 Gynaecological Surgery 
 
Hysterectomy with ovarian preservation is associated with up to a 33% reduction in rates 
of ovarian cancer [35]. In addition, data suggests tubal ligation can produce similar 
protective effects with reduced incidence [47] and mortality [48] from ovarian cancer. 
The mechanism by which these surgeries reduce ovarian cancer risk is unclear. It has 
been suggested that this may reflect a degree of ovarian screening which occurs prior to 
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such operations. Others argue that tubal ligation and hysterectomy both prevent 
carcinogens such as talc from reaching the ovaries, although the potential impact of either 
of these mechanisms is unlikely to produce such large effects. Thirdly, it is possible that 
both procedures could affect ovarian function and ovulation through disruption of the 
ovarian blood supply. These theories remain to be substantiated. 
1.1.3.6 Genetic factors 
 
Between 5-10% of all ovarian cancer are thought to be hereditary; the result of mutations 
in a cancer predisposition gene. BRCA1 and BRCA2 gene mutations are the most 
commonly associated with familial ovarian and breast cancer, and are inherited in an 
autosomal dominant pattern. Mutations in the BRCA1 gene, located in chromosome 17, 
carry a 40-60% and 90% lifetime risk of ovarian and breast cancer respectively. In 
addition these women carry an increased risk of fallopian tube (RR 50-120) and primary 
peritoneal cancer (RR 50) [49]. BRCA2 mutations carry a lower risk of ovarian cancer in 
the order of 20-30% lifetime risk [50]. 
Ovarian cancer also forms part of the spectrum of cancers seen with hereditary 
nonpolyposis colorectal cancer syndrome (HNPCC). This is the result of mutation in the 
genes responsible for DNA mismatch repair and is expressed in an autosomal dominant 
pattern. Typically HNPCC is associated with early onset colorectal cancer, with the 
lifetime risk of ovarian cancer being approximately 12%. HNPCC is also associated with 
other extra-colonic cancers such as endometrial, upper gastrointestinal and renal [51]. 
Ovarian cancer is related to other familial cancer syndromes such as Peutz-Jegher and 
Multiple Endocrine Neoplasia type I [52]. These syndromes only account for those in 
which a genetic mutation has been identified; it is likely that there are others which remain 
to be discovered. 
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1.1.4 Mechanisms of ovarian carcinogenesis 
 
There are four theories of causation for ovarian cancer, which attempt to explain the risk 
factors discussed previously. 
1.1.4.1 Incessant Ovulation Hypothesis 
 
This hypothesis suggests that the process of ovulation damages the ovarian epithelium. 
This can lead to erroneous DNA repair, especially if there is a short interval between 
individual ovulations. The progressive damage to the DNA from inaccurate repair could 
lead to the development of cancer [53]. This hypothesis would explain the protective 
effects seen with the OCP and pregnancy which both inhibit ovulation. A study supporting 
this theory suggested that each year of ovulation equated to a 20% increase in lifetime 
risk of ovarian cancer in women under thirty [54]. The protective effects seen with the 
progesterone only pill which does not inhibit ovulation cannot be accounted for in this 
model [30]. 
1.1.4.2 Gonadotrophin hypothesis 
 
This hypothesis originates from both animal and epidemiological studies. Mice exposed to 
high levels of gonadotrophin are shown to have an increased risk of ovarian cancer [55]. 
Cramer et al suggest that the raised level of gonadotrophin does not cause ovarian cancer 
per se, but induces ovarian secretion of oestrogen which induces proliferation and 
transformation of ovarian epithelium. They suggest that this hypothesis would explain the 
reduced risk seen in parous women and those using the OCP, both of whom have low 
levels of gonadotrophin. In addition, it explains the increased incidence seen in 
postmenopausal women and those with Polycystic Ovarian Syndrome (PCOS), where 
gonadotrophin levels are significantly elevated [27]. 
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1.1.4.3 Androgen hypothesis 
 
Risch et al suggest that androgens may play a role in ovarian carcinogenesis, since the 
ovary is known to contain androgen receptors, and androgens have been shown to 
stimulate growth in ovarian cancer cell lines [56, 57]. Epidemiologically the theory is 
supported by the increased risk seen with PCOS when levels of androgens are increased 
[58]. In addition, the OCP is known to reduce androgen levels, which could potentially 
explain its protective effects [59]. 
1.1.4.4 Progesterone hypothesis 
 
Progesterone is an anti-mitotic, which has been shown to increase wild type p53 tumour 
suppressor gene and induce apoptosis in ovarian cancer cell lines [57]. The rate of 
ovarian cancer in hens has been reduced by administration of progesterone [60]. 
Epidemiological data supports a role for progesterone through the protective effects of 
pregnancy, OCP and the progesterone only pill, all of which increase circulating levels of 
progesterone [61]. 
1.1.5 Pathology 
1.1.5.1 Histological Types of Epithelial Ovarian Cancer 
 
Primary ovarian neoplasia can arise from a large variety of cell types and can behave in a 
benign, malignant or borderline (low malignant potential) manner. The diversity of disease 
is highlighted by the classification of over 120 subtypes, with over 30 being malignant [62]. 
Ovarian epithelium is derived embryologically from the celomic epithelium, which gives 
rise to the Mullerian ducts from which the epithelium of the fallopian tube, endocervix and 
endometrium are derived. Hence, differentiation of ovarian neoplastic cells can produce 
various histological types. Tumours differentiating along the fallopian tube pathway 
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produce serous subtype, endocervical produce mucinous subtype, and cells from the 
endometrial pathway produce endometrioid and clear cell subtypes. 
Serous cystadenocarcinoma 
The serous subtype of ovarian cancer is the most common, accounting for 40-50% of 
cases [5, 10]. They are associated with a poor prognosis compared with other subtypes. 
However, this is likely to be due to their relatively late presentation. When stage is 
corrected for, there is no difference in prognosis [63]. 
Endometrioid adenocarcinoma 
Endometrioid tumours of the ovary are malignant in 80% of cases, and represent 25% of 
all ovarian cancers. They have a similar appearance to colonic metastases which are 
known to spread trans-celomically to the ovaries [64]. Ovarian endometrioid tumours have 
a strong association with both pelvic and ovarian endometriosis with the suggestion that 
these tumours may in fact represent malignant transformation in endometriosis [65]. A 
concomitant endometrial carcinoma is present in up to 20% of cases, often raising a 
dilemma as to whether these tumours are synchronous separate primaries or metastases 
from one organ to another. If the tumours are confined to each organ then the prognosis is 
good, favouring the independent primary hypothesis [65]. 
Mucinous cystadenocarcinoma 
Traditionally mucinous cancers accounted for approximately 10% of all ovarian cancers, 
although this rate is now thought to be lower. Overall they have a relatively favourable 
prognosis; this is probably due to the preponderance of early stage at presentation [5, 10]. 
Typically, they can present as huge pelvic masses, and tend to be resistant to platinum 
chemotherapy. Those that do present late, however, tend to have a poorer prognosis in 
comparison to other subtypes [66]. 
Clear Cell adenocarcinoma 
Clear cell cancers represent approximately 5% of ovarian cancers [5, 10]. They are 
strongly associated with endometriosis, even more so than endometrioid subtypes [67]. In 
comparison with serous cancers they tend to present earlier; however, they are more 
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likely to display platinum insensitivity. In consequence, when correcting for stage, their 
prognosis is poor when compared with other subtypes [5, 68]. 
Undifferentiated carcinomas 
Undifferentiated ovarian cancer incidence varies considerably between studies and 
accounts for between 5-25% of all ovarian cancers They present at a late stage, are 
chemoresistant and as such carry a very poor prognosis [5, 10]. 
 
The subtypes described above reflect the genuine heterogeneity which occurs in ovarian 
cancer. The influence of the histological type on prognosis is difficult to predict since 
strong independent factors such as stage and degree of cytoreducibility at surgery 
contribute greatly to prognosis and compound any potential effects exerted by the subtype 
of cancer. This heterogeneity also makes ovarian cancer studies more challenging, 
especially as some suggest that each subtype is a separate disease entity and should be 
investigated as such. 
1.1.5.2 Histological Grade 
 
The histological grade of a tumour refers to a system used to quantify the microscopic 
appearance of the cells into well (G1), moderate (G2) and poorly differentiated (G3). 
Numerous systems exist to produce this score and include consideration of nuclear 
atypia, number of mitoses and architectural appearance of the cells. The grading systems 
aim to provide prognostic information regarding the tumour; however, due to the 
heterogeneity of ovarian cancers the same system does not appear applicable to all 
subtypes. For example, only nuclear atypia provides prognostic information in clear cell 
tumours, whereas all three components are useful in serous, endometrioid and mucinous 
subtypes [69]. Overall grading is not considered to be a useful independent prognostic 
factor, although it can be useful on a sub-stage level, especially in early stage disease [5]. 
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Immunohistochemical characteristics 
 
Many metastatic adenocarcinomas can involve the ovary such as colorectal, gastric, 
breast, pancreas, gall bladder, renal and other gynaecological malignancies. 
Morphologically, these tumours may appear very similar and as such a potential 
metastatic origin should always be considered when assessing an ovarian tumour. This is 
especially true of mucinous ovarian tumours; a recent study demonstrated less than 3% of 
true ovarian cancers were mucinous.  This figure is much lower than in earlier literature, 
suggesting that metastatic mucinous tumours have previously been incorrectly deemed 
ovarian in origin [70]. Since such similarities exist in tumour morphology light microscopy 
can be unreliable. Immunohistochemistry provides crucial additional information on a 
WXPRXU¶V FKDUDFWHULVWLFV DQG OLNHO\ RULJLQ ZKLFK ZLOO FOHDUO\ LQIOXHQFH PDQDJHPHQW DQG
subsequent prognosis [71]. 
The cornerstones of ovarian immunohistochemistry are antibodies specific to cytokeratin 7 
and 20, Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (Ca125). Mucinous 
ovarian cancers tend to be CK7+, Ca125+ and CEA-, CK20-, although there are always 
exceptions. This most commonly occurs in mucinous tumours in which CK7 and CK20 
can be positive in both colorectal and ovarian cancer [71]. However, ovarian tumours tend 
to be diffusely positive for CK7 and only focally positive for CK20, with the opposite 
occurring in colorectal tumours [72]. 
Extra-colonic ovarian metastases can be more challenging to distinguish 
immunohistochemically since most are CK7+ and CK20-. The use of additional markers 
such as oestrogen and progesterone receptor (ER and PR) as well as gross cystic 
disease fluid protein-15 can be used to distinguish a breast primary, in which these 
markers are usually positive [73]. With pancreatic cancers, Wilms Tumour 1 is usually 
negative, with the majority of ovarian cancers being positive [74]. Renal clear cell cancers 
can mimic ovarian cancers, when the use of CD10 a renal cell carcinoma antigen can be 
useful [75].  
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Practically, the determination of the site of tumour origin does not rely solely on 
histological morphology and immunohistochemical profiles but on the combination of 
these features coupled with clinical and radiological information. The importance of a 
cohesive and thorough assessment of all these components highlights one of the major 
roles of an oncology multi-disciplinary team (MDT) meeting. 
1.1.5.3 Stage 
 
Staging in ovarian cancer is traditionally surgical i.e. based on the operative findings at the 
commencement of the procedure. This is typically performed through a longitudinal 
midline abdominal incision, although more recently laparoscopic staging has been 
performed [76]. With the increasing role of neoadjuvant chemotherapy (discussed later), 
there is a trend towards image guided staging, typically with computed tomography (CT) 
and integrated positron emission tomography and CT (PET/CT) [77]. However, it should 
be noted that currently the gold standard for staging of ovarian cancer is a laparotomy. 
Ovarian cancer most commonly spreads trans-peritoneally, although lymphatic spread is 
also seen. Therefore, close inspection and biopsies of the peritoneal surfaces including 
the diaphragm, para-colic gutters and omentum are required to detect microscopic 
metastases. In addition, ascites or peritoneal washings are assessed cytologically. The 
role of both pelvic and para-aortic lymphadenectomy in ovarian cancer staging remains 
controversial, particularly in advanced disease. In presumed early stage disease the risk 
of occult metastases in lymph nodes is approximately 10-20% [78, 79]. Therefore, without 
lymph node sampling many patients would be under-staged. This is of particular 
importance when determining adjuvant treatment following surgery and has been 
implicated in producing contradictory results between clinical trials in which thorough 
staging was inconsistently performed [80]. 
The major challenge to treating ovarian cancer effectively relates to the vast majority of 
patients presenting with advanced stage disease. Over the period in which the cohort of 
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patients in this study were diagnosed, a number of ovarian cancer series were reported in 
which over half the cases presented at stage III-IV [3, 10, 81-83]. 
There exists a number of staging systems for ovarian cancer, although the International 
Federation of Gynaecologists and Obstetricians (FIGO) system is the most widely used. 
This was adapted into its current format in 1987 [84]. 
In essence, stage I disease is limited to the ovaries, stage II is limited to the pelvis, stage 
III extends outside the pelvis and stage IV has distant metastases usually in the chest or 
liver parenchyma (Figure 1.2 and Figure 1.3 and appendix 1). Clinical staging is vitally 
important for planning of treatment and represents the strongest independent predictor of 
prognosis. 
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One ovary, capsule intact; no 
tumour on ovarian surface
Implants on uterus and/or 
tubes
Ovaries with ruptured capsule or tumour on ovarian 
surface; malignant cells in ascites/washings
Both ovaries, capsule intact; no 
tumour on ovarian surface
Extension to other pelvic 
tissues, pelvic side wall, broad 
ligament, mesovarium
 
Figure 1.2 Ovarian Carcinoma Staging. A, Stage Ia. B, Stage Ib, C. Stage Ic. D, Stage IIa. E, 
Stage IIb. Illustration adapted from DiSaia et al. Clinical Gynecologic Oncology [85]. 
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C: Peritoneal deposits beyond pelvis >2cm or 
regional lymph nodes metastasis
D: Liver parenchymal metastases, lung involvement or 
distant metastases 
A: Implants in other pelvic tissues with 
malignant cells in ascites/washings
B: Microscopic or <2cm deposits beyond pelvis including 
peritoneal surface of liver
 
Figure 1.3 Ovarian cancer staging A: Stage IIc, B: Stages IIIa and IIIb, C: Stage IIIc, 
D: Stage IV. Illustration from adapted from DiSaia et al. Clinical Gynecologic Oncology [85]. 
 
1.1.6 Diagnosis 
1.1.6.1 Symptoms and signs 
 
Symptoms of ovarian cancer are typically non-specific and vague leading to late 
presentation and ultimately poor prognosis. This has led to ovarian cancer being named 
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³WKH VLOHQW NLOOHU´ DOWKRXJK WKLV GHILQLWLRQ LV not strictly true since 95% of patients have 
symptoms prior to diagnosis [86]. The vagueness of these symptoms does, in the majority 
of cases, lead to them being ignored or discounted by both the patient and the General 
Practitioner. 
In the early stage of disease, premenopausal women may develop irregular menses. If a 
pelvic mass is compressing the bladder or rectum then urinary frequency or constipation 
may develop. Acute symptoms such as pain secondary to ovarian rupture or torsion are 
rare. 
In the advanced stages, symptoms are usually related to ascites and omental and bowel 
metastases. These symptoms include abdominal distension, bloating, nausea and 
constipation. Not surprisingly, these symptoms are often attributed to irritable bowel 
syndrome until the clinical signs become more obvious. In a survey of almost 2000 
women with ovarian cancer, 70% had gastrointestinal symptoms, 58% pain, 34% urinary 
symptoms and 26% pelvic discomfort [86].  
Classical signs which highlight the possibility of ovarian cancer in postmenopausal women 
are the detection of a pelvic mass, often fixed, in association with ascites (shifting 
dullness) and a palpable mass in the upper abdomen (omental cake). However, only 3% 
of palpable masses of less than 5cm are malignant in this population. The risk is clearly 
increased with the detection of ascites and an omental cake [87]. 
1.1.6.2 Investigation 
 
The gold-standard investigation and staging of suspected ovarian cancer is via a 
laparotomy; however, this carries significant morbidity especially when a number of 
suspected cancers prove to be benign. Further investigations are divided into radiological, 
haematological and histopathological. 
Serum tumour markers are often used when a pelvic mass is detected. Ca-125 is an 
antigen derived from celomic epithelium and is the classical serum marker for ovarian 
cancer. Unfortunately, it is relatively non-specific with a number of benign conditions 
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causing elevated levels, including endometriosis, pelvic inflammatory disease, 
menstruation, pregnancy, and rheumatoid arthritis. In addition, various other malignancies 
are able to produce an elevated Ca-125 such as colorectal and breast cancers [88]. Bast 
et al demonstrated that elevations in serum Ca-125 levels were seen more frequently in 
women with ovarian carcinoma (82%) compared to women in the general population (1%), 
women with benign disease (6%) or women with non-gynaecological cancers (28%) [89]. 
Ca-125 is also useful as a guide to chemotherapy response and is discussed later. 
Other tumour markers can be useful in highlighting whether a pelvic mass could 
potentially be a metastasis from another primary site. For example, CEA (colorectal) [90], 
Ca-153 (breast) [90], and Ca-19.9 (pancreatic) [91]. 
The first line imaging modality for a pelvic mass is ultrasound. This can usually determine 
the origin of the mass, although in difficult cases pelvic Magnetic Resonance Imaging 
(MRI) can be useful [92]. In those patients with an ovarian mass, various features can 
increase the suspicion of ovarian cancer (see RMI below). Although laparotomy is the 
gold-standard for staging of ovarian cancer, cross sectional imaging can be useful 
preoperatively in treatment planning. For example, the site of surgery (Cancer Unit or 
Centre) and who will be operating (sub-specialty trained Gynaecological Oncologist or 
General Gynaecologist). In addition, with increasing use of neoadjuvant chemotherapy 
image guided staging is utilised. There appears to be no difference in the accuracy of CT 
and MRI for ovarian cancer staging [93]. 
Image guided biopsies are increasingly being used to confirm the diagnosis of ovarian 
cancer, either through ultrasound guided aspiration of ascitic fluid providing cytology, or a 
CT guided biopsy of an omental cake or pelvic mass to provide tissue for histological 
analysis. In general, a tissue diagnosis is preferred, however, adenocarcinoma cells in 
ascites cytology coupled with an elevated Ca-125 would be deemed adequate for the 
diagnosis of ovarian cancer prior to neoadjuvant chemotherapy. 
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1.1.6.3 Risk of Malignancy Index 
 
An elevated Ca-125 level, as previously mentioned, is associated with ovarian cancer. In 
addition there are various features on an ultrasound scan which raise the suspicion that 
an ovarian mass may be malignant. The Risk of Malignancy Index (RMI) represents an 
algorithm which incorporates the ultrasound features of a pelvic mass with the Ca-125 
level and the SDWHQW¶VPHQRSDXVDOVWDWXVWRSURGXFHDTXDQWLWDWLYHDVVHVVPHQWRIWKHULVN
of an individual mass being malignant [94]. The RMI has been shown to give a sensitivity 
of 85% and specificity of 97% for predicting ovarian cancer if the score is greater than 200 
[94]. This has been tested on retrospective and prospective data with encouraging results 
[94, 95]. The model has been subject to some adaptation into the most widely used format 
at present (Table 1.1) [96]. The advantage of such a predictive model is that it allows 
effective planning of when, where and who performs a patient¶s surgery. This is 
particularly pertinent as observational data suggests that there is an improved outcome 
from ovarian cancer when initial surgery is carried out by a Gynaecological Oncologist in a 
Cancer Centre [97]. This model has been successfully used to triage patients in peripheral 
units for referral into Cancer Centres in the UK [98]. 
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Table 1.1 The modified risk of malignancy index developed by Tingulstad et al [96]. 
Parameter Score 
Ultrasound appearances 
Multilocular cyst 
None or one features = 1 
 
Two or more features = 3 
Solid areas 
Bilateral lesions 
Ascites 
Intra-abdominal metastases 
 
Menopausal status 
Post-menopausal 3 
Pre-menopausal 1 
 
Ca-125 level U/ml 
RMI= ultrasound score x menopausal score x Ca-125 
1.1.7 Screening 
 
Ovarian cancer typically has a late presentation which is thought to account for the high 
case: fatality ratio, since early stage disease is associated with an 85% 5-year survival. 
Ovarian cancer screening (OCS) aims to detect cases early, with subsequent benefits 
from improved survival rates. As with any screening test there are a number of hurdles 
including adequate sensitivity, specificity and acceptability of the test. Cost benefit 
considerations and ultimately the effectiveness at reducing mortality rates need to be 
assessed. At present there is no conclusive evidence to suggest that OCS is effective. 
Preliminary data exists from a randomised controlled trial (RCT) of 22 000 women. Out of 
those women within the trial who developed ovarian cancer those that participated in 
screening had an improved median survival (72 months) compared with controls (42 
months) [99]. Additional evidence from a Japanese OCS study showed an increased 
proportion of stage I cancers in screened women compared with unscreened women 
(59% vs. 30%) [100]. 
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OCS consists of two components, firstly a serum Ca-125 measurement and secondly a 
trans-vaginal ultrasound scan (TVS). These have been used individually and in 
combination. Significant improvements have been made to these tests. For example, 
using serial Ca-125 measurements, as opposed to an isolated test, allows trends in the 
level to be detected. This is thought to improve specificity, since only levels which 
continue to rise are indicative of ovarian cancer. Many elevated levels which then 
subsequently fall are the result of a benign process [101]. Use of abnormal ovarian 
morphology is more predictive of ovarian cancer than ovarian volume [102]. Thirdly, 
screening only postmenopausal women who have a proportionally higher incidence of 
ovarian cancer would make such screening more specific. In addition, conditions which 
can lead to a misleading abnormality on TVS, or a benign Ca-125 elevation such as 
endometriosis, fibroids, pelvic infection (PID), pregnancy and menstruation do not 
commonly occur in this age group [102]. 
There are two populations to consider for screening, the general population and those 
with a strong family history of ovarian and/ or breast cancer. The aim is to develop a 
strategy that has greater than 90% sensitivity for detecting ovarian cancer in 
asymptomatic women, with an acceptable false positive rate. This rate is often set at a 
maximum of ten operations in women without ovarian cancer for every case of ovarian 
cancer detected [102]. Currently, there are two large RCTs in the general population to 
assess the impact of OCS on ovarian cancer mortality. The Prostate, Lung, Colorectal and 
Ovarian Cancer screening study is a US-based study of over 74 000 women. The women 
being screened have an annual Ca-125 and TVS, and follow up will continue for at least 
13 years following randomisation [103]. The United Kingdom Trial Of Ovarian Cancer 
Screening (UKCTOCS) is a similar study with 200 000 women; results are expected by 
2012 [102]. 
In the high risk population with a strong family history, there is again sparse data to 
support screening at present. The multi-centre UK Familial Ovarian Cancer Screening 
Study (UK-FOCSS) is underway to assess potential benefits in this challenging patient 
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group. The additional problem posed in this population is the relatively high proportion of 
primary peritoneal cancers (a subgroup of ovarian cancer) occurring. These are not 
reliably detected by Ca-125 and TVS [104]. 
1.1.8 Surgery 
 
Surgery in ovarian cancer varies according to the stage of disease. In presumed early 
stage disease it is vital to perform thorough surgical staging, whereas in advanced 
disease optimal debulking of the tumour represents the main surgical goal. 
1.1.8.1 Early stage disease 
 
Ovarian cancer can only be termed early stage if a thorough staging laparotomy has been 
performed. A series by Young et al highlighted the importance of staging in patents with 
disease which appears to be confined to the ovaries. Those patients undergoing 
suboptimal staging had a 5 year survival of only 60% compared with survival of over 90% 
in those patients in whom thorough staging had been performed. This difference is likely 
to be due to inclusion of some patients with more advanced disease in the group with 
inadequate staging, where occults metastases could be missed. Clearly, inclusion of 
these cases would lead to a lower than expected survival rate [105]. 
In a patient where an ovarian cancer is suspected, a frozen section of the mass enables 
an intra-operative diagnosis to be made, with subsequent staging if necessary. There are 
limitations to frozen section with sensitivity being reported to be as low as 65% [106]. 
Optimal staging, if an ovarian cancer is confirmed, consists of peritoneal fluid for cytology, 
biopsies of suspicious areas on the peritoneal surfaces, including the diaphragm, 
omentectomy, pelvic and para-aortic lymph node dissections. Lymph node dissections are 
particularly important since up to 15% of apparent stage I cancers have nodal metastases 
[107]. Finally, a total abdominal hysterectomy and removal of the remaining ovary is 
performed. In carefully selected cases, where the woman wishes to retain her fertility, a 
unilateral oophorectomy can be performed with preservation of the uterus and 
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contralateral ovary. Careful follow up is required with Ca-125 and TVS. Completion 
surgery is usually recommended after child bearing. 
1.1.8.2 Advanced disease 
 
In patients with advanced ovarian cancer the surgical goal remains the removal of as 
much disease as possible at primary laparotomy. This approach is supported by 
numerous studies suggesting the degree of debulking surgery is an independent 
prognostic factor (Figure 1.4) [108]. Each 10% increase in maximum cytoreduction was 
associated with a 5.5% increase in median survival time. The definition of maximal 
cytoreduction varies from tumour nodules of <2cm through to no visible macroscopic 
disease [109-111]. The measurement of residual disease is inaccurate and frequently 
underestimated [112]. It may also be more relevant to measure total residual tumour 
volume as opposed to the maximum diameter of the residual disease nodules [108]. 
 
Figure 1.4 Survival of patients with stage IIIC epithelial ovarian cancer based on the 
maximum size of residual tumour after laparotomy and tumour resection. Adapted from 
Heintz et al (2003) [113]. 
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The rationale for cytoreductive surgery relates to three theoretical considerations - 
physiological benefits, improved tissue perfusion and growth fraction, and enhanced 
immunological competence of the patient. 
Often SDWLHQWV¶ symptoms improve after a large volume of tumour and ascites is removed, 
alleviating nausea, discomfort and satiety. The reduction in intestinal symptoms may 
improve the nutritional status of the patient prior to further adjuvant treatment.  
Large bulky tumours tend to contain areas which are necrotic and poorly vascularised, 
which will be exposed to suboptimal concentrations of chemotherapeutic agents. In 
addition large tumour masses tend to contain a high proportion of non-dividing cells which 
will be resistant to the mechanisms employed by most chemotherapy. Debulking surgery 
produces smaller volumes of disease with improved blood supply and high growth fraction 
therefore allowing greater exposure of potentially more sensitive tumour cells to 
chemotherapy. 
The fractional kill hypothesis of Skipper [114] postulates that a constant proportion of cells 
are killed with each cycle of treatment. Therefore the smaller the initial tumour burden at 
the start of treatment, the less cycles of treatment will be required to eradicate all the 
tumour cells. Hence, if a tumour burden is reduced prior to chemotherapy i.e. debulked, 
fewer cycles of chemotherapy will be needed to eradicate disease. The less treatment 
exposure needed reduces the potential for drug resistance to occur. However, large 
tumours have a greater chance of having inherent resistance prior to treatment, potentially 
negating this benefit. Another benefit of cytoreduction is related to enhanced 
immunological responses, since large tumours exert a greater non-specific 
immunosuppressive effect. In addition, recognition of tumour-associated antigens may be 
overwhelmed by large numbers of tumour cells [115]. 
In spite of the evidence suggesting a role and survival advantage from maximal surgical 
effort and optimal cytoreduction some still question its role in advanced ovarian cancer 
[116]. There is no prospective data supporting its role, and the ability to optimally debulk a 
tumour may be a reflection of the biological aggressiveness of the tumour as opposed to 
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the skill of the surgeon. The morbidity and impact on quality of life may be unacceptability 
high after radical surgery, especially when newer chemotherapy agents have a greater 
effect on ³log kill´ than surgery. Overall, the evidence regarding the optimum surgical 
approach to ovarian cancer remains controversial, with evidence and biological 
hypothesises promoting both radical and conservative approaches. 
1.1.8.3 Gynaecological oncology sub-specialisation 
 
There is strong evidence to suggest that the training and experience of the surgeon 
treating patients with ovarian cancer influences survival. Patients are more likely to be 
optimally staged, achieve optimal cytoreduction and ultimately survive longer if treated by 
a gynaecological oncologist as opposed to a general surgeon or general gynaecologist 
[97, 117]. This forms the basis for sub-specialisation of gynaecological cancer care in the 
UK with centralisation and coordination of care within recognised Cancer Centres. 
1.1.9 Chemotherapy 
1.1.9.1 Early stage disease 
 
Adjuvant treatment in early stage ovarian cancer is determined by the grade and sub-
stage of disease. Guthrie et al established the same prognosis with and without adjuvant 
chemotherapy in stages 1A and 1B (grade 1 and 2), with both groups having a 5 year 
survival of over 95%. In those patients with poorly differentiated tumours (grade 3), or 
stage 1C-IV, further treatment was deemed necessary [118]. 
The evidence for adjuvant treatment of early stage ovarian cancer is derived mainly from 
two parallel RCTs, the International Collaborative Ovarian Neoplasm Trial 1 (ICON1) and 
the Adjuvant Chemotherapy Trial in Ovarian Neoplasia (ACTION) [80].  In the ICON1 trial 
stage I and IIA disease was included, however, optimal surgical staging was not required 
to enter the trial. Hence, an unquantifiable number of patients would have had undetected 
occult metastases i.e. stage III disease. Patients were randomised to platinum based 
chemotherapy or observation. There was an improved 5 year survival in the treatment arm 
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of 73% compared with 63% in the control arm. In the ACTION trial about a third had 
optimal staging, and randomisation was to either platinum chemotherapy or observation, 
similar to ICON1. There was a survival advantage in the optimally staged patients in the 
observation arm compared to those without optimal staging. In the non-optimally staged 
patients there was a survival advantage in the chemotherapy, compared to the control 
arm, in optimally staged patients there was no difference seen. The differences in survival 
seen in the ACTION study might be explained by a number of occult stage III tumours 
being included with the suboptimally staged patients. If this is the case then benefit is 
likely to be achieved with chemotherapy. In those optimally staged patients i.e. true stage 
I disease, this survival advantage with chemotherapy may not be present. The conclusion 
from these studies is that chemotherapy is warranted in non-optimally staged early 
ovarian cancer but this benefit may not be as relevant in those who remain early stage 
after thorough staging [80]. The optimum type and duration of chemotherapy is yet to be 
confirmed, but is likely to be either three or six cycles of either single agent carboplatin or 
carboplatin in combination with taxol. The results of GOG 175 will hopefully provide these 
answers. 
1.1.9.2 Advanced disease 
 
Systemic chemotherapy has formed a major component of treatment in advanced ovarian 
cancer for many years. The platinum based compounds were introduced in the 1970s, 
initially cisplatin followed by carboplatin. The anticancer activity of platinum drugs results 
from their ability to link themselves between strands of DNA. This inhibits DNA replication, 
DNA repair and induces apoptosis. Paclitaxel was incorporated into platinum regimes in 
the 1990s. Paclitaxel is derived from the bark of the Pacific Yew Tree. Taxanes bind to 
tubulin preventing disassembly of microtubules and this inhibits mitosis during the M 
phase of the cell cycle. 
Cisplatin replaced cyclophosphamide as a single agent showing improved survival and 
reduced toxicity rates [119]. The introduction of a second generation platinum analogue, 
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carboplatin was then introduced. This was superior to cisplatin with reduced 
gastrointestinal side effects, especially nausea and vomiting. Less nephrotoxicity, 
neurotoxicity and ototoxicity was noted, although carboplatin was seen to be more 
myelosuppressive [120, 121]. An RCT (ICON 2) compared carboplatin with 
cyclophosphamide, adriamycin and cisplatin (CAP) - the established standard regime at 
the time. This study confirmed that single agent carboplatin was as effective as CAP with 
less grade 3 and 4 toxicities [122].  
Following the establishment of platinum agents as the primary form of chemotherapy in 
advanced ovarian cancer, paclitaxel was introduced as a potential adjunct. Initial studies 
compared combinations of paclitaxel with either cisplatin or carboplatin, two studies both 
demonstrated similar DFS and OS with the two regimes but the toxicity profile was 
improved in the carboplatin/ paclitaxel arm [123, 124]. In addition a semi-synthetic 
mechanism has produced a second generation taxane called docetaxel. This has been 
shown to reduce neurotoxicity and haematological suppression compared to paclitaxel 
when used in combination with carboplatin [125].  
There are four main studies which assessed the use of platinum agents in conjunction 
with paclitaxel [126-129].  These trials were all asking the same basic question - is 
combined paclitaxel/ platinum superior to platinum based controls? The GOG 111 was the 
first to report and compared cisplatin/ paclitaxel with cyclophosphamide/ cisplatin and 
found improved OS in the paclitaxel arm [127]. The OV10, a European study with similar 
study arms, confirmed these findings [129]. However, these studies were contradicted in 
the GOG132 in which cisplatin/ paclitaxel produced no survival advantage compared with 
single agent cisplatin [128]. The most recent study to report, ICON3, compared 
carboplatin/ paclitaxel with either single agent carboplatin or CAP (this study was 
commenced before the findings of ICON 2 were known i.e. that carboplatin is superior to 
CAP). ICON3 demonstrated no difference in OS between the two study arms [126]. There 
are a number of explanations for differences in the findings of these large RCTs. Firstly, 
differing platinum compounds were used, either carboplatin or cisplatin. Carboplatin is 
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now known to be superior. There was also significant cross over to paclitaxel in the non-
paclitaxel arm when disease progression or recurrence occurred. Finally, there was a 
suggestion that the control arms in the OV10 and GOG111 trials had suboptimal doses of 
platinum in the control arm [130]. Overall, the evidence has produced confusion and 
ultimately variation in clinical practice. Often, the combined approach of carboplatin/ 
paclitaxel is being favoured in the younger, fitter patients who are more able to tolerate the 
increased risk of toxicity. The UK national guidelines suggest that carboplatin can be used 
as a single agent or in combination with paclitaxel [131]. 
1.1.10 Treatment of recurrent disease 
 
First line chemotherapy in advanced ovarian cancer, with platinum and paclitaxel, yield 
response rates of 80% with 40-60% complete response. In spite of this initial response the 
majority relapse, with median PFS of 18 months [132]. Recurrent ovarian cancer is 
incurable; however, use of chemotherapy may significantly prolong survival. The duration 
of remission is crucial in deciding which form of chemotherapy to use. Disease which 
recurs after more than 12 months of platinum treatment are deemed platinum sensitive, 
since it is likely that the tumour will respond to repeat administration of platinum agents. 
There is also evidence that addition of paclitaxel may improve OS, even if this was used in 
prior regimes [133]. This is supported by the results of ICON4 which demonstrated 
improved OS with carboplatin/ paclitaxel over single agent chemotherapy in relapsed 
disease [134]. 
The use of single agent paclitaxel and liposomal doxorubicin are recommended for those 
tumours which are platinum resistant (recurring within six months of last platinum 
chemotherapy), since the likelihood of response to further platinum is 10-20% [135]. 
Topotecan is usually reserved as a third line option [136]. The failure of current cytotoxics 
to cure patients with chemosensitive disease at presentation, and the progressive 
development of drug resistance at relapse, is responsible for the poor overall 5 year 
survival. This provides the impetus to pursue novel therapeutic strategies. 
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1.1.11 Novel chemotherapy regimes 
1.1.11.1 Dose dense, maintenance and novel combination 
 chemotherapy 
 
There is some evidence that escalating the dose of chemotherapy produces increased 
survival. A study by Kaye et al demonstrated an improved OS with double the typical dose 
of cisplatin, although this difference disappeared on long term follow up [137]. A similar 
RCT (SCOTROC4), which is yet to report, is comparing a similar dose-escalating 
schedule with carboplatin. A weekly, as opposed to three weekly, administration of 
paclitaxel may provide advantages in reducing toxicity and improving response rates, 
even in platinum refractory disease [138]. Extended courses of cisplatin have not been 
shown to alter PFS or OS [139], however, there is early evidence that prolonged treatment 
with paclitaxel improves PFS and reduces platinum resistance [140].  
There are numerous studies attempting to alter combinations of chemotherapy regimes 
and include new agents, an example is ICON5, a five arm study including carboplatin, 
paclitaxel, liposomal doxorubicin and gemcitabine. This study assessed the role of adding 
a third cytotoxic agent (liposomal doxorubicin or gemcitabine) to carboplatin and 
paclitaxel. The data is still maturing, although there does not appear to be any 
improvement in PFS with any of the aforementioned combinations [141].  
1.1.11.2 Intra-peritoneal administration 
 
Intra-peritoneal (IP) chemotherapy has the theoretical advantage that it acts directly on 
the tumour cells. There is evidence that there may be a survival advantage with IP 
delivery of platinum agents [139, 142]. There are limitations in that there will only be 
benefit if adequate peritoneal circulation of the chemotherapy is possible, which is unlikely 
in cases of advanced suboptimally debulked tumours. There are also catheter-related 
problems and potentially increased toxicity. The results of the recent GOG172 study 
comparing IP carboplatin and paclitaxel with conventional intravenous administration 
showed a marginal improvement in OS but with significant increase in toxicity. This 
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treatment route is yet to become established [143], although is the focus of a Cancer 
Research UK study which is randomising patients with advanced ovarian cancer to either 
standard chemotherapy (carboplatin and paclitaxel) or standard chemotherapy with IP 
carboplatin [144]. 
1.1.11.3 Neoadjuvant chemotherapy 
 
Various studies have investigated the role of neoadjuvant chemotherapy, principally in 
tumours which on pre-operative assessment were deemed unlikely to be resectable. 
Essentially neoadjuvant chemotherapy refers to the administration of chemotherapy prior 
to surgery. This approach does not appear to impact on survival rates and may improve 
the resectability of the tumour [145, 146]. Currently, there are two main trials looking at 
this approach in advanced ovarian cancer, the CHORUS trial (CHemotherapy OR Upfront 
Surgery) and the EORTC 55971 trial. Whilst CHORUS is still recruiting, provisional reports 
from the EORTC trial have suggested that there is no improvement in OS with 
neoadjuvant chemotherapy, but the rate of optimal debulking is increased and surgical 
complication rates are reduced. Once data from these trials has matured it is likely that a 
move towards neoadjuvant chemotherapy will occur. 
1.1.11.4 Agents to overcome chemoresistance 
 
Cisplatin binds to DNA which results in erroneous DNA replication and subsequent cell 
death through the DNA mismatch repair system (MMR). During development of platinum 
resistance components of the MMR system can be inactivated such as the gene hMLH1 
(through methylation). Therefore, drugs such as decitabine, a demethylation agent, may 
reactivate hMLH1 and restore platinum sensitivity [147]. Other methods of platinum 
resistance include mechanisms which reduce the intracellular concentration of platinum 
through reduced uptake or increased efflux. Permeability glycoprotein (Pgp) is over 
expressed in platinum resistant cells, resulting in increased efflux of platinum from the cell. 
Trials using Pgp inhibitors have only had limited success [148].  
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1.1.12 Novel targeted therapies 
 
The increased understanding of tumour biology provides a number of potential therapeutic 
targets. These include the use of growth factor inhibitors, anti-angiogenic therapy, gene 
therapy and immunotherapy. 
1.1.12.1 Growth factor inhibitors 
 
Epidermal growth factor receptor (EGFR) is one of the most extensively studied growth 
factors in ovarian cancer. Cefitinib and Erlotinib are tyrosine kinase inhibitors which block 
signal transduction from EGFR receptors. These drugs have provided a good response in 
lung cancer but the effects in ovarian cancer have been disappointing [149]. A similar 
tyrosine kinase inhibitor, Lapatinib, which acts on both EGFR and Her2 receptors, is being 
assessed in advanced ovarian cancer by the GOG. 
Raf-1 kinase inhibitor has been shown to have some inhibitory action in ovarian cancer. 
This occurs through the prevention of signal transduction in the Raf pathway, which is 
responsible for cell growth and proliferation [149]. The P13K/Akt pathway also stimulates 
cell growth and proliferation and is amplified in 30% of ovarian cancers. Inhibitors of this 
pathway are in development. MTOR is a downstream target of the P13K/Akt pathway, for 
which inhibitors are at a phase I stage of development [149]. 
1.1.12.2 Apoptosis inducers 
 
Phenoxodiol is a topoisomerase II inhibitor, which induces apoptosis and may have a role 
in re-sensitising paclitaxel resistant ovarian cancer [149]. This is achieved by inhibiting the 
X-linked inhibitor of apoptosis protein (XIAP); XIAP is shown to active on paclitaxel 
resistant tumours [150]. Monoclonal antibodies which stimulate TRAIL pathway apoptosis 
are discussed in a later chapter. 
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1.1.12.3 Anti-angiogenic therapy 
 
Bevacizumab is a mAb which binds to and inactivates all isoforms of VEGF-A leading to 
inhibition of angiogenesis. Phase II studies demonstrated a 17% response rate amongst 
patients with recurrent ovarian cancer the median time to recurrence being ten months 
[151]. VEGF receptor tyrosine kinase inhibitors are also being developed. A large 
multinational RCT comparing standard chemotherapy with carboplatin and paclitaxel, with 
standard treatment plus Bevacizumab is ongoing (ICON7). 
Thalidomide is known to produce anti-angiogenic effects and has been shown to have 
some modest effects in stabilising recurrent ovarian cancer [149]. Carboxyamidotriazole is 
a calcium channel blocker with anti-angiogenic properties which has some activity in 
ovarian cancer. In addition PDGF receptor inhibitors are also showing some promise in 
arresting angiogenesis and tumour growth in ovarian cancer [149]. 
1.2 The Immune System 
 
The immune system is comprised of two separate but complimentary systems; the innate 
system provides the first line of defence against infectious agents, whilst the adaptive 
system provides a more versatile and targeted immune response. The two systems work 
synergistically and rarely in isolation. The cells of the innate system provide a crucial role 
in initiating and directing adaptive immune responses and also participate in the removal 
of pathogens targeted by this system. 
1.2.1 Innate immune system 
1.2.1.1 Complement 
 
The complement system consists of a large number of plasma proteins which react with 
one another to opsinise pathogens and induce inflammatory responses. Complement 
factors are distributed as inactive precursors before the triggering of the complement 
cascade triggers sequential activation of individual factors resulting in a large rapid 
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amplification of the complement response. The complement cascade can be triggered by 
three distinct pathways, the classical, alternative and MB lectin, all of which converge to 
generate the same effector molecules and hence produce the same effects. 
The classical pathway can be triggered by direct interaction with pathogens (innate 
response) or through binding to antibody:antigen complexes (adaptive response). The MB 
lectin pathway is initiated by binding of mannan-binding lectin, a serum protein, to factors 
on the surface of the pathogen. The alternative pathway is triggered by stabilisation of 
C3b on the surface of pathogens, which under normal circumstances would be inactivated 
to iC3b. The activation of the complement cascade, via any of the three pathways, 
produces three effects, recruitment of inflammatory cells, opsonisation of pathogens and 
killing of pathogens. Killing of pathogens is achieved through the formation of the 
Membrane Attack Complex which creates pores in the cell membrane leading to cell 
death. C3b also covalently binds to the bacterial cell membrane (opsonisation) enabling 
phagocytes to internalise them. Thirdly C3a, C4a and C5a mediate an acute inflammatory 
response by stimulating mast cells to release histamine, chemokines, interleukins, 
leukotrienes, prostaglandins and thromboxanes, resulting in increased vascular 
permeability and recruitment of appropriate inflammatory cells. 
1.2.1.2 Phagocytes 
 
Phagocytes are the principal cells involved in ingesting and destroying foreign material, 
the predominant types are macrophages and neutrophils. These cells recognise foreign 
material by the expression of Pathogen Associated Molecular Patterns (PAMPs) via 
Pattern Recognition Receptors (PRR). The interaction between PAMPs and PRRs 
triggers a number of events including phagocytosis and release of cytokines with 
subsequent initiation of the acute inflammatory response [152]. 
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1.2.1.3 Natural killer (NK) cells 
 
NK cells are a type of lymphocyte defined by the expression of CD56 and the absence of 
CD3. NK cells play an important role in innate immunity by mediating direct cytotoxicity 
and secreting cytokines such as IFNJ, IL-10, IL-13 and TNFD [153]. NK cell activity is 
dependent on a complex balance between inhibitory and stimulatory receptors which 
interact through MHC class molecules on potential target cells. Ultimately the NK cell will 
be triggered or inhibited depending on the balance of these signals. The loss or absence 
of HLA class I molecules on the surface of the target cell tends to produce triggering of the 
NK cell [154]. Once activated the NK cells trigger apoptosis in the target cell through 
initiation of the caspase cascade. Apoptosis may also be induced through interaction of 
fasL and TNF Related Apoptosis Inducing Ligand (TRAIL) with the respective death 
receptors [155]. 
1.2.1.4 Gammadelta (JG) T cells 
 
Most T cell receptors consist of two polypeptide chains (D and E) similar to the Fab 
fragments of an immunoglobulin molecule. There is a small subgroup of T cells which 
have different polypeptide chains (J and G) making up the receptor [152]. These  JG T cells 
are distinct as they are able to respond to antigens without the need for presentation 
through HLA molecules. The TCR in this subclass is able to recognize a range of 
epitopes, reducing the need for clonal expansion. These cells are thought to remove 
damaged and stressed cells [156]. Mice deficient in this cell type are predisposed to 
tumour development [157, 158]. 
1.2.1.5 Dendritic cells (DCs) 
 
DCs along with macrophages and B cells are known as professional APCs, as they 
present antigen via HLA class I and II molecules, to cytotoxic and helper T cells (signal). 
Immature DCs originate in the bone marrow and migrate to peripheral tissues, where they 
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recognise and ingest foreign material. In this immature form they lack the ability to 
stimulate T cells. Following exposure to a pathogen or stressed cells the DC is activated 
and migrates to regional lymph nodes where maturation and morphological changes 
occur. These provide the vital second signal for activation of naïve T cells. These cells 
therefore represent an important interface between the innate and adaptive immune 
systems [152]. 
1.2.2 The adaptive immune system 
1.2.2.1 B-cells 
 
B-cells originate from the bone marrow. During maturation these cells undergo 
rearrangements in the genes which encode the variable regions on their surface 
immunoglobin, the B-cell receptor (BCR). This produces a population of cells with highly 
diverse, specific receptors able to respond to a wide range of antigenic stimuli. Once a B-
cell encounters the specific antigen for which its BCR is coded, it binds and internalises 
the antigen. Subsequent processing finally occurs, resulting in the antigen being 
expressed on the cell surface combined with a HLA class II molecule; this enables 
interaction with other immune cells. B-cells may develop into plasma cells, which following 
clonal expansion, are capable of producing large qualities of identical immunoglobulin with 
a specific antigenic target [152, 159, 160]. 
1.2.2.2 Antibodies 
 
Antibodies, or immunoglobulins, are produced by activated B-cells. They bind to unique 
antigenic sequences on foreign organisms which initiate a specific, targeted immune 
attack. The structure of the antibody incorporates two identical light and heavy protein 
FKDLQV ZKLFK VFKHPDWLFDOO\ DUH LOOXVWUDWHG E\ D ³<´ VKDSHG PROHFXOH (Figure 1.5). This 
molecule possesses a stem, the Fragment crystalline (Fc), and two arms, the Fragment 
antigen binding unit (Fab).   The Fc unit binds to the effector cells while the Fab units, 
which contain a highly variable region, bind to specific antigenic sequences on the 
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pathogen. There are a number of Fc subtypes which determine the class of antibody and 
include IgG, IgE, IgA and IgD. Different effector cells have Fc receptors for a particular 
subclass of antibody and hence each antibody type triggers different effector mechanisms 
[152]. 
 
  
 
Figure 1.5 The antibody structure. A simplified schematic representation of an antibody 
molecule showing (A) the variable (red) and constant regions (blue), and (B) the heavy 
(green) and light chains (yellow). Figure adapted from Immunobiology. Chapter 3. Janeway et 
al [152]. 
1.2.2.3 T-cells 
 
T-cells can be divided into two main groups; those expressing CD8 molecules, cytotoxic T 
lymphocytes (CTLs), and those expressing CD4 molecules, helper T cells (Th). These are 
co-receptors for HLA class I and II respectively. 
Immature T cells lacking both CD4 and CD8 are produced in the bone marrow, prior to 
migration and maturation occurring in the thymus. In the thymus both CD molecules are 
initially expressed, one type is then removed and it is this which determines the ultimate 
cellular phenotype. As everyone is born with the same T-cell repertoire it is essential to 
select the cells that are necessary for each individual. The process governing this 
maturation of T-cells in the thymus eventually results in the destruction of the majority. 
Only approximately 2% become viable mature T-cells. T-cells recognising the individual¶s 
inherited HLA are selected (positive selection), and those capable of responding too 
A B 
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strongly to self antigens are removed (negative selection) in order to prevent auto-
immunity. Ultimately T-cells will be produced which express either CD4 or CD8 co-
receptors. 
CD8+ cells 
These cytotoxic T-cells have TCR which bind to HLA class I molecules on the surface of 
cells displaying peptides which are typically from viral infection or abnormal cellular 
functioning. The mechanism of cell killing is similar to NK cells. 
CD 4+ cells 
Naïve CD4 cells can differentiate upon activation into different subtypes, which vary in the 
cytokines they produce and hence in their function. The determining factors involved in 
this process are unclear. Some cytokines relate to cell-mediated immunity through the 
activation of macrophages and NK cells, others produce a humoral response with 
stimulation of B-cells to produce vast quantities of immunoglobulin. The nature of the 
antigenic stimulus dictates the proportion of each cell¶s type and hence the nature of the 
immune response, i.e. cell mediated or humoral. 
1.2.2.4 Human leukocyte antigen (HLA) 
 
HLA is the human form of Major Histocompatibility Complex (MHC), whose function is to 
bind peptide fragments from pathogens and display them on the cell surface for 
recognition by the appropriate T-cells. The result of the interaction between MHC and T-
cells is varied and dependent on the specific cell type which binds. There are two main 
subtypes of HLA (class I and II). In addition, there are several different genes encoding 
HLA of each subtype and these are also highly polymorphic. This in essence means that 
each individual carries a large number of different HLA molecules and the variation in 
types between individuals is also high. 
HLA class I is a heavy chain polypeptide which is expressed on the cell surface and is 
associated with a light chain (E2microglobulin). HLA class I, which is expressed on 
virtually all human cells, presents antigens which occur during abnormal cellular 
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conditions. The antigen is processed within the cell by the proteosome and transported to 
the endoplasmic reticulum and Golgi apparatus and finally to the cell surface by 
transporter proteins (TAP 1 and 2). During processing the peptide is bound to 
E2microglobulin before finally combining at the cell surface with the heavy chain to 
produce the HLA-peptide complex, which becomes a target for cytotoxic T-cells [152]. 
HLA class II molecules are expressed by a more limited population of cells. Expression is 
limited to B-cells, DCs, macrophages, endothelial and stressed epithelial cells. The 
primary role of HLA class II molecules is to present antigens to CD4 cells [152]. 
1.2.2.5 Regulatory T-cells 
 
Regulatory T-Cells (Treg) or suppressor T-cells are a subpopulation of CD4+ T-cells 
which also express high levels of IL-2 receptor (CD25) and transcription factor Forkhead 
box p3 (Foxp3) [161]. Treg are primarily produced in the thymus, although a small 
proportion develops peripherally. Treg produce their effects through a number of cytokines 
including IL-10 and transforming growth factor E (TGFE) [162]. Physiologically, Tregs 
prevent unwanted autoimmune reactions and curtail the immune response once the 
original stimulus is neutralised [163]. The suppressive effects of Tregs may be harnessed 
by pathogens and cancers to evade immune response [164].  
1.2.2.6 Cytokines 
 
Cytokines are low molecular weight proteins which are secreted by cells to produce 
various responses. They consist of a number of types including interleukins, colony 
stimulating factors, TNFs and interferons (IFNs). The functions of the various cytokines 
are diverse, reflecting the array and complexity of the cytokine groups. In broad terms 
these functions include control of cellular differentiation, upregulation of receptors, the 
initiation of the inflammatory response, anti-tumour and anti-viral activity, direct 
cytotoxicity and priming of the adaptive immune response. 
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1.3 Tumour Immunology 
 
Tumour immunology represents an area of rapidly developing cancer research. This 
consists of exploration of the mechanisms which underlie immunological recognition and 
elimination of cancer and the mechanisms through which tumours evade such attack. 
However, the theory behind the immune system being able to recognise and eliminate 
tumours was first postulated 100 years ago [165]. This concept was later termed cancer 
immunosurveillance, although technological limitations at that time prevented significant 
development of the theory. With the emergence of transgenic mouse technology, coupled 
with the production of monoclonal antibodies to specific immune factors, the 
immunosurveillance hypothesis has attracted renewed attention. Modern molecular 
techniques allow robust, specific investigation of this model. As our knowledge of the 
concept expands it appears that not only does the immune system exert a suppressive 
effect on tumour cells, it also acts as a Darwinian type model to select and promote 
tumour cells with lower immunogenicity - this concept is termed immunoediting [166, 167]. 
1.3.1 Cancer immunosurveillance in mice 
 
Initial interest in the concept of immunosurveillance was developed in the 1950s, however, 
this hypothesis lost favour over the subsequent 20 years. This was primarily due to results 
from experiments on nude mice, thought to be immunodeficient, which failed to show the 
predicted increase in methylcholanthrene (MCA) induced and spontaneous tumours 
compared with wild type controls [168]. With hindsight these seemingly negative findings 
can be explained by the demonstration that nude mice are not as immunodeficient as first 
DVVXPHG7KH\KDYHD ORZEXWGHWHFWDEOH OHYHORIĮȕ7-cells [169] and normal levels of 
NK cells; the existence and role of which was not known at that time [170]. In addition 
these mice had a fully functioning innate system, whose influence on the adaptive immune 
system was not appreciated [171]. Hence, the nude mouse is an imperfect model because 
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low levels of cancer immunosurveillance probably occur, explaining the negative findings 
of such studies [168, 172]. 
Some of the most convincing data relating to the theory of immunosurveillance comes 
from work done using transplantation techniques between immunocompetent and 
immunodeficient mice, which highlight the specific influence of lymphocytes. 
Immunodeficient mice lacked the recombinase activating gene-2 (RAG-2). RAG-2 is 
required to rearrange lymphocyte antigen receptors; hence, mice lacking RAG-2 will lack 
functional T, B and NK cells. Following exposure to MCA, 129/SvEv RAG-2-/- mice 
developed sarcomas more rapidly than wild type controls [167]. Similar effects were 
observed with spontaneous tumours. When tumours from both types of mice were 
transplanted into an immunodeficient host tumour growth was observed. However, when 
tumours from both groups were transplanted into immunocompetent hosts 40% of those 
arising in immunodeficient donors were rejected. Hence, tumours which developed in 
immunodeficient environments were significantly more immunogenic than those which 
developed in wild type controls. This gives some convincing evidence for the sculpting 
effect of the immune system on tumour characteristics i.e. immunoediting [167]. 
1.3.2 IFNJ in cancer immunosurveillance 
 
Interest in immunosurveillance was rekindled following a series of studies involving IFNJ. 
Injection of a neutralising antibody for IFNJ resulted in the blocking of tumour rejection in 
mice transplanted with established tumours [173]. Similar effects were seen with the 
increased incidence of MCA-induced tumours in IFNJ insensitive mice compared to wild 
type controls. Mice lacking either one of the subunits of the IFNJ receptor (IFNGR1) or 
STAT1, a crucial transcription factor in the pathway, led to a 10 - 20 fold increase in 
tumour formation compared to wild type mice [174]. These findings have been reproduced 
by others [175]. In addition, the tumours produced in IFNGR1 deficient mice grew 
aggressively when transplanted into immunocompetent hosts. Therefore, tumours lacking 
IFNGR1 had their immunogenicity blocked because of an inability to respond to IFNJ. 
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The relationship between IFNJ and lymphocytes on tumour suppression was investigated 
using mice lacking either a functioning IFNJ pathway (IFNGR1 or STAT1 deficient), 
functioning lymphocytes (RAG-2-/-) or both. As expected, MCA-induced tumours occurred 
more frequently than in wild type controls, however, there was no synergistic effect seen 
within the mice lacking both functional lymphocyte and IFNJ pathways [167]. This 
suggests, not surprisingly, that there is significant overlap in the anti-tumour effects of 
IFNJ and lymphocytes. This is supported by the finding that mice lacking both IFNGR1 
and perforin (a prime mediator of cytotoxic T lymphocyte killing), were not at significantly 
increased risk of tumour formation compared with those with only one defective pathway 
[175]. 
The source of IFNJ utilised during cancer elimination appears to originate primarily from 
Ȗį7-cells. Gao et al GHPRQVWUDWHGDQLQFUHDVHGLQFLGHQFHRIWXPRXUVLQPLFHODFNLQJȖį
T-cells which was equivalent to that of IFNJ deficient mice [176]. The production of IFNJ in 
this pathway is thought to be mediated by IL-12. IL-12 is a potent cytokine produced by 
macrophages which stimulate release of IFNJ. IL-12 dependent rejection of sarcomas was 
blocked by IFNJ neutralising antibody [177]. 
Although evidence suggests that IFNJ is critical in immunosurveillance, it was not clear 
whether the tumour cell itself was a direct target for IFNJ activity. Using tumour cell 
transplantation models, MCA-induced tumour cells which were engineered to be 
unresponsive to IFNJ, (by over expression of a dominant negative mutant for IFNGR1), 
were transplanted along with controls into wild type mice. The tumour cells rendered 
unresponsive to IFNJ grew more aggressively than the controls, suggesting that tumour 
cells are a physiological target of IFNJ in the tumour rejection process [173]. 
1.3.3 Specific effects of IFNJ on tumour cells 
 
IFNJ has been shown to upregulate components of the MHC class I pathway, resulting in 
increased immunogenicity and ultimately tumour rejection [178]. IFNJ has marked anti-
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proliferative effects on tumour cells through the induction of cell cycle inhibitors such as 
p21 [179] and p27 [180]. Pro-apoptotic pathways can also be induced through IFNJ 
promotion of genes producing caspase-1, Fas and Fas ligand, which can trigger 
programmed cell death [181-183]. Release of potent chemokines from tumour cells can 
be induced by IFNJ, CXCL-9 and CXCL-10 (IP-10) and act as powerful chemo-attractants 
for specific leukocytes as well as inhibiting angiogenesis [184, 185]. Although the 
aforementioned effects of IFNJ on tumour cells have been clearly demonstrated in 
isolation, the relative contribution of each to the process of immunosurveillance is unclear. 
1.3.4 Immunosurveillance in humans 
 
Having established evidence of immunosurveillance using mouse models, can these 
findings be extrapolated into humans? The evidence for immunosurveillance in humans is 
much less developed. However, there are three main areas of evidence. One obvious 
cohort, in whom the potential effects of the immune system on tumour formation might be 
observed, is in those individuals with immune deficiency. Immunodeficiency can be both 
congenital, acquired or through the effects of immunosuppressive drugs. Unfortunately, 
these patients are also more prone to viral infections, and in consequence, to virally 
LQGXFHG WXPRXUV VXFK DV .DSRVL¶V VDUFRPD DQG FHUvical cancer which are caused by 
Human Herpes Virus 8 and Human Papilloma Virus respectively [186]. Hence any effect 
of immune suppression on non-virally induced tumour, which is likely to be more subtle, 
may be clouded by such observations. There are three lines of enquiry pointing to a 
potential role for immunosurveillance in humans. Evidence from immunosuppressed 
transplant patients, immune responses to established cancers and the prognostic 
significance of lymphocytes within tumours. 
1.3.4.1 Tumour formation in transplant patients 
 
Evidence for an increased relative risk of many non-virally associated tumours have been 
documented in renal [187] and cardiac [188] transplant patients. These included colon, 
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lung, bladder and renal cancers. There is the possibility that a hitherto unknown viral 
cause exists, but with current understanding it appears that drug-induced immune 
suppression results in increased risk of tumour formation. This may result from de novo 
tumours or through the outgrowth of occult tumours previously suppressed by the 
functioning immune system. 
1.3.4.2 Immune responses to tumours in humans 
 
Clearly the transplantation techniques used in the mouse model would not be applicable 
to humans. Therefore in vitro approaches have been adopted to demonstrate immune 
responses to tumour antigens. Autologous typing is an example of such a technique. 
Tumour cell lines were established from patients with melanoma and then used to assess 
humoral and cellular responses. This system identified T-cells (both CD4 and CD8) with 
antibodies specific to tumour cell surface antigens [189]. NY-ESO-1, a tumour specific 
antigen, provides an excellent illustration of current understanding and evidence 
surrounding specific immune cellular responses to tumours. NY-ESO-1 has been 
identified in some melanoma, bladder and lung cancers [190]. The antibody to this has 
only been detected in tumours expressing the antigen and not in NY-ESO-1 negative 
tumours or normal controls [191]. The antibody is further linked to the presence of the NY-
ESO-1 positive tumour since surgical removal leads to disappearance of the antibody 
[192]. There is some evidence that suggests that patients with spontaneous immunity to 
NY-ESO-1 carry a more favourable prognosis. This is yet to be established. 
The innate immune system also appears to play a role in immunosurveillance. MICA and 
MICB (MHC class 1 glycoprotiens) act as tumour cell surface ligands for interaction with 
1.FHOOVDQGȖį7-cells. They are non-classical MHC proteins which do not associate with 
ȕPDFURJOREXOLQRU UHTXLUH7$3IRUH[SUHVVLRQ [193]. MICA/B is only found in the large 
and small intestine of normal tissues, but is seen in lung, breast, kidney, ovarian and 
colon cancers [194]. Interaction of NK c aQG Ȗį 7-cells with MICA/B is via NKG2D 
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receptors, with inhibition of cell lysis produced by pre-treatment with inhibitory monoclonal 
antibody to NKG2D [195]. 
MICA/B has been linked with immunosurveillance following the correlation, in vivo, of 
MICA/B expression in tumours with tumour infiltration by Ȗį 7-cells [194]. Secondly, 
soluble MICA shed by tumour cells causes downregulation of NKG2D receptors on T-cells 
leading to a reduced responsiveness of tumour antigen specific T-cells. This may be a 
method by which a tumour evades immune attack [196]. 
1.3.4.3 Tumour infiltrating lymphocytes 
 
Over recent years the presence of tumour infiltrating lymphocytes (TILs) has been shown 
to exert some influence on tumour behaviour. In particular Zhang et al studied 174 
advanced ovarian carcinomas and demonstrated that a favourable clinical outcome could 
be predicted by the presence of intratumoral TILs [197]. Similar studies in colorectal 
cancer demonstrated the same prognostic influence [198]. These studies as well as 
others involving lung, gastric and oesophageal cancer [166], all suggest a profound 
influence of the immune system on the behaviour and control of established tumours. This 
influence appears to be exerted on established cancers, i.e. those which have escaped 
immunosurveillance. However, it is likely that similar effects are occurring at a sub-clinical 
level to eliminate or suppress occult tumours. 
Tregs are CD4+ T-cells which  release cytokines such as IL-10 [199] and TGF-E [200] to 
inhibit the function of other T-cells. Physiologically, Tregs prevent unwanted autoimmune 
reactions [163]. Tumours, however, may highjack these cells to prevent effective immune 
response to tumour antigens [164, 201]. This was illustrated in a murine model with 
transplanted tumours, which were rejected when the recipient mice were pre-depleted of 
Tregs [202] Ȗį 7-cells represent a further subset of T- cells which have inhibitory 
properties with exposure to TGF-E promoting an inhibitory role. However, they also have 
stimulatory roles dependent on the cytokine milieu [203]. Tumour-DVVRFLDWHG Ȗį 7-cells 
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have been associated with inhibition of anti-tumour immune responses through the 
inhibition of NK cells [204]. 
1.3.5 Cancer immunoediting 
 
In spite of the numerous studies pointing to a protective effect from the immune system 
against tumour development, tumours are seen occurring in patients with intact immune 
systems. Hence, if the immune system is able to detect and destroy tumour cells then 
tumour cells must develop methods of evading such attack. This concept is central to 
tumour biology, namely that they escape the mechanisms that operate to suppress them. 
Shankaran et al demonstrated in a mouse model that tumours which develop in the 
absence of an intact immune system appear to be more immunogenic [167]. Takeda at el 
[205], whose work focuses on TRAIL-mediated cytotoxicity in tumours, assessed the 
influence on characteristics of tumours which developed in the presence or absence of a 
functioning TRAIL pathway. Tumours developed in mice with the TRAIL blocking antibody, 
produced tumours that were sensitive to TRAIL-mediated cytotoxicity. However, tumours 
established with a functioning TRAIL pathway, produced tumours that were resistant to 
TRAIL killing. This suggests that tumours exposed to the TRAIL pathway need to develop 
phenotypes which could evade such attacks :KHUHDV WKRVH JURZQ LQ D ³75$,/-IUHH´
environment did not require this evasion to develop and hence were sensitive to TRAIL-
mediated attack when exposed [205]. 
This series of experiments shows that tumours are imprinted by the immunological 
environment in which they form. Tumours developing within an environment containing an 
intact immune system produce cells which are rendered resistant to immune attack and/ 
or recognition. This phenomenon is likely to occur from the selection pressures exerted by 
the immune system. Specifically, tumour cells which develop mutations allowing evasion 
of the immune system will have a survival advantage and hence be selectively favoured 
as the tumour grows. The selective pressure of the immune system is highlighted by the 
sensitivity to immune attack of tumours developed in the absence of a functioning immune 
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system. Mutations producing the ability to evade the immune system do not provide a 
survival advantage in an immunodeficient environment and therefore are not positively 
selected. This leads to a tumour which remains sensitive to immune-mediated cytotoxicity. 
During tumour development a series of selected mutations will occur leading to sculpting 
of the tumour. This happens at an early, sub-clinical stage, and hence clinically apparent 
tumours will already have been attenuated by the sculpting effects of the immune system. 
1.3.5.1 Refining the immunosurveillance theory 
 
The original concept of immunosurveillance suggested that cells from the adaptive 
immune system produced a protective role against potential cancers developing by 
recognition and elimination of such cells. It now appears that the innate as well as the 
adaptive system is involved. The influence of the immune system is not limited to merely 
preventing tumour development, but also imposes an influence on the immunogenicity of 
tumours which do develop. This sculpting, or editing, effect occurs through Darwinian- 
style selection pressures exerted on the tumour, in which tumour cells able to evade 
immune attack are positively selected. This process has been termed immunoediting 
[206]$SRWHQWLDOPRGHOIRUKRZWKLVSURFHVVRFFXUVLQYROYHV³WKH three Es ´- elimination, 
equilibrium and escape (Figure 1.6). 
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Figure 1.6 The three Es of cancer immunoediting. (a) Elimination corresponds to 
immunosurveillance. (b) Equilibrium represents the process by which the immune system 
selects and/ or promotes tumour cell variants with increased capacity to survive immune 
attack. (c) Escape is the process wherein the immunologically sculpted tumour expands in 
an uncontrolled manner in the immunocompetent host. Developing tumour cells (blue), 
tumour cell variants (red), additional tumour cell variants (orange), stroma (grey) and white 
flashes represent lymphocytic cytotoxic activity against tumour cells. Diagram adapted from 
Dunn et al [166]. 
 
Elimination 
This phase represents the initial concept of immunosurveillance - i.e. the killing of tumour 
cells by the immune system. Immunological recognition and elimination of tumour cells at 
this stage is similar to that seen with anti-microbial effects. The initiation of the anti±
tumour effects occurs from the stromal disruption resulting from the invasive tumour 
growth pattern and angiogenesis. This releases inflammatory chemokines that summon 
FHOOV RI WKH LQQDWH V\VWHP 1. Ȗį 7-cells and macrophages) to the source of danger 
[207]. These cells recognise tumour cells via NKG2D or TCR receptors on the tumour 
surface [208]. The end result of these early interactions is the production of IFNJ. A 
positive feedback loop involving various chemokines, including IL12, produces a rapidly 
increasing level of IFNJ, leading to a number of IFNJ-dependent processes including anti-
proliferative [180], pro-apoptotic [209] and angiostatic [184] effects, which lead to tumour 
killing. In addition, IFNJ activates macrophages and NK cells which produce further cell 
death through the TRAIL [205] and caspase pathways [210]. As a result of these 
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processes dead tumour cells are made available for recruitment by the adaptive immune 
system in to the process. 
The following step relates to the development of tumour-specific adaptive immune 
responses. Immature DCs that have been recruited to the tumour site are activated by 
cytokines which are either released by the innate system in response to the tumour, or via 
direct interaction with NK cells [211]. The DCs ingest tumour antigens from the cell debris 
produced from the killed cells, following which they migrate to regional lymph nodes [212]. 
In the lymph node DCs activate naive tumour-specific Th1 CD4+ T-cells which in turn 
facilitate the development of tumour specific CD8+ CTLs [213]. The specific CD4+ and 
CD8+ T-cells then migrate to the tumour site where they proceed to kill antigen positive 
tumour cells. In addition to direct killing these T-cells also produce vast amounts of IFNJ 
which stimulates further IFNJ specific anti-tumour responses. 
This process must be repeated for each new cancer which develops, since each will be 
antigenically unique and hence require specific adaptive immune responses. This 
constant need for ongoing immunosurveillance might in part explain the increased 
incidence of cancers in the elderly population where it is recognised that immune function 
deteriorates. 
Equilibrium 
Any tumour cells that have the ability to avoid being killed enter into a phase of 
equilibrium, during which time the immune system has the ability to contain, but not fully 
eliminate, the tumour cells. This is similar to the old concept of tumour dormancy [214]. 
This cell population is genetically unstable with microsatellite and chromosomal instability 
which leads to a constantly evolving heterogeneous group of cells with frequent 
production of new clones. Tumour variants with increased ability to avoid immune attack 
will be positively selected in a Darwinian-style model. Hence, the tumour becomes 
increasing resistant to immune attack until it is able to escape and grow unhindered by the 
inhibitions of the immune system. This period of equilibrium is the longest of the three 
 52 
phases and may occur over many years. For example, there can be a 20 year interval 
between initial carcinogen exposure and clinical detection of a tumour [215]. 
Further evidence is offered from case reports of renal transplant patients with donor-
derived melanoma even when the donor has no history of malignancy. It is suggested that 
the immune suppression required following transplantation allowed the escape of occult 
WXPRXUZKLFKZDVEHLQJKHOGLQHTXLOLEULXPE\WKHGRQRU¶VLQWDFWLPPXQHV\VWHP[216]. 
Escape 
Multiple tumour sculpting events, in the equilibrium phase, leads to an immunogenic 
phenotype capable of growing in the presence of a functioning immune system.  This 
requires evasion of both the adaptive and innate systems. There is evidence that tumours 
can exert inhibitory effects through the release of immunosuppressive cytokines such as 
TGF-ȕDQG,/-10, or via mechanisms involving T-cells with immunosuppressive properties 
(Treg) [199, 200]. 
Changes in the tumour at a cellular level can also produce alterations in tumour 
recognition and the effectiveness of immune attack. Loss of MHC [217], shedding of 
NKG2D ligands (MICA/B) [196] and development of IFNJ insensitivity [174] produce 
reduced immunogenicity. Kaplan et al demonstrated that 25% of lung adenocarcinoma 
cell lines were unresponsive to IFNJ due to absence or dysfunction of components in the 
IFNJ pathway [174]. Cellular changes can also prevent immune-mediated cellular 
destruction, for example, through defects in the TRAIL pathway [205]. 
Improved understanding of immune elimination of tumour cells may enable augmentation 
RI D SDWLHQW¶V QDWXUDO LPPXQH UHVSRQVe to stimulate tumour rejection. Further 
understanding of the escape phase, in terms of the specific mechanisms tumours employ 
to evade the immune system, will allow strategies to be developed which unmask tumour 
immunogenicity and thereby re-sensitise tumours to immune attack. 
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1.3.5.2 Immunoediting in ovarian cancer 
 
The vast amount of evidence pertaining to immunoediting originates from mouse models. 
However, evidence does exist to illustrate the effects of the immune system on humans 
and   particularly in ovarian cancer. NK cells are sparsely seen in ovarian cancers, with 
activity been significantly reduced in comparison to normal ovaries [218, 219]. A reduction 
in NK activity in peripheral blood was seen to correlate with disease progression, [218] 
and reduced  function of NK cells has been demonstrated in tumour-associated 
lymphocytes (TALs) obtained from the ascitic fluid of patients with advanced ovarian 
cancer [220]. These NK cells had reduced IL2 induced proliferation and reduced secretion 
of IFNJ [220]. 
Tumour associated macrophages (TAMs) are found in abundance in ovarian cancers with 
some evidence suggesting they may actually promote tumour growth [221]. This may be 
due to the release of cytokines by TAMs which result in inhibition of tumour-specific 
effector T-cells [222], although this has not been associated with prognosis [223].  
With regard to the adaptive immune system, Zhang et al studied 186 advanced ovarian 
carcinomas and demonstrated a favourable clinical outcome with the presence of CD3+ 
TILs [197]. TILs were present in significant numbers in 55% of tumours, with associated 
elevated levels of IFNJ and IL2 (a T-cell growth factor), suggesting a functionally active 
infiltration. Patients with TILs had a 38% 5 year survival compared to only 4% in those 
without, this was independently prognostic [197]. There was an association between 
presence of TILs and the likelihood of optimal surgical debulking, suggesting that 
spontaneous anti-tumour immune responses may restrict infiltrative tumour growth [197]. 
These findings were recently supported by Tomsova et al, however, they distinguished 
between stromal and epithelial TILs and found that only intraepithelial TILs were an 
independent predictor of survival [224]. In addition, an inverse relationship has been 
GHPRQVWUDWHGEHWZHHQȖį7-cells and prognosis in 95 advanced ovarian cancers, thereby 
supporting the immunosuppressive effects of these cells [158]. 
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In late stage ovarian cancer Woo et al demonstrated an increased percentage of Tregs. 
This was associated with low levels of IL-2, IFNJ and TNFE [225]. Other workers have 
illustrated an inverse correlation between tumour infiltrating Tregs and overall survival 
independent of stage or extent of debulking surgery [226]. Wolf et al, using FOXP3 as a 
marker of Treg expression, also found them to be a negative prognostic factor [227]. Sato 
et al examined the relationship between levels of Tregs and cytotoxic (CD8+) cells. A high 
CD8+:Treg ratio was associated with a 70% reduction in mortality, suggesting a close 
relationship between immune cytotoxic activity and Tregs in ovarian cancer [228]. 
When considering these data, and the aforementioned evidence from mouse models, it 
appears that ovarian cancer is immunogenic mediating both cellular and humoral 
responses from the adaptive and innate systems. The influence of these cells, and 
associated cytokines, on prognosis and tumour behaviour suggests that the interaction 
and manipulation of the immune system by ovarian cancer, i.e. immunoediting, appears to 
be a genuine phenomenon.  
1.3.6 Immunotherapy in ovarian cancer 
 
The origin of cancer immunotherapy can be traced back to William Coley who, in the 
1890s, observed that bacterial infection adjacent to a partly resected tumour could induce 
an effective anti-tumour response [229]. 
Cancer immunotherapies, or cancer vaccines, are terms used for harnessing the immune 
system in the targeting of cancer cells for antigen specific elimination. This encompasses 
a variety of strategies from prophylactic to therapeutic vaccines with active and passive 
immune responses. Passive immunotherapy is based on transfer of ex-vivo activated 
immune cells, immuno-modulators (e.g. IFNJ) or monoclonal antibodies. These strategies 
do not generate an immunological memory and hence the duration of their effect is 
limited. Active immunotherapy is aimed at activating the patient¶s own immune system 
against tumour antigens, which has the advantage of producing immunological memory 
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with potentially longer lasting effects. The majority of trials have so far centred on passive 
techniques and in particular the use of monoclonal antibodies [230]. 
The major challenge in developing successful therapeutic vaccines includes the following: 
(i) the identification of suitable tumour-associated antigens (TAAs) with tissue-specific 
expression, (ii) the development of strategies to induce an immunological response 
sufficient to eliminate the tumour cells and (iii) the development of techniques to overcome 
the immuno-evasive mechanisms inherent in tumour biology. 
1.3.6.1 Monoclonal antibodies 
 
Monoclonal antibodies (mAb) are increasingly used to target various pathways involved in 
oncogenesis including growth factor inhibitors and anti-angiogenic factors. Whist some 
mAb such a herceptin (trastuzumab) have become established treatments in breast 
cancer, the role of mAb in ovarian cancer is less clear [231]. 
In ovarian cancer the most extensively studied mAb relating to growth factor pathways are 
Erb1 (EGFR) and Erb2 (Her2). Since 20 - 30% of ovarian cancers are reported to 
overexpress Her2, trastuzumab, a mAb against Her2, was evaluated. This had a very 
limited clinical response rate of 7%. This was especially disappointing as only tumours 
with moderate to high immunohistochemical expression of Her2 were included, which 
accounted for less than 10% of all tumours assessed [232]. There are other Her2 mAb 
trials ongoing using different drugs, the results of which are hoped to provide improved 
efficacy. 
TRM-1 is a TRAIL-R1 agonist mAb which is able to activate apoptosis through the TRAIL 
pathway. It appears to be active as a single agent in addition to potentiating the effects of 
established chemotherapy agents such as cisplatin and paclitaxel.  The studies, however,  
are all at phase I stage at present [233]. 
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1.3.6.2 Adoptive T-cell transfer 
 
Adoptive cellular therapy is a novel approach to passive immunotherapy through the use 
of gene-modified autologous T-cells. Kershaw et al, in a recent phase I study, used 
modified T-cells, with reactivity against the alpha-folate receptor, a TAA of ovarian cancer. 
The results were disappointing with no effect on tumour load and a rapid decline in the T-
cell population after 48 hours [234]. Further studies involving T cells with reactivity to WT-
1, another ovarian TAA, are ongoing. There remains much interest in the use of adoptive 
T-cells although strategies need to incorporate techniques to prolong T-cell persistence. 
1.3.6.3 Immuno-modulators 
 
Various immunological cytokines have been investigated in the treatment of ovarian 
cancer. IFNJ is the most extensively researched. The potent anti-tumour effects seen in 
vitro led to its introduction into a phase II trial with the then standard chemotherapeutic 
regime of cisplatin and cyclophosphamide. Patients with advanced ovarian cancer, 
demonstrated improved PFS [235, 236]. However, when repeating the trial with modern 
chemotherapeutic agents (carboplatin and taxol) OS was reduced in the IFNJ arm and the 
trial was abandoned [237]. Potential explanations include a reduction in the dose of 
standard chemotherapeutic agents in the IFNJ arm due to treatment toxicities, or 
potentially the role of longer term IFNJ administration on the proliferation of Tregs with 
subsequent immunosuppressive effects [238]. Therefore the role of IFNJ in ovarian cancer 
is yet to be established. 
1.3.6.4 Active vaccination 
 
Active vaccines can include peptides, whole proteins or tumour cell lysates, with the 
principle of these strategies being to challenge the immune system with TAAs processed 
by APCs. The processed antigens are then presented to CD8+/CD4+ TCRs in conjunction 
with HLA class I/II to mediate CD8+ lysis. The TAAs used in vaccines are classified 
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according to the mechanism of action, for example mutational antigens refer to altered 
forms of a protein occurring in cancer cells, e.g. caspase-8 [239] and p53 [240]; 
amplification antigens refer to altered levels of a protein occurring, e.g. Her2/neu [241].  
An example of a current vaccination strategy used in ovarian cancer is Oregovomab.  This 
is a murine monoclonal antibody which binds with high affinity to circulating Ca-125. The 
Ca-125:antibody complex is processed by APCs, such as macrophages and DCs, which 
produce an adaptive immune response with production of antigen-specific antibodies. This 
is an example of an ³DQWLERG\ DV DQWLJHQ´ VWUDWHJ\ [242]. Oregovomab has been 
associated with improved overall survival in phase II trials in recurrent ovarian cancer 
[243, 244]. In a placebo controlled RCT of patients in clinical remission from advanced 
ovarian cancer, Oregovomab was used as a maintenance treatment. Overall, this failed to 
demonstrate prolonged remission [245]. Subgroup analysis, however, revealed that 
patients with optimal surgical resection, prior to maintenance with Oregovomab, did show 
improved OS. This is the basis for a subsequent trial investigating this subgroup of 
patients (IMPACT) [245].  
1.3.6.5 Subverting immune escape mechanisms 
 
In spite of developing activated tumour specific T-cells and immuno-modulators, these 
techniques may fail to exert their effector function due to an immunosuppressive tumour 
microenvironment [230]. Several approaches are being investigated to modify this 
environment through the use of immuno-stimulatory compounds. Indoleamine 2,3-
dioxygenase (IDO) is an important enzyme which can contribute to tumour tolerance via 
the inactivation of T-cell effector functions and the development of Tregs [246]. IDO has 
been shown to be produced by tumour cells [247]. Concomitant inhibition of IDO during 
vaccination may therefore improve T-cell activation. 1-methyl-tryptophan inhibits IDO and 
has shown some benefits when used with chemotherapeutic agents that have an immune 
cell activating function such as paclitaxel [248]. Similar inhibitors to PGE2, VEGF and 
 58 
TGF-E, all of whom have immunosuppressive effects in the tumour microenvironment, are 
being investigated. 
A second axis to reduce immunosuppression in tumours is to eliminate intratumoural 
Tregs. This may be possible through monoclonal antibodies to CD25, which are 
predominantly expressed in Tregs [249]. 
A combined approach to vaccination with standard chemotherapeutic agents may have 
some merit, since chemotherapy produces tissue necrosis with release of immune 
activators which facilitate tumour antigen presentation to cancer vaccines. In addition, 
chemotherapy has been shown to preferentially eliminate and inactivate Tregs. This has 
been demonstrated with cyclophosphamide, producing immuno-stimulation which could 
be coupled effectively with a cancer vaccine [250]. 
Low dose radiation has been shown to induce upregulation of MHC class I expression and 
may improve tumour antigen presentation [251].  Therefore coupling of immunotherapy 
with radiation and/ or chemotherapy may be beneficial.  
1.3.7 Prognosis 
 
The prognosis of patients with ovarian cancer is related to a number of established clinical 
variables. In addition there are novel molecular, histological and serum parameters 
presented as useful makers of tumour behaviour which can assist in our understanding of 
carcinogenesis and may be of use clinically in the planning and development of future 
treatments. 
1.3.7.1 Established prognostic parameters 
 
Age, as with most cancers, predicts survival, with worsening prognosis with increasing 
age. Even adjusting for stage, patients younger than 50 years have a 5 year survival of 
40% compared with about 15% for those older than 50 years [5]. This is likely to reflect 
numerous factors which are coupled to age such as co-morbidities and general health. 
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Stage represents the strongest prognostic indictor in ovarian cancer (Figure 1.7). 
Typically, 5 year survival for fully staged patients with stage I disease is 76 - 93%, 
depending on tumour grade. For stage II 5 year survival is  60 - 74%, for stage IIIA 41%, 
for stage IIIB and C 25%, and for stage IV 11% (Figure 1.8) [5]. 
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Figure 1.7 Survival of patients with epithelial ovarian cancer by stage [252]. 
 
The grade of a tumour correlates with survival especially in early stage where grade I 
tumours have a 5 year survival of 91% compared to approximately 75% for grades II and 
III.  Similar differences occur in more advanced disease but to a lesser degree [5]. 
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Figure 1.8 Survival of patients with epithelial ovarian cancer by substage. Adapted from 
Heintz et al [113]. 
 
As previously discussed the amount of residual tumour following surgery represents a 
significant independent prognostic variable.  This has produced fervent debate with regard 
to surgical approaches for ovarian cancer. 
There has been a slight improvement in prognosis in recent years, which is thought to 
reflect the introduction of platinum-based chemotherapy. Overall the 5 year survival for 
women with ovarian cancer remains poor at approximately 30% [113]. 
1.3.7.2 Novel prognostic markers 
 
Ovarian cancer is a heterogeneous disease and therefore the use of various clinical and 
pathological markers which can predict the behaviour of an individual tumour is very 
useful. Biomarkers can be either prognostic (relating to survival) or predictive (relating to 
tumour behaviour other than survival, e.g. response to chemotherapy). They allow a 
clinician to provide patients with information on the likely outcome of their disease. This 
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enables patients and relatives to prepare psychologically, financially and practically for the 
future. It also allows planning of treatment resources and enables meaningful 
comparisons to be made between different groups of patients after correcting for 
confounding prognostic variables. Furthermore, applying equal stratification of known 
prognostic factors within experimental arms of a clinical trial allows the effect of the 
intervention to be independently assessed. 
Since there are clear advantages to accurately predicting prognosis, novel markers are 
constantly being sought. New independent markers are those which predict outcome and 
which are not dependent on an association with an established prognostic factor. As these 
factors add prognostic information, and are not surrogates for known factors, they also 
imply causation. Discovering a molecular marker with independent prognostic or 
predictive power may therefore reveal the importance of a particular intracellular process 
and identify a target to which novel therapy can be developed. For a prognostic marker to 
become clinically useful it must be reproducible, add additional value to current markers 
and have biological plausibility with regard to carcinogenesis [11]. Most biomarkers are 
derived from analysis of serum or tissue and are related to one of the aspects key 
hallmarks of carcinogenesis [253]. 
1.3.7.3 Serum biomarkers 
 
Ca-125 is the most studied tumour marker in ovarian cancer; however, its usefulness is 
controversial. Some studies suggest that elevated preoperative Ca-125 in stage I disease 
gives a relative risk of dying of disease of 6.37 [254]. Low postoperative Ca-125 following 
optimal debulking may be independently predictive of prognosis. In addition, variations in 
the kinetics of the Ca-125 response during chemotherapy may also be prognostic. 
Low preoperative haemoglobin and high platelet count are associated with poor 
prognosis. These parameters have been successfully used in a trial setting to produce a 
normogram which accurately predicts both PFS and OS [255]. 
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Tumour cells release pro-coagulant and fibrinolytic factors which result in fibrin split 
products (D Dimers). There is some evidence that raised D Dimers may predict poor 
prognosis, although associations with occult thromboembolism may play a role [12]. 
1.3.7.4 Tissue biomarkers 
 
Cell cycle and apoptosis regulatory proteins, which play an obvious role in tumour biology, 
have been highlighted as potential biomarkers including p27, p21, p53, cyclin D and E 
which are discussed elsewhere. 
Elevated expression of pro-apoptotic protein bax has been demonstrated to be 
independently predictive of chemosensitivity and prolonged survival in advanced ovarian 
cancer. In contrast Bcl-XL, an anti-apoptotic protein, is related to chemoresistance and 
poor prognosis, although is not independent [12]. 
Growth factor receptors, such as EGFR and Her-2/neu, have also been shown to be 
overexpressed in ovarian cancer.  Various studies have related overexpression with poor 
prognosis [256]. 
Tissue matrix metalloproteinases (MMP) represent a large group of zinc- and calcium- 
dependent proteolytic enzymes which are capable of degrading most constituents of the 
extracellular matrix. As such, they are associated with metastatic potential in tumours. 
Various studies illustrate a negative effect on survival with high expression of MMPs [12]. 
1.3.8 Exploring novel prognostic marker and tissue  microarrays 
 
Molecular markers may be found in bodily fluids (e.g. urine and serum), cell lines or 
cancer tissue. Cancer induces molecular change in genes which can be detected at 
through alterations in DNA, RNA or protein expression.  
The classical starting point for detection of aberrant pathways in carcinogenesis is at the 
genome level. However, not all genetic defects result in changes at a protein level, the 
level which is required to exert a biological effect. Therefore, it is often more practical to 
detect abnormal protein expression, from which genetic abnormalities can be sought. 
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Immunohistochemistry (IHC) is a commonly used tool for assessing protein expression. 
Over recent years a high throughput platform has been developed to enable rapid and 
consistent analysis of tissue immunohistochemically.  This technique is called Tissue 
Micro Array (TMA) [257]. 
Traditionally IHC studies relied on staining whole sections of tissue, which was labour 
intensive and time consuming when analysing large numbers of samples. In addition, 
since only a limited number of slides could be processed at any one time, multiple IHC 
runs were needed. This could produce considerable variation in the experimental 
conditions, and may introduce inconsistencies in analysis. Studies in which large numbers 
of samples were used proved inefficient with high reagent cost and the consumption of 
large amounts of archived tissue. 
To address these drawbacks the concept of transferring small samples of many tissue 
blocks into a single block was explored, and a number of techniques have been 
attempted. The most recent technique was developed by Konnen et al who described the 
use of a custom built instrument, called a Tissue Microarrayer, which produced 0.6mm 
wide cylindrical tissue cores from archived blocks which could be transferred to holes 
precisely punched out in a recipient paraffin block [257]. 
TMA methods reduce reagent costs, variability of experimental conditions and is more 
time efficient [257]. The use of TMAs in ovarian cancer was validated by Rosen who 
stained six copies of a TMA containing 45 ovarian cancers for ER, Ki-67 and mutant p53. 
There was a high concordance of protein expression between the whole tissue sections 
(used as the gold standard) and the TMA cores [258]. 
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1.4 Aims 
 
There is intense interest in defining prognostic markers which would provide both the 
physician and the patient with more accurate assessments of likely tumour behaviour. In 
addition, new prognostic markers can be signposts towards potential targets for molecular 
therapies, as well as allowing tailoring of established treatments based on the likelihood of 
effect. This thesis is based on defining the potential effects of immune and angiogenic 
pathways on ovarian cancer through assessment of the relationship between specific 
biomarkers and ovarian cancer behaviour. The prognostic significance of these 
biomarkers will hopefully allow greater selectivity of treatment and indicate abnormalities 
within tumour metabolism which could be targets for novel therapeutic agents. 
 
Immunohistochemistry is a commonly used tool for assessing protein expression, and in 
particular prognostic markers. This thesis utilised advances in the technology surrounding 
IHC by using the TMA. The TMA represents a high throughput platform for IHC which 
reduces reagent costs, amount of tissue required, variability of experimental conditions 
and is more time efficient when compared with traditional techniques [257]. The TMA with 
coupled database had been previously validated [259]. 
 
There is a large weight of evidence illustrating the considerable influence of the immune 
system on tumour development and progression, especially the need for tumours to 
develop mechanisms to evade immune attack. These mechanisms are not clear, hence, 
studying the expression of elements within the IFNJ pathway (the pathway which is 
predominantly involved in the anti-tumour activity of the immune system), may provide an 
insight into immune evasion in ovarian cancer. By assessing immunohistochemically the 
expression of IFNGR1, STAT1, p27 and caspase 1 in relation to clinicopathological 
features, particularly prognosis, has allowed us to test the hypothesis that defects within 
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this pathway will lead to a poorer prognosis. Patients expressing an intact IFNJ pathway 
should benefit from IFNJ therapy. 
The TNFD super-family represents an apoptotic pathway related to tumour cell killing; 
TRAIL is one of the ligands in the pathway [260]. The evidence of dysregulation of TRAIL 
both in tumour development and in tumour resistance to chemotherapy, as well as in its 
potential therapeutic role, provides an interesting avenue of investigation using the 
ovarian cancer TMA. The hypothesis follows that tumours with low expression of DR4 and 
DR5 (TRAIL receptors) would be less prone to TRAIL mediated-attack and therefore 
apoptosis. This would be reflected in reduced patient survival. If this proved correct these 
patients would be ideal for TRAIL ligand or anti-TRAIL mab therapy.  
 
Angiogenesis has been established as a vital component among the mechanisms 
involved in tumour growth and metastasis [261, 262]. VEGF-A is the most extensively 
researched angiogenic protein. Previous research has produced inconsistent evidence 
with regard to the importance of VEGF in ovarian cancer and its relation to prognosis. The 
hypothesis was that tumours with high expression of VEGF would have extensive 
angiogenesis and a poor prognosis. If this proved correct they would be ideal candidates 
for bevacizumab therapy. 
 66 
2 Materials and Methods 
2.1 Ovarian Cancer Tissue Microarray 
2.1.1 Tissue microarray construction 
 
An overview of the steps involved in producing a TMA is outlined in Figure 2.1. Firstly, 
potential cases were identified from a prospectively maintained clinical database (Figure 
2.2). The original pathology reports from potential cases were reviewed, following which 
archival tissue for each case was then assessed contemporaneously by a gynaecological 
pathologist. This enabled identification of representative tissue biopsy sites as well as 
exclusion of inappropriate cases, for example, metastatic disease from other sites (Figure 
2.3). Tissue cores were then physically extracted from the appropriate blocks at sites 
determined from the previously stained haematoxylin and eosin (H & E) stained sections. 
This was performed using the Beecher Instruments Manual Tissue Microarrayer. The 
donor cores were inserted into the recipient tissue array blocks in a grid pattern (Figure 
2.4 and Figure 2.5). A meticulous record of the positioning of the tissue from each tumour 
was produced (Figure 2.6). The final TMA blocks were then sectioned (5Pm) and mounted 
on microscope slides in preparation for immunohistochemical analysis (Figure 2.7).  
The cases included were recruited from those patients diagnosed with ovarian cancer 
between 1st January 1982 and 31st December 1997. The cohort of cases considered for 
inclusion numbered 424 after initial exclusions had been made. It was possible to find 
pathology reports for 403. Following contemporaneous review further cases were 
excluded due to lack of availability of suitable tissue, or the cases not representing ovarian 
cancer e.g. borderline tumours. Ultimately, tissue cores from a total of 339 surgically 
treated primary ovarian cancers were represented in four TMA blocks with two 
representative cores from each case being used to construct two copies of the TMA 
(Figure 2.2). 
Initial validation and assessment of the TMA has been performed by Rolland and Deen 
[259]. The use of CK7, CK20, CEA and Ca-125 were used to confirm that expression of 
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these proteins was consistent with established patterns seen in previous studies. This 
work confirmed that the TMA was capable of being used for immunohistochemical 
analysis and that the pattern of expression of these commonly studied proteins was 
consistent with established parameters [259]. 
 Five copies of the TMA were available for analysis; however, only two copies were used 
for immunohistochemical assessment of the various markers. Previous work has identified 
that the accuracy of assessment of a biomarker is high when assessing two copies of a 
TMA, i.e. two samples from each tumour. The assessment of more copies failed to 
improve accuracy significantly [258]. In addition, the cost of reagents and limiting tissue 
wastage had to be considered. Conversely, the loss of tumour cores needed to be 
accounted for, which tended to occur during the antigen retrieval process. Previous work 
using the current TMA suggested that the rate of loss was 8 - 10%.  This compares to 
rates of 2 - 25% in other studies [258]. Overall, using two copies of the TMA allowed 
efficient use of tissue and reagents, whilst maintaining accurate assessment of protein 
expression. 
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Figure 2.1 A schematic of the current mechanism of tissue microarray construction. An 
arraying device is used to obtain a core biopsy from a tissue block at a location of interest 
defined by previous examination of a stained section. The core is then transferred from the 
donor block to the recipient block, where it is placed, by gentle pressure on the stylus, into a 
pre-made hole at a specific location. Once the recipient block is completely filled (as 
determined by the design of the individual array), it is sectioned to reveal 0.6 mm diameter 
circles of tissue from each case. The array sections may be visualised by all methods used 
for conventional formalin-fixed, paraffin-embedded tissue sections. Figure adapted from 
Rimm et al [263]. 
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Figure 2.2 A schematic displaying the excluded cases. The study numbers were allocated 
before the database had been audited for duplicate cases and too many were issued, hence 
30 duplicate cases. Borderline tumours were erroneously included on the first array block 
EXWVXEVHTXHQWO\H[FOXGHG7KHUHZHUHRWKHUUHDVRQVZK\FDVHVZHUHQ¶WLQFOXGHGLQWKHILQDO
array following their histopathological review. Two cases were accidentally arrayed twice. 
Despite the complex logistics, 339 individual cases of primary ovarian cancer treated 
surgically were represented on the four final array blocks from the investigated cohort of 441 
presenting between 1982 and 1997 at DCGH. Diagram from previous thesis, Rolland [259]. 
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Figure 2.3 Identification of representative areas to include on the array. H&E sections. 
Sections of these blocks were reviewed, typed and graded by a pathologist with extensive 
experience in gynaecological oncology. The most representative areas on the H&E slides 
were marked [259]. 
 
 
 
Figure 2.4 Identification of representative areas to sample. Marking the blocks. Using the 
H&E slides, the corresponding representative blocks identified were selected. The marker 
dots from the H&E slides were transferred onto the blocks to mark the area for extraction by 
the microarrayer [259]. 
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Figure 2.5 The Beecher tissue microarrayer [259]. 
(A) Positioning of a recipient block beneath the tissue microarrayer turret. A tissue core is 
accurately removed at the position highlighted by the marker points precisely sampled and 
then transferred using a needle punch (N) mounted on a swinging turret (T) from the donor to 
the recipient block (R). The turret moves upwards and downwards, allowing the needles 
maneuverability in the Z axis, ensuring that a correct depth of sample is transferred.  
(B) The perpendicular orientation of the micrometers is illustrated (M). These alter the 
alignment of the turret and needle punch in precise increments. This enables each sample to 
be accurately placed close to adjacent tumour cores in the X and Y axes to produce rows 
and columns of tumours which are readily identified using a grid. 
 
Figure 2.6 An example of a TMA grid used for scoring of tumour cores. The numbers 
correspond to an individual tumour. K represents the position of a section of kidney tissue, 
which was used to aid orientation of the microscope slide with the TMA grid.  
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Figure 2.7 A final recipient TMA block. Once the all the donor cores were inserted, the block 
was heated for 10-15 minutes at 37°C and the surface leveled using a glass microscope slide. 
The TMA block was then ready to be sectioned using a standard microtome [259]. 
2.1.2 Clinicopathological aspects of the tissue microarray 
2.1.2.1 Age 
 
The age of the patients at diagnosis was available for all but one patient with a range of 
24 - 90 years. The age distribution was compared with data produced from a large 
epidemiological study by SEER [10] (Table 2.1). This illustrates that the age distribution of 
patients within the TMA dataset was comparable with a typical ovarian cancer population. 
The age of a patient is known to be a prognostic factor in a number of diseases, and this 
appears to be the case with the patients included in the TMA. On testing the data in SEER 
categories, increasing age was seen to be associated with reduced survival although in 
this form it was not an independent prognostic factor (Table 2.2) (Figure 2.8).This is 
consistent with another group¶V findings [5]. However, when age was assessed in its 
continuous form, age did exert independent prognostic power (Table 2.3). This finding is 
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again consistent with the work of others and further supports the validity of the dataset 
contained within the TMA [6]. Since there was an apparent independent contribution of 
age (as a continuous variable) with prognosis, it was included in the Cox model for 
assessment of the various molecular markers in the thesis. 
Table 2.1 The age distribution of patients in the ovarian TMA database when categorised and 
compared according to the Surveillance, Epidemiology and End Results (SEER) programme 
of the National Cancer Institute. 
Age Categories 
Years 
Cases in SEER 
series (n) 
Cases in SEER 
Series (%) 
Cases in TMA 
database (n) 
Cases TMA 
database (%) 
 783 4 1 <1 
30-59 9690 43 135 40 
 11905 53 202 60 
     
Total 22378 100 338 100 
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Figure 2.8 A Kaplan Meier plot of age within the Ovarian TMA database when reclassified into 
the categories used in reporting the SEER data. A statistically significant worsening of 
survival is seen with advancing age. Log rank= 15.85, p<0.001. Note that age <30 years at 
diagnosis only has one data point and is therefore represented by a single point.
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Table 2.2 Cox multivariate analysis of independent prognostic factors and age data divided 
into SEER categories. In this model age was not an independent factor. 
Variable Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
 
  
FIGO Stage 
  
  I 1  
  II 2.424 (1.426-4.121)  
  III 4.621 (2.864-7.456)  
  IV 5.901 (3.394-10.261) <0.001 
 
  
Optimal Debulking 
  
  Yes 1  
  No 2.238 (1.600-3.131) <0.001 
 
  
Patient received 
Chemotherapy   
  No 1  
  Yes 0.441 (0.315-0.617) <0.001 
 
  
Age at diagnosis (years) 
SEER categories   
   1  
  30-59 2.070 (0.286-14.992) 0.471 
   3.242 (0.449-23.417) 0.244 
Table 2.3 Cox multivariate analysis of independently prognostic factors showing that age 
data as a continuous variable was an independent prognostic factor. 
Variable Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
 
  
FIGO Stage 
  
  I 1  
  II 2.567 (1.503-4.383)  
  III 4.719 (2.914-7.643)  
  IV 6.562 (3.737-11.523) <0.001 
 
  
Optimal Debulking 
  
  Yes 1  
  No 2.131 (1.519-2.991) <0.001 
 
  
Patient received 
Chemotherapy   
  No 1  
  Yes 0.437 (0.312-0.613) <0.001 
 
  
Age at diagnosis (years) 
Continuous data 1.024 (1.014-1.035) <0.001 
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2.1.2.2 Pathology 
 
The 339 cases included in the TMA were mostly epithelial ovarian cancer (98.5%), which 
is above the 90% normally seen in unselected series [264]. This probably reflects the 
referral of the rarer subtypes from DCGH to a supra-regional centre.  With the exception 
of the low rates of non-epithelial cancers, the breakdown of histological type was 
otherwise typical (Table 2.4). 
In line with the published frequencies, represented in parenthesises, 52% of the cases 
were of the serous subtype (40-50%), 12% were endometrioid (12-18%), 10% were 
mucinous (9-15%), 7% were clear cell (4-6%), and 16% were undifferentiated (5-25%) [5, 
10]. Borderline ovarian cancers made up 8% of all cases reviewed (up to 15%) [84]. 
This series was more likely to have cases with higher grade disease (66%) than generally 
reported (47%) [5]. This may be a true difference but is more likely to reflect the well 
documented difficulty in objectively reproducing the commonly used grading systems for 
all histological types between observers [265]. There is also variation in how ovarian 
cancers are graded by individual pathologists.  Some workers alter their grading system 
depending on the histological type [266], others grade all subtypes with standard grading 
systems such as the WHO classification [62] or FIGO [264]. Therefore, due to the 
inconsistencies in grading of ovarian cancers, it is difficult to draw any meaningful 
conclusions from comparisons with other studies. 
Tumour grade did appear to have prognostic significance on univariate analysis (Figure 
2.9). However, this was not maintained on multivariate analysis (Table 2.5).  This 
suggests that the impact of tumour grade on prognosis is dependent on other markers of 
tumour biology including stage and response to chemotherapy. Since tumour grade was 
not an independent prognostic marker, it was not included in the Cox model for assessing 
new markers. 
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Table 2.4 The distribution of histological subtypes and grades of tumours within the TMA. 
Histological type Number % of series (n=339) 
Epithelial 334 99 
  Serous 178 53 
  Serous papillary 21 6 
  Endometrioid 42 12 
  Mucinous 35 10 
  Undifferentiated 54 16 
  Clear cell 25 7 
 
Non-epithelial 5 
1 
  Yolk Sac 1 
  Teratoma 1 
  Granulosa 1 
  Mixed Mullarian 2 
 
Borderline cancers* 30/369 8 
 
Grade   
  Un-gradable** 2 1 
  Well differentiated (G1) 39 11 
  Moderately differentiated (G2) 73 22 
  Poorly differentiated (G3) 225 66 
* 30 borderline cases were excluded during the creation of the 339 sized series  
** 1 yolk sac tumour and 1 clear cell tumour were considered un-gradable 
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Figure 2.9 A Kaplan Meier plot of grade within the Ovarian TMA database. A statistically 
significant worsening of survival is seen with poorly differentiated (G3) compared to 
moderate and well differentiated (G1 and G2) tumours. Log rank= 13.23, p<0.001. 
Table 2.5 Cox multivariate analysis of independently prognostic factors showing that tumour 
grade was not an independent prognostic factor. 
Variable Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 
Continuous data 1.026 (1.015-1.038) <0.001 
 
  
FIGO Stage 
  
  I 1  
  II 2.434 (1.410-4.201)  
  III 4.662 (2.857-7.606)  
  IV 6.167 (3.486-10.910) <0.001 
 
  
Optimal Debulking 
  
  Yes 1  
  No 2.031 (1.442-2.861) <0.001 
 
  
Patient received 
Chemotherapy   
  No 1  
  Yes 0.440 (0.313-0.618) <0.001 
 
  
Histological grade 
  
  G1 1 0.258 
  G2 1.327 (0.820-2.149) 0.250 
  G3 1.425 (0.931-2.176) 0.101 
 
 78 
2.1.2.3 Stage 
 
Data was available for 330 of the 339 cases, with the classical distribution of cases 
according to stage being seen. The majority of cases presented at an advanced stage 
with 63% being stage III or IV (Figure 2.10) (Table 2.6). These frequencies are consistent 
with those of other contemporaneous cohorts [3, 5, 10, 81-83].  Using the F2 test no 
association between stage and age was revealed (in SEER categories), although 
worsening grade was associated with a more advanced tumour stage (13.55, p= 0.035).  
Not surprisingly there was a significant association between stage and survival both in 
univariate and multivariate analysis (Table 2.7 and Figure 2.11). This aids to validate both 
the survival and stage data [5]. Since stage was clearly an independent prognostic factor 
LWZDVLQFOXGHGLQ&R[¶VPRGHOVIRUDVVHVVPHQWRIRWKer markers. 
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Figure 2.10 A histogram demonstrating the distribution of cases within the FIGO stage 
groupings. 
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Table 2.6 The distribution and survival of cases divided according to FIGO stage. 
FIGO stage Cases- n (%) Mean survival (months) 
Median 
survival 
(months) 
5-year overall 
survival (%) 
I 85 (26) 129.4 137.6 60 
II 37 (11) 79.3 40.7 38 
III 168 (51) 26.3 13.0 10 
IV 40 (12) 15.4 7.3 5 
Missing data 9     
Total 330    
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Figure 2.11 A Kaplan Meier plot of stage within the Ovarian TMA database. A statistically 
significant worsening of survival is seen with increasing stage. Log rank= 114.24, p<0.0001. 
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Table 2.7 Cox multivariate analysis of independently prognostic factors showing that tumour 
stage was an independent prognostic factor. 
Variable Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
 
  
Age at diagnosis (years) 
Continuous data 1.026 (1.013-1.036) <0.001 
 
  
Optimal Debulking 
  
  Yes 1  
  No 1.996 (1.419-2.807) <0.001 
 
  
Patient received 
Chemotherapy   
  No 1  
  Yes 0.437 (0.311-0.614) <0.001 
 
  
FIGO Stage 
  
  I 1 <0.001 
  II 2.463 (1.428-4.247) 0.001 
  III 4.868 (2.979-7.956) <0.001 
  IV 6.545 (3.706-11.559) <0.001 
2.1.2.4 Surgery 
 
There were 13 cases in which information regarding cytoreduction was unavailable. Of   
those remaining, 130 (40%) had no macroscopic disease after surgery (optimally 
debulked), 89 (27%) had tumour deposits of less than 2cm and 107 (33%) had deposits of 
greater than 2cm. Overall survival was better in patents who were optimally debulked 
compared with the two other groups (Figure 2.12). This relationship was still apparent 
when cases with any macroscopic disease were compared with no macroscopic disease 
(Figure 2.12). These relationships were seen to be independently prognostic in the Cox 
model (Table 2.8). 
The proportion of cases debulked to <2cm in the literature range from 36 - 87% [5, 63, 97] 
and those with no visible macroscopic disease from 15 ± 85% [5, 109, 110]. This series 
data were well within these ranges, therefore further supporting its consistency. Optimal 
debulking by either standard is an accepted independent prognostic factor, which was 
found to be the case in this series, again validating the dataset. Most recent literature 
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defines optimal debulking as no macroscopic disease. Therefore, this simpler definition of 
optimal debulking was used when including debulking status in subsequent survival 
analyses. 
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Figure 2.12 A Kaplan Meier plot of the degree of surgical debulking with survival in the 
Ovarian TMA database. (A) Illustrates survival when categorised into three groups. This 
demonstrated significant reduction in survival with increasing volumes of residual disease. 
Log rank= 130.11, p<0.0001. (B) Categorised into two groups. This illustrates statistically 
significant worsening of survival with any macroscopic disease. Log rank= 107.41, p<0.0001. 
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Table 2.8 Cox multivariate analysis of independently prognostic factors showing that 
residual disease after surgery when separated into two or three groups was an independent 
prognostic factor. 
Variable Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 
Continuous data 1.023 (1.012-1.034) <0.001 
 
  
FIGO Stage 
  
  I 1  
  II 2.579 (1.489-4.465)  
  III 4.795 (2.913-7.892)  
  IV 6.210 (3.480-11.079) <0.001 
 
  
Patient received Chemotherapy 
  
  No 1  
  Yes 0.426 (0.303-0.601) <0.001 
 
  
Residual disease (3 groups) 
  
  No macroscopic disease 1  
  Macroscopic disease (<2cm) 1.675 (1.154-2.432) 0.007 
  Macroscopic disease (>2cm) 2.555 (1.743-3.748) <0.001 
 
  
Residual disease (2 groups) 
  
  No macroscopic disease 1  
  Macroscopic disease 1.996 (1.419-2.807) <0.001 
2.1.2.5 Survival 
 
All survival rates were calculated from the date of surgery to the date of death, and these 
were compared to histology reports to ensure accuracy. Data were 100% complete. 
Patients were followed up according to a local protocol, three monthly for two years, 6 
monthly for 5 years and thereafter annually and indefinitely. The date of latest follow up 
was recorded in the database to facilitate calculation of latest known survival date. Data 
were available for 336 cases (99% complete). Data concerning date of death were also 
available for 99% of cases.  Using this data, patient survival status was coded as 0 (alive) 
or 1 (dead). When the database was locked on 31st November 2005, 57 (17%) of patients 
were still alive. The precise cause of death was not specifically recorded but anecdotally 
the majority died of related causes with only four women known to have died from causes 
not attributable to ovarian cancer. 
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The data concerning date of diagnosis, latest follow-up, date of death and survival status 
were used to generate crude overall survival (OS) data with 1 year and 5 year survival 
rates. There were three instances of missing data (99% complete). 24 patients (7%) died 
within a 30 day period following surgery. OS ranged from 0 ± 271 months with a mean OS 
of 60.5 months (95% CI 50.6 ± 70.44) and median OS of 19.5 months (95% CI 15.5 ± 
23.5). The crude one year OS was 63.7% and the corresponding five year measurement 
25% (Figure 2.13). Mean, median and crude five year OS decreased in a stepwise 
manner within the FIGO stage categorisation with stage I cancer having a median OS of 
137.6 months and a five year OS of 60% whereas stage IV cancers had a median OS of 
7.3 months and a five year OS of 5% (Table 2.6). 
During the follow up period, which ranged up to 270 months, 83% of women died. The 
majority of these women are likely to have died from ovarian cancer, which was the 
anecdotal observation. However, the case fatality rate appears higher than expected 
given the established fatality rate of approximately 65% [267]. In spite of the higher than 
expected fatality rate, known associations with clinicopathological factors with accepted 
independent prognostic value was consistently reproduced in this series. Therefore, it was 
decided that although the fatality rate was high, the otherwise expected correlations with 
previous studies of ovarian cancer survival, allows for its valid use in assessing novel 
prognostic marker expression. In addition, as the markers assessed compared differences 
in survival within the tumour population, any confounding effects on survival would be 
equally attributable to all patients within the cohort. 
Reasons for this worse survival might include patient factors (older age group, worse 
performance status), tumour factors (above average number of high grade cases) and 
treatment factors (inadequate staging procedure, inadequate treatment, delays in 
diagnosis). Similar observations, suggesting that survival rates in the UK for 
gynaecological cancer were poor in comparison with other developed countries, has led to 
implementation of changes to the framework of cancer services. These improvements 
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have been coordinated through initiatives such as The NHS Cancer Plan [268] and The 
Cancer Reform Strategy [269].  
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Figure 2.13 A Kaplan Meier plot of overall survival in the Ovarian TMA database. Illustrating 
both one and five year survival of 65% and 25% respectively. 
2.2 Immunohistochemistry 
 
The principle method of investigation used during this work consisted of 
immunohistochemistry (IHC); a technique which utilises the specific interaction between 
antigens and antibodies to produce an accurate representation of the expression of a 
particular protein within tissue. This technique can be used on freshly frozen tissue or 
Formalin Fixed Paraffin Embedded (FFPE) tissue, which may have been stored for a 
number of years. FFPE tissue is known to produce stable conditions, which maintains 
tissue morphology for many years [270].  All the tissue used during this work was provided 
from archived FFPE. This study related to comparative differences in protein marker 
expression between tumours and how this altered prognosis. Therefore, as the aim was 
not to determine variations in relation to non-cancerous tissue, marker expression was not 
investigated in normal ovaries.  
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2.2.1 Processing of samples 
 
Following surgical removal, the tissue was usually fixed for 24 hours but longer for larger 
tissue specimens, in 10% NBF. The samples that were used originated from cases 
between 1982 and 1997, and therefore had been archived for between 6 and 23 years. 
Chemical fixation enables the preservation of tissue. However, due to cross linking of 
molecules within DNA, RNA and protein, alternations in molecular structure can occur. 
These bonds can only be disrupted by hydrolysis [271]. Cross linking of proteins has the 
advantage of stabilizing the antigens involved in IHC, however, these antigens may be 
hidden and result in reduced immunoreactivity [272]. 
The immunoreactivity of some tissue is seen to reduce with time. This is related to the 
techniques used in fixation and the tissue type. NBF was the fixation method employed on 
the tissue within this study, which has been shown to preserve antigenicity well [273].  
All the tissue used during the experiments including the TMA, whole sections of ovarian 
cancer and positive control tissue were cut into ȝm thick sections. These were mounted 
onto slides which were positively charged; this improved the adherence and reduced the 
risk of tissue loss during processing. The control tissue used was normally tonsil, which 
was known to express all the markers under investigation in the study. For assessment of 
each marker two copies of the TMA were used. This allowed efficient use of the study 
tissue whilst still maintaining accuracy approaching that of whole sections [258]. Whole 
sections of ovarian cancer from the study cohort we used to assess the pattern of staining 
of each marker prior to assessment of expression on the TMA. 
The tissue was embedded in paraffin wax which required removal prior to tissue 
processing. The slides were heated at 60ºC in an oven for 10 minutes to soften the 
paraffin. The slides were then placed in a xylene bath (stored in a fume cupboard) for 20 
minutes to dissolve the wax. Rehydratrion of the tissue was then achieved by immersing 
the slides in graded ethanol baths (100, 95 and 75%) for 10 seconds in each. 
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2.2.2 Antigen retrieval 
 
For tissue embedding the chemical fixation and heating of the tissue at 60OC leads to 
denaturing of the antigenic epitopes. Formalin fixation can lead to cross linking of 
unrelated proteins to the target antigen resulting in masking and ultimately reducing 
immunogenicity. To improve immunogenicity of the tissue, treatment with antigen retrieval 
solutions can be used, prior to application of the primary antibody [274]. Two antigen 
retrieval solutions were employed during this work, Citrate buffer at pH 6.0 or Ethylene 
Diami Tetracetic Acid (EDTA) at pH 8.0 - 9.0 (Table 2.9). An 800W microwave was used 
to heat the retrieval solution. 
2.2.3 Preventing non-specific binding 
 
IHC relies on primary antibodies binding to specific amino acid sequences to accurately 
locate a particular protein. Unfortunately, it is possible for antibodies to bind to unrelated 
proteins through hydrophobic interactions. This will lead to non-specific staining. Normal 
swine serum (NSS) was used to prevent this type of interaction occurring. NSS will mask 
the hydrophobic sites on the tissue, responsible for non specific binding, which would 
otherwise interfere with the specific interaction of the antibody and epitope.  
2.2.4 Primary antibody 
2.2.4.1 Selection 
 
The primary antibodies selected for IHC on FFPE tissue should be related to epitopes 
which are known to be active following the fixing and embedding process. Fortunately, in 
this work there were commercially available antibodies for all of the proteins studied. 
Commercially developed antibodies have a number of advantages; they have proven 
specificity, are available in sufficient quantities, and in general have been used in 
previously published work. 
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2.2.4.2 Titration 
 
The optimal working dilution for a specific antibody equates to the concentration at which 
consistent specific staining is produced with no or minimal background staining. The 
optimum antibody concentration will be affected by a number of variables including the 
fixation technique and storage method used on the tissue.  The time elapsed between 
sectioning and staining the tissue along with the antigen retrieval methods used will also 
influence the affinity of the antibody to the epitope. The age and storage conditions of the 
primary antibody and whether an avidin-biotin blocking step is performed may alter its 
activity [275].   
Clearly, due to the numerous factors which could potentially affect the concentration of 
primary antibody required to produce optimum staining, titration of the antibody is 
required.  The antibody concentration suggested by the manufacturer was used as a 
guide, and serial dilutions around this concentration were used to determine the optimum 
conditions. Occasionally, variation in the application time of the antibody provided 
improvements in the quality of staining, however, the majority of antibodies required 60 
minutes application. 
2.2.4.3 Negative control  
 
The negative control had all of the reagents applied to it with the exception of the primary 
antibody. This ensured that all staining of experimental tissue was produced by the 
specific interaction between the antibody and epitope. In place of the primary antibody, 
either NSS or an antibody of the same subclass and coding for non-human epitopes were 
used. 
2.2.5 Washing 
 
The slides were mounted onto Shandon cover plates and placed into Shandon 
6HTXHQ]DVOLGHUDFNVThis system utilises a capillary gap produced by holding the slide 
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and cover plate upright and apart by a fixed distance with reagents applied via a small 
reservoir above. This ensures that consistent volumes of reagents are incubated with 
each slide (Figure 2.14). 
Thorough washing of the sections between steps with Tris Buffered Saline (TBS) was 
essential.  This prevented both drying of the tissue sections and non-specific staining 
produced from interaction of residual reagents which had not bound to the target protein.  
 
 
Figure 2.14 7KH6KDQGRQFRYHUSODWH6HTXHQ]DV\VWHP 
2.2.6 Signal amplification 
 
The technique of IHC relies firstly on the ability of an antibody produced in another 
species (e.g. mouse, goat, rabbit) to recognise a human antigen. Secondly, the reaction of 
an oxidizing agent, such as HorseRadish Peroxidase (HRP), with a chemical which 
produces a colour change (chromogen) e.g. ¶-DiAminoBenzidine (DAB). 
Initially a direct method of antigen staining was used.  This involved an enzyme labelled 
µprimary antibody¶ which recognised the specific antigen within the tissue. The application 
of a substrate chromogen (i.e. a substrate which produces a coloured end product) reacts 
with the primary antibody to produce staining at sites on the tissue where the antibody has 
bound (Figure 2.15) [275]. 
The direct method has been widely replaced by a two step, or indirect method, which 
allows amplification of the signal, produced, and was used in this work.  This technique 
involved binding of the primary antibody to the tissue antigen as in the direct method, 
however, following this an enzyme labelled µsecondary antibody¶ is added. This secondary 
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antibody binds to the primary antibody (now the antigen). This can be at multiple sites and 
thus numerous secondary antibodies can bind to a single primary antibody producing an 
amplification effect (Figure 2.15) [275]. 
 
 
 
A B
 
Figure 2.15 Direct method: Enzyme labelled µprimary antibody¶ reacts with tissue antigen (A). 
Two step indirect method: Enzyme labelled µsecondary antibody¶ reacts with µprimary 
antibody¶ bound to tissue antigen (B). Figures adapted from Immunohistochemical Staining 
methods 3rd Ed. DAKO [275].  
 
Following the amplification of the secondary antibody, a further amplification in signal is 
achieved when applying the enzyme component.  This consists of a (strept)avidin-biotin-
enzyme complex (ABC), and exploits a phenomenon whereby one molecule of 
streptavidin, a protein produced in bacterium Streptomyces, can bind four molecules of 
biotin (vitamin B7). This enables streptavidin to bind to biotinylated antibodies, as well as 
biotin complexed with an enzyme, to react with a chromogen (Figure 2.16). HRP was the 
enzyme linked to the avidin-biotin complex, and when H[SRVHG WR WKHFKURPRJHQ¶-
diaminobenzidine (DAB), oxidises DAB to produce a brown substrate which can be seen 
during light microscopy [275]. 
The secondary antibody used is biotinylated; it is engineered to express multiple 
molecules of biotin, each able to bind avidin once. The following two reagents are then 
mixed and given at least 30 minutes to associDWHWKH\DUH³$´VWUHSWDYLGLQDQG³%´biotin 
complexed with HRP. When associated LQWR ³$%´ HDFK VWUHSWDYLGLQ PROHFXOH ELQGV
several biotin-HRP complexes.  After addition to the tissue each multi-HRP expressing 
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complex can bind to each biotin site on the secondary antibody, therefore multiplying the 
sites available for chromogen binding many times in comparison with the direct method 
(Figure 2.16) [275].  
 
 
Figure 2.16 In the ABC method, the streptavidin-biotin-enzyme complex reacts with the 
biotinylated secondary antibody. Figure adapted from Immunohistochemical Staining 
Methods 3rd Ed. DAKO [275].  
 A commercially produced kit was used for this work:  
(StreptABCComplex/ HRP Duet, Mouse/ Rabbit - K0492; Dako, Ely, UK).  
A- streptavidin in 0.01 mol/L PBS, 15mmol/L NaN3; pH 7.2 diluted to 1:100  
B- biotinylated horseradish peroxidase in 0.01 mol/L PBS, 15mmol NaN3; pH 7.2 diluted 
to 1:100  
C- biotinylated goat anti-mouse/rabbit secondary antibody diluted to 1:100.  
 
Avidin binding capacity can be seen in normal tissues. This could potentially lead to 
ELQGLQJRI³$%´WRVLWHVRQWKHWLVVXHXQUHODWHGWRWKHDQWLERG\FRPSOH[UHVXOWLQJLQQRQ-
specific staining. To eliminate this problem incubation of the tissue with avidin and biotin 
SULRUWRWKHDSSOLFDWLRQRIWKH³$%´VROXWLRQZLOOVDWXUDWHWKHVHVLWHVDQGSUHYHQWELQGLQJRI
³$%´WRDQ\WKLQJRWKHUWKDQWKHVHFRQGDU\DQWLERG\[276]. 
A commercial blocking kit was used to perform this: (Avidin-Biotin blocking kit ± SP-2001, 
Vector Laboratories, Burlingame, US). 
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2.2.7 Visualisation of the primary antibody 
 
The chromogen DAB was used to highlight the location of the antibody complex. This 
complex consisted of the primary and secondary antibody to which the streptavidin-biotin 
proteins with HRP are bound. The classical brown colour is produced by oxidisation of 
DAB by HRP. The brown substrate is clearly seen on light microscopy, and even by the 
naked eye if protein expression is strong.  
Some tissues contain endogenous peroxidase activity which can produce nonspecific 
staining by oxidizing DAB in areas which do not contain the primary antibody complex. 
This can be prevented by blocking any endogenous peroxidase activity before the antigen 
retrieval step. This is achieved using 0.3% hydrogen peroxide in methanol, produced by 
adding 4mls 30% hydrogen peroxide to 400mls methanol. 
The staining was of DAB was intensified by the application of 0.5% copper sulphate in 
0.8% sodium chloride. Haematoxylin then was used to counter-stain the background blue. 
The tissue slides were dehydrated in the graded alcohols, xylene was used to remove the 
ethanol, before allowing the slides to dry in a fume cupboard. The cover slips were 
mounted in the slides using Distyrene, Plasticiser and Xylene (DPX) in preparation for 
light microscopy. 
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Table 2.9 7KH µLQ-KRXVH¶ SUHSDUDWLRQ RI VROXWLRQV PRVW FRPPRQO\ XVHG LQ
immunohistochemistry. 
Solution Materials Company Quantity Method 
Citrate 
buffer 
concentrate 
Citric Acid Sigma-Aldrich, 
Gillingham, UK 
21g Working dilution- Add 450mls 
dH2O to 50mls citric acid 
concentrate. Adjust the pH to 6.0 
with 5 mmol HCl or NaOH. 
NaOH 
pellets 
Sigma-Aldrich, 
Gillingham, UK 
10g 
dH2O In-house 500mls 
EDTA 
concentrate 
TRIS Sigma-Aldrich, 
Gillingham, UK 
12.1g Working dilution- Add 450mls 
dH2O to 50mls EDTA concentrate. 
Adjust the pH to 8.0 with 5 mmol 
HCl or NaOH. 
EDTA Sigma-Aldrich, 
Gillingham, UK 
374g 
dH2O In-house 500mls 
TBS Tris Base Sigma-Aldrich, 
Gillingham, UK 
6.06g For 1000mls of 0.05m Tris, 
0.15 NaCl TBS- Dissolve Tris base 
in 90ml dH2O and adjust ph with 
10mmol HCl to 7.6. Dissolve NaCl 
in 100mls dH2O. Add remaining 
dH2O. 
 NaCl Sigma-Aldrich, 
Gillingham, UK 
8.76g 
 dH2O In-house 1000mls 
0.5% 
Copper 
Sulphate 
solution 
CuSO4 Sigma-Aldrich, 
Gillingham, UK 
2.5g For 500mls 0.5% CuSO4 solution- 
Add 2.5g CuSO4 to 500mls dH2O 
and add 4.0g NaCl. NaCl Sigma-Aldrich, 
Gillingham, UK 
4.0g 
dH2O In-house 500mls 
dH2O: Deionised Water  NaOH: Sodium Hydroxide 
TBS: TRIS Buffered Saline   NaCl: Sodium Chloride 
CuSO4: Copper Sulphate  EDTA: Ethylene Diamine Tetracetic Acid 
Tris: TRIS(hydroxymethyl)aminomethane  
2.2.8 IHC protocol 
 
The following protocol summarises the methods above and was used as the template for 
each experiment.  
1. Place TMA slides into a slide basket and then heat in an oven at 60º for 10 minutes. 
2. Immerse the slide basket in a xylene bath for 10 minutes. Repeat this step using an 
additional xylene bath. 
3. Immerse the slide basket in graded ethanol baths from 100% to 95% to 75% for 10 
seconds in each. 
4. Immerse the slide basket into a hydrogen peroxide (0.3%) and methanol bath for 15 
minutes. 
Steps 2-4 should be performed in a fume cupboard. 
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5. Wash the slides in a container of tap water with constant irrigation of fresh tap water. 
Avoid direct water current over side baskets. 
6. Immerse the slide basket in 500mls of the specific antigen retrieval solution made up to 
the required dilution and pH placed in a microwavable plastic container. Place the 
container in the microwave (800W) and heat for 10 minutes on high power and then 10 
minutes on low power. 
7. Wash the slides in a container of tap water with constant irrigation of fresh tap water. 
Avoid direct water current over side baskets. 
8. Using Sequenza cover plates mount the slides and place them in a Sequenza rack. 
9. Wash the sections with TBS. 
10. $SSO\ȝORI166GLOXWHGLQ7%6WRHDFKVOLGHIRUPLQXWHV 
11. $SSO\ȝORIDYLGLQ'VROXWLRQ to each slide for 15 minutes and before rinsing three 
times with TBS. Next aSSO\ȝORIELRWLQVROXWLRQ to each slide for 15 minutes. 
12.  Rinse the slides with TBS three times, for 5 minutes each time. 
13.  $SSO\ȝORIRSWLPDOO\GLOXWHGprimary antibody to each slide, with the exception of 
the negative control. Leave for 60 minutes. 
14. For the negative controO DSSO\ ȝO RI DQ DSSURSULDWH negative control 
immunoglobulin, or TBS if such an antibody is not available. Leave for 60 minutes. 
15. Wash the sections three times, for 5 minutes each time, with TBS. 
16. $SSO\ȝORIthe secondary antibody (UHDJHQW³&´) diluted to 1:100 in TBS, to each 
slide. Leave for 30 minutes.  
17. Wash the sections three times, for 5 minutes each time, with TBS.  
18. 3UHSDUH WKH³$%´VROXWLRQ WKLVPXVWEHDWGRQHDW OHDVWPLQXWHVEHIRUH WKH³$%´
can be used. 7KH³$%´VROXWLRQLVSURGXFHGE\FRPELQJDQGGLOXWLQJUHDJHQW³$´DQG ³%´WR
1:100, by adding equal quantities to the appropriate volume of TBS.  
19. $SSO\ȝORIWKH³$%´FRPSOH[WRHDFKVHFWLRQ. Leave for 60 minutes. 
20. Wash the sections three times, for 5 minutes, with TBS. 
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21. Dilute DAB to 1:50 in its substrate buffer. $SSO\ȝORI'$% to each slide. Leave for 
5 minutes. Repeat this step 3. 
22. Wash the sections three times, for 5 minutes each time, with TBS. 
23. $SSO\ ȝO RI  FRSSHU VXOSKDWH VROXWLRQ WR HDFK VOLGH. Leave for 5 minutes. 
Repeat this step. 
24. Wash the sections three times, for 5 minutes each time, with TBS. 
25. $SSO\ȝO of haematoxylin to each slide. Leave for 5 minutes. Repeat this step. 
26. Dismount the slides from the Sequenza rackDQGFRYHUSODWHV. Wash the slides in a 
container of tap water with constant irrigation of fresh tap water. Avoid direct water current 
over side baskets. 
27. Remount the slides in the slide basket and dehydrate them by rotating them through 
the graded alcohol baths in reverse order to the step, spending 10 seconds in each. 
28. Place the sections into a xylene bath for 10 seconds and repeat this step in a further 
xylene bath. 
29. Mount slide covers onto the slides using DPX and leave the slides overnight. 
Steps 27-29 should be performed in a fume cupboard. 
 
2.2.9 Specific immunohistochemical protocols for individual 
markers  
2.2.9.1 IFNGR1 protocol 
 
The standard methodology was used as described in the general methods section. 
500mls of pH 6.0 citrate buffer was used for antigen retrieval. Test sections were 
incubated with 100µl of mouse anti-human Interferon-gamma receptor 1 (IFNGR1) 
monoclonal antibody (MMHGR-1, Tebu-Bio©) which was found to be optimally diluted at 
1/50 (v/v) in TBS for 60 minutes at room temperature. This commercial antibody had been 
previously validated [277]. Positive control tissue comprised whole sections of colorectal 
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cancer. The primary antibody was omitted from the negative control, which was left 
incubating in NSS. 
2.2.9.2 Evaluation of IFNGR1 staining 
 
The tumour cores were assessed by two experienced observers (TD and PhR).  Two 
different copies of the TMA were used which provided two samples from different areas of 
the tumour in each case. The cores were scored independently by the observers with a 
consensus being reached in difficult cases and those were scoring differed by more than 
5%. There was high concordance between observers with less than 10% of cores 
requiring reassessment. This concordance is in line with previous authors findings [278]. 
Following initial review of the staining characteristics a semi-quantitative system, using 
both intensity and percentage of cells staining, was adopted as the most accurate method 
of demonstrating marker expression. The scoring was performed in a coded manner with 
observers blinded to the clinical and pathological parameters of the case. To utilise both 
the staining intensity (graded as: 0 - absent, 1 - weak, 2 - moderate, 3 - strong) and 
distribution (% of cells staining) in the assessment of each core, an intensity score was 
calculated (% cells staining × intensity of staining).  To produce a single value of marker 
expression for each tumour a mean value was calculated for the IS of the two cores from 
each tumour. To determine low and high expression the median intensity score for the 
cohort was used, with an intensity score of greater than 90 defining high IFNGR1 
expression. 
2.2.9.3 STAT1 protocol 
 
Standard protocol described in the general methods section was used. 500mls of pH 6.0 
citrate buffer was used for antigen retrieval. Test sections were incubated with 100µl of 
mouse anti-human STAT1 monoclonal antibody (ST1-3d4, Zymed©) which was found to 
be optimally diluted at 1/50 (v/v) in TBS for 60 minutes at room temperature. This was a 
commercial antibody which has previously been used in analysis of STAT1 expression in 
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breast cancer [279]. Positive control tissue comprised whole sections of normal tonsil. The 
primary antibody was omitted from the negative control, which was left incubating in NSS. 
2.2.9.4 Evaluation of STAT1 staining 
 
The expression of STAT1 was seen in two main sub-cellular locations, namely the 
cytoplasm and the nucleus. As such, the analysis consisted of scoring each tumour 
separately for these two locations. 
There were a number of scoring systems for cytoplasmic expression of STAT1.  We opted 
to use that of Chen et al [280] in which tumours were deemed positive if greater than 5% 
of tumour cells expressed STAT1. As for nuclear STAT1, no such previous studies were 
found and therefore any nuclear STAT1 was taken as positive. These scoring systems 
were decided prior to any interpretation of the cores. All tumour cores were scored 
independently by two scorers, both with extensive experience of TMA work (TD & AA). 
Those cores in which there was discrepancy were reassessed and agreement reached. 
2.2.9.5 p27 protocol 
 
The standard methodology was used as described in the general methods section. 
500mls of pH 9.0 EDTA buffer was used for antigen retrieval. Test sections were 
incubated with 100µl of mouse anti-human p27kip1 monoclonal antibody (M7203, DAKO) 
which was found to be optimally diluted at 1/50 (v/v) in TBS for 60 minutes at room 
temperature. This commercial antibody has been previously validated and used on 
colorectal and breast carcinomas [281]. Positive control tissue comprised whole sections 
of tonsil. The primary antibody was omitted from the negative control, and was replaced 
with mouse IgG1 to Aspergillus niger glucose oxidase, an enzyme not present in human 
tissue and hence a suitable negative control (X0931, DAKO). 
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2.2.9.6 Evaluation of p27 staining 
 
The expression of p27 was seen in two main sub-cellular locations, namely the cytoplasm 
and the nucleus. As such the analysis consisted of scoring each tumour separately for 
these two locations. Numerous methods exist for evaluation of immunohistochemical p27 
expression, with most studies designing novel scoring systems. In consequence, adoption 
of the established system of intensity scoring (see IFNGR1 methods) was deemed an 
appropriate system [282]. This system incorporates both the intensity and proportion of 
tumour cells staining. This scoring system was decided prior to any interpretation of the 
cores. All tumour cores were scored independently by two scorers, both with extensive 
experience of TMA work (TD & AA). Those cores in which there was discrepancy were 
reassessed and agreement reached. To determine low and high expression the median 
intensity score was used, with an intensity score for cytoplasmic and nuclear p27 of 
greater than 40 and 25 respectively defining high expression.  
2.2.9.7 Caspase 1 protocol 
 
The standard methodology was used as described in the general methods section. 
500mls of pH 6.0 citrate buffer was used for antigen retrieval. Test sections were 
incubated with 100µl of rabbit anti-human caspase 1 polyclonal antibody (06-503 Upstate 
Biotechnology) which was found to be optimally diluted at 1/40 (v/v) in TBS for 60 minutes 
at room temperature. This was a commercially developed antibody which has been used 
previously in immunohistochemical analysis of pancreatic carcinoma and detects 
expression of the pro-enzyme (p45) and active p20 subunit [283]. Positive control tissue 
comprised whole sections of tonsil. The primary antibody was omitted from the negative 
control, which was left incubating in NSS. 
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2.2.9.8 Evaluation of caspase 1 staining 
 
The expression of caspase 1 was seen almost exclusively in the cytoplasm. Yang et al 
used a semi-quantitative analysis which used intensity and proportion of tumour cells 
displaying immunoreactivity, therefore, a similar system was adopted for analysis of the 
TMA [283]. This scoring system was decided prior to any interpretation of the cores. All 
tumour cores were scored independently by two scorers, both with extensive experience 
of TMA work (TD & AA) Those cores in which there was discrepancy were reassessed 
and agreement reached. To determine low and high expression the median intensity 
score was used, with an intensity score of greater than 150 defined as high expression. 
2.2.9.9 VEGF protocol 
 
The standard methodology was used as described in the general methods section. 
500mls of pH 6.0 citrate buffer was used for antigen retrieval. A pre-diluted rabbit-anti-
human VEGF antibody was used (SP28, Abcam, Cambridge, UK). Optimisation of the 
staining was performed on ovarian cancer whole section mounts, using a range of 
incubation times. Two hour incubation was chosen to stain the arrays as it showed the 
best results with minimal background staining. Positive control tissue comprised whole 
sections of tonsil. The primary antibody was omitted from the negative control, which was 
left incubating in NSS. 
2.2.9.10 Evaluation of VEGF staining 
 
When staining was positive, it was primarily of cytoplasmic location and its pattern was 
uniform among the cancer cells within each core. The staining ranged in intensity from 
mild to strong and was initially recorded as such. However, to interpret the expression, 
and for the purposes of analysis, a scoring system was designed to identify potentially 
sensitive tumours to anti-VEGF therapies. As such cases were categorised as either 
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³KLJK´ expressors (represented by the strongly-VWDLQHG JURXS RU ³ORZ expressors 
(comprised of the negative, weak and moderate groups). This scoring system was 
decided prior to any interpretation of the cores. All tumour cores were scored 
independently by two scorers, both with extensive experience of TMA work (TD & AA). 
Those cores in which there was discrepancy were reassessed and agreement reached. 
2.2.9.11 DR4 and DR5 protocol 
 
The standard methodology was used as described in the general methods section. 
500mls of pH 6.0 citrate buffer was used for antigen retrieval. Test sections for DR4 and 
DR5 were incubated with 100µl of rabbit anti-human DR4 polyclonal antibody (H-130, 
Santa Cruz) and goat anti-human DR5 polyclonal antibody (616380, Calbiochem) 
respectively. The antibody to DR4 was found to be optimally diluted at 1/30 (v/v) and DR5 
at 1/50 (v/v) in TBS for 60 minutes at room temperature. These were commercial 
antibodies which had been previously validated [284, 285]. Positive control tissue 
comprised whole sections of tonsil. The primary antibody was omitted from the negative 
control, which was left incubating in NSS. 
2.2.9.12 Evaluation of DR4 and DR5 
 
Expression of DR4 and DR5 was mainly in the cytoplasm, with occasional nuclear staining 
with DR5. The expression of both proteins was homogenous with all cells in the cores 
being either positive or negative. Scoring was initially recorded as intensity and the 
percentage of cells staining. For the purposes of analysis, and in line with previous 
DXWKRUV¶ZRUN [286], cores were deemed positive if there was any immunoreactivity. This 
scoring system was decided prior to any interpretation of the cores. All tumour cores were 
scored independently by two scorers, both with extensive experience of TMA work (TD & 
AA) Those cores in which there was discrepancy were reassessed and agreement 
reached. 
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Table 2.10 Summary of immunohistochemical protocols and antibodies used in individual 
marker studies. 
Antigen Antibody Type Company 
Clone 
Code Dilution 
Antigen 
retrieval 
solution 
Positive 
Control 
Tissue 
Negative 
Control 
IFNJ 
receptor 
1 
IgG1 
Monoclonal 
Mouse 
Tebu-Bio, 
Peterbrough, 
UK 
MMHGR-
1 1:50 
Citrate 
pH 6.0 
Colorectal 
cancer 
Omission 
of primary 
antibody 
NSS 
STAT1 
IgG1-
Kappa 
Monoclonal 
Mouse 
Zymed, 
S. 
Francisco, 
US 
ST1-3D4 1:50 Citrate pH 6.0 Tonsil 
Omission 
of primary 
antibody 
NSS 
P27 
IgG1-
Kappa 
Monoclonal 
Mouse 
DAKO, Ely, 
UK SX53G8 1:50 
EDTA 
pH 9.0 Tonsil 
Mouse 
IgG1 
X0931, 
DAKO 
Caspase 
1 
IgG 
Polyclonal 
Rabbit 
Upstate 
Biotech, 
Herts, UK 
06-503 1:40 Citrate pH 6.0 Tonsil 
Omission 
of primary 
antibody 
NSS 
VEGF 
IgG1 
Monoclonal 
Rabbit 
Abcam, 
Cambridge, 
UK 
SP-28 Pre-diluted 
Citrate 
pH 6.0 Tonsil 
Omission 
of primary 
antibody 
NSS 
DR4 
IgG 
Polyclonal 
Rabbit 
Santa Cruz, 
CA, US H-130 1:30 
Citrate 
pH 6.0 Tonsil 
Omission 
of primary 
antibody 
NSS 
DR5 
IgG 
Polyclonal 
Goat 
Calbiochem, 
Darmstadt, 
Germany 
616380 1:50 Citrate pH 6.0 Tonsil 
Omission 
of primary 
antibody 
NSS 
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2.3 Statistical tests 
 
The statistical analyses were all performed using the computer package SPSS versions 
11.0 & 13.0. 
2.3.1 Null and alternative hypothesis and p values 
 
Many statistical tests assessing differences between groups use null and alternative 
hypotheses. If the null hypothesis is correctly accepted, there is no difference between 
groups. Accepting the alternative hypothesis indicates that there is significant difference 
between the groups. A false positive result is that which occurs when the null hypothesis 
is incorrectly rejected. Conversely a false negative occurs when the alternative hypothesis 
is falsely rejected. 
A p value gives the probability that the null hypothesis has been incorrectly rejected. This 
is expressed as a value between zero and one. p values close to one suggest that the 
observed difference has occurred by chance, whereas those close to zero are more likely 
to represent genuine differences. If a p value is 0.05, this would indicate that there is a 5% 
chance the observed difference has occurred by chance i.e. a false positive. Typically a p 
value of less than 0.05 is used to indicate differences that are statistically significant. 
2.3.2 Univariate analysis ± Persons Chi squared (F2) test 
 
Much of the data produced in this study was of a qualitative nature, this necessitated 
division of clinicopathological characteristics into groups. Since the data was qualitative 
comparisons between groups required the F2 test. This test compares the frequency of 
observed results (O) against expected frequencies (E) if there was no difference between 
the groups. A contingency table of the data is produced. The categories are cross 
tabulated against each other forming tables which range in size from 2 x 2 upwards, 
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dependent upon the subdivision of the categories.  If positive and negative expression of a 
marker is being compared with grade 1, 2 or 3 disease a 2 x 3 table would be formed 
containing six individual cells. The difference between O and E is calculated for each 
variable, and to ensure all values are positive the square is used.  For example:  
    [E-O]2 
              E 
The results of each of these calculations are added together to give the F2 value: 
   F2 = 6 [E-O]2 
            E 
Hence, the higher the value of F2 the greater the difference between the observed and 
expected values.  The calculation of the p value incorporates the F2 value and the number 
of degrees of freedom, which can be gleaned from the table. In this work the value was 
calculated through statistical software. The degrees of freedom relates to the number of 
factors being compared. The degrees of freedom = (number of columns - 1) x (number of 
rows - 1). 
The F2 test LVDVLPSOLILHGYHUVLRQRI)LVKHU¶V([DFWWHVWWKHF2 test compares favorably if 
the cells within the table contain above the specified minimum number. No more than 20% 
of cells should contain less than five cases and no cells should be empty, WKH )LVKHU¶V
Exact test was used if these parameters were not met. Yates correction was applied when 
the numbers in a fourfold table were small. The Yates correction reduced the F2 value by 
subtracting 0.5 from the difference between the observed and expected values. This 
reduces the risk of overestimating statistical significance if the data sets are small [287]. 
These methods are automatically applied by the statistical package SPSS. 
2.3.3 Univariate analysis of associations with survival 
2.3.3.1 Mean and median survival times 
 
The simplest illustration of survival between groups is through the calculation of average 
survival time. This can be represented by either the mean or the median survival time. 
The mean is most appropriately used in normally distributed data and median in non-
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parametric data sets. For the purposes of analysis both values were calculated, although 
as the data was non-parametric the median survival times were most relevant. 
2.3.3.2 Kaplan-Meier plot 
 
At any point in time patients entered into a study are either alive, dead or lost to follow up. 
To achieve the most accurate representation of survival no patients should be lost to 
follow up and analysis should be performed once all the patients have died. Realistically 
this is rarely possible and would take an unfeasible amount of time. A Kaplan-Meier 
calculation allows analysis of survival in incomplete data sets i.e. with patients lost to 
follow up and some still being alive. 
To perform a Kaplan-Meier analysis a life table is constructed which consists of SDWLHQWV¶ 
survival time from shortest to longest. At regular time intervals the proportion of patients at 
risk of dying is calculated. As patients are lost to follow up they are censored i.e. removed 
from subsequent analyses. The resulting cumulative survival is plotted against time as a 
curve with censored cases being denoted by ³´ When comparing groups of patients 
within a population a separate life table is constructed for each group with the resultant 
survival curve. These curves are plotted on the same axis to enable comparison. 
For this analysis to be accurate various assumptions are made, firstly, censoring of 
patients is a random event and that these cases would behave no differently from the 
other cases in the group they originated from. An example where bias could be introduced 
DW WKLVSRLQW LV WKDWGHDGSDWLHQWVGRQ¶WDttend follow up for obvious reasons, and if the 
death is not known, the patient may be incorrectly censored, hence biasing the results. In 
addition, patients may be censored if death occurs from another cause; this is only 
statistically valid if the cause of death is completely unrelated to the risk of dying from the 
disease being studied.  Kaplan-Meier analysis also assumes that patients entered into the 
study early have the same long term survival prospects as those entered later. Lastly, the 
survival data should be continuous and not grouped to the nearest follow up point [287]. 
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2.3.3.3 Log rank statistic 
 
A Kaplan-Meier plot displays the differences in survival between groups graphically. 
Whilst apparent differences may be observed between survival curves, the statistical 
significance can not be deduced from the plot. A log rank test can be applied to the data 
to determine whether any differences are statistically significant. As in Kaplan-Meier 
analyses, life tables are constructed and sequential calculations of observed and 
expected deaths occurring in each group is made each time a death occurs. This is 
performed using a 2 x 2 table of observed and expected deaths in each group with a F2 
test applied. When data are censored, they are excluded from subsequent analyses. The 
end result is a number of F2 values representing each death day which is then used to 
generate the log rank statistic and the p value. 
A log rank test allows interpretation of survival differences across the whole study period, 
as opposed to assessing survival rates at arbitrary time points. For the test to be accurate 
the same assumptions made in the Kaplan-Meier analysis must hold true. In addition the 
relative proportions of deaths occurring in each group should not change over the study 
period. Therefore, if the Kaplan-Meier survival curves cross, indicating variation in the 
relative proportions of deaths between the groups, then the log rank test should not be 
applied [287]. 
 
2.3.3.4 Multivariate analysis of associations with survival ± Cox 
proportional hazards model  
 
The log rank test applied in survival analysis provides an estimate of the likelihood that an 
individual factor affects prognosis; however, it does not allow for the potential influence of 
associated factors which could produce a confounding effect. In addition, it does not 
calculate the magnitude of the effect on survival. To address these issues a multivariate 
analysis was performed using the Cox regression model. This analysis measures 
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interrelationship between multiple variables and produces an estimate of the degree of 
effect produced called a hazard ratio (HR). 
This model produces a baseline survival curve and calculates the HR for each variable by 
measuring the effect of adding and removing each variable from the model. This provides 
an estimate of the independence and size of effect for each variable on the overall hazard 
rate. The HR produced for each variable reflects the increased or decreased likelihood of 
death at any time point due to this factor. A HR of one indicates the factor has no 
influence on survival. A HR of greater than one means the factor is associated with 
increased likelihood of death, and less than one with a reduced likelihood of death. The 
further the HR is from one the greater the effect of the factor on prognosis. 95% 
confidence intervals (CI) are also generated. These delineate the range of values within 
which the true HR has a 95% chance of lying. For a factor to have a statistically 
independent effect on survival the CI range must lie either wholly above or below one. A 
factor with a 95% CI which straddles one could have either a negative or positive effect on 
survival and therefore is not a statistically significant independent prognostic factor.  
Factors may appear statistically significant on univariate log rank testing but fail to be 
significant on Cox analysis, i.e. 95% CI straddles one. This suggests that the variable is 
confounded by other factors which are truly prognostic; this factor is simply acting as a 
surrogate. For example, if a particular factor simply reflects the stage of a cancer, then on 
univariate analysis it will appear significant since stage is strongly prognostic. However, 
when this factor is included in a Cox model with stage, the confounding effect of stage is 
accounted for and the factor will fail to be significant. 
Similarly to Kaplan-Meier DQG ORJ UDQN WHVWLQJ WKH &R[ PRGHO DVVXPHV WKDW D IDFWRU¶V
effect on prognosis remains constant throughout the study period. Therefore, factors with 
Kaplan-Meier curves that cross should not be included in this model because in that 
situation this assumption is not valid. Clearly factors which are not statistically significant 
prognostic factors on univariate analysis should not be included in a Cox model [288]. 
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3 The Interferon Gamma Pathway 
3.1 Introduction 
3.1.1 Interferons  
 
Interferons are a group of cytokines of which there are two types. Type I, which include 
interferon alpha (,)1Į) and beta (,)1ȕ), are produced by most cells. Type II, of which 
interferon gamma (IFNJ) is the sole member, is only produced by specific immune cells. 
IFNJ is structurally different to those in group I, binds to a different receptor and is coded 
for on a different gene locus. IFNJ has a pivotal role in immune response through a 
number of mechanisms, including its direct anti-proliferative and pro-apoptotic effects on 
stressed cells and its indirect effects on immune cells such as macrophages. Macrophage 
stimulation by IFNJ produces direct anti-tumour and anti-microbial effects and also 
induces them to release chemokines to trigger immune infiltration [289]. 
3.1.2 Interferon gamma receptor 
 
The functional IFNJ receptor is made up of four subunits, two ligand binding IFNGR1 
chains DOVRNQRZQDVĮFKDLQV and two signal transducing IFNGR2 chains (also known 
DVȕFKDLQV. The receptor belongs to the class II cytokine receptor family since it binds 
ligands in a µV¶-shape formed within the extracellular domain [290]. In lymphocytes, 
IFNGR2 is thought to be the rate limiting factor since IFNGR1 is usually found in surplus 
at the cell surface [291]. Both IFNGR chains lack intrinsic kinase/ phosphatase activity 
and hence must be associated with additional signalling machinery to achieve signal 
transduction [292, 293]. This is accomplished through binding of Janus tyrosine kinase 
(Jak) 1 and 2, and signal transducer and activator of transcription 1 (STAT1), to specific 
motifs in the intracellular domain of the IFNJ receptor [294] (Figure 3.1). 
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Figure 3.1 Polypeptide chain structure of the human IFN receptor. The IFN receptor consists 
of two species-matched polypeptides. The IFN receptor D chain is required for ligand binding 
and signalling. The IFN receptor E chain is required primarily for signalling and plays only a 
minor role in ligand binding. The intracellular domain of the receptor D chain contains two 
functionally important sequences: (1) an LPKS sequence required for D chain association 
with the tyrosine kinase Jak1, and (2) a YDKPH sequence that, when phosphorylated, forms 
the docking site for latent Stat1. The intracellular domain of the receptor E chain contains a 
functionally important box1/ box2 sequence required for Jak2 association. Figure adapted 
from Bach et al [295]. 
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3.1.3 Interferon gamma signal transduction and STAT1 
 
Ligand binding of two IFNJ molecules to the associated pair of IFNGR1 induces auto-
phosphorylation and activation of Jak2; this in turn trans-phosphorylates Jak1. Activated 
Jak1 proceeds to phosphorylate a functionally critical tyrosine residue on each IFNGR1 
chain, which leads to the formation of two adjacent docking sites for the SH2 domain of 
latent STAT1 [178]. The STAT1 pair recruited to the docking sites of the two IFNGR1 
molecules is phosphorylated, probably by Jak2, before forming an activated STAT1 
homodimer and dissociating from the receptor. The phosphorylation of the four critical 
tyrosines (Jak1, Jak2, IFNGR1 and STAT1) has been demonstrated to occur in less than 
one minute of treatment with IFNJ [292]. The activated STAT1 homodimer enters the 
nucleus and binds to DNA at promoter elements which initiate or suppress transcription of 
IFNJ related genes (Figure 3.2). Whilst STAT1 acts as a transcription factor for numerous 
pathways, it appears that it is the sole transcription factor for the IFNJ pathway. This was 
demonstrated in STAT-/- mice which displayed similar unresponsiveness to IFNJ as 
IFNGR1-/- mice [296]. 
In type 1 IFN pathways, STAT1 can bind with other molecules, such as other STAT and 
IRF molecules, to produce different signalling effects. This is known as 
heterodimerization, although the STAT1:STAT1 homodimer formed during IFNJ signalling 
remains the most common binding combination [297]. A number of different stimuli result 
LQ SKRVSKRU\ODWLRQ RI 67$7 LQFOXGLQJ W\SH , Į DQG ȕ DQG W\SH ,, J) IFN, 
lipopolysaccharide, IL-2, IL-12, 71)ĮDQGSODWHOHWGHULYHGJURZWKIDFWRU[298]. The ability 
of STAT1 to activate or suppress gene transcription relies on the presence of other 
transcription factors at the promoter element, for example IRF-9, specificity protein-1 and 
heat shock factor-1 [299]. 
Although STAT1 homodimers are most closely related to IFNJ there are (as 
aforementioned) other pathways which utilise STAT1. This suggests that the functioning 
of STATs may be more refined than originally thought. There is some suggestion that the 
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concentration and rate of STAT activation may influence the type of signalling produced 
[296]. It is also recognised that STATs can form heterodimers, which will clearly affect 
their function. These factors coupled with the previously mentioned inhibitory factors 
associated with STAT1 result in a complex, dynamic signalling system which provides a 
number of functions, not simply the transmission of IFNJ signals. 
There is some early evidence of a STAT1-independent signalling pathway for IFNJ. This 
may exert proliferative effects, as opposed to the anti-proliferative effects, of the 
STAT1:IFNJ pathway, possibly through an as yet unknown IFNJ receptor [300]. 
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Figure 3.2 Proposed signalling mechanism for IFNJ pathway. Figure adapted from Bach et al 
[295]. 
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3.1.4 Interferon gamma regulated genes 
 
IFNJ has diverse functions that include anti-viral, anti-proliferative, pro-apoptotic and 
immune modulation effects. The anti-proliferative effects of IFNJ are primarily translated 
through p21 and p27, which are produced from IFNJ dependent genes with IFNJ 
stimulation resulting in increased transcription of both. These molecules are cyclin 
dependent kinase (CDK) inhibitors. CDK is required during the cell cycle with inhibition 
causing arrest in the G1-S phase. IFNJ also downregulates c-myc which is responsible for 
activating cyclin:CDK complexes and inducing transcription of genes required for S phase 
[301] .  
p27, also known as Kip 1, is expressed in most cells and, along with p21, is a member of 
the Cip/Kip family of cell cycle inhibitors [302]. The established role of p27 is to bind and 
inhibit cyclin-cyclin dependent kinase (CDK) complexes, thereby inhibiting cell cycle 
progression between G1 and S phase [303]. p27 binds to cyclin D and CDK4 in the 
cytoplasm which promotes translocation of the complex to the nucleus. In non-cycling 
cells, p27 binds to cyclinD-CDK4 complexes as well as cyclinE-CDK2. The p27-cyclinE-
CDK2 complex results in inhibition of CDK2 resulting in cell cycle arrest. In proliferating 
cells levels of cyclinD-CDK4 increase and preferentially bind p27 resulting in degradation 
of p27, this produces release of cyclinE-CDK2 from p27. The liberation of CDK2 from p27 
results in loss of inhibition, and subsequent stimulation of cell cycle progression [302], 
(Figure 3.3). This anti-proliferative effect gives p27 a significant role as a tumour 
suppressor gene. p27 is rarely mutated and is predominantly regulated at a post-
transcriptional level by degradation in the ubiquitin-proteosome pathway [304]. As 
previously alluded to, some of the anti-proliferative effects of IFNJ are through p27, hence 
its inclusion in the current study.  
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Figure 3.3 Cip/Kip protein (p27) regulates cyclin-CDK complexes in the cytoplasm. p27 acts 
as a bridge between cyclin D and cdk4 to promote their association. Following binding, p27 
enhances the nuclear translocation of the complex. Once in the nucleus, nascent cyclin-D-
CDK complexes titrate p27 from cdk2, thereby inducing cell cycle progression. Upon cell 
cycle arrest, the levels of p27 increase, saturate D type proteins and then bind to cyclin-E-
cdk2 to block catalytic activity of the kinase. 
With such a well documented tumour suppressor role, it is intriguing that such controversy 
exists as to the prognostic significance of p27, including its sub-cellular location. Low p27 
expression has been associated with poor prognosis in a range of malignancies including 
breast, colorectal, ovary, prostate, bladder and pancreatic tumours [306-309]. Other 
studies contrast these findings with a loss of p27 producing a favourable prognostic 
outcome in pancreatic [310], colon, oesophageal and endometrial cancers [311]. 
Therefore the prognostic influence of p27 as part of the IFNJ pathway is clearly of interest, 
especially in view of the controversial findings of previous studies. 
The pro-apoptotic effects of IFNJ are mediated through a number of pathways including 
Fas and 71)Į. IRFs are a family of transcription factors induced by type I and II IFN 
pathways and as such are associated with a variety of immune, cell cycle regulation and 
apoptotic effects. Interferon regulatory factor 1 (IRF1), a tumour suppressor gene, is 
thought to play a central role in producing the apoptotic effects of IFNJ [312]. This is 
primarily through the activation of caspase 1 [181] and discussed later. Levels of IRF1 
may be the determining factor as to whether IFNJ induces or protects against apoptosis. 
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Exposure of cells with high levels of functioning IFNJ receptor to IFNJ produces a rapid 
activation of STAT1, thereby inducing high levels of IRF1 which in turn trigger the 
apoptotic pathway. However, if cells have low levels of IFNJ receptor, then exposure to 
IFNJ produces lower levels of phosphorylated STAT1 and in consequence low levels of 
IRF1. These lower levels of IRF1 are not sufficient to trigger apoptosis [291]. This is 
illustrated in experiments in which over expression of IFNJ receptor in cells usually 
expressing low levels, changes the response to IFNJ exposure from an anti-apoptotic/  
proliferative effect to a pro-apoptotic effect [291]. This may explain the differing responses 
of cell types to IFNJ. Another member of the IRF family, IRF2, acts as a suppressor of 
IRF1, by binding to the same gene promoter elements [313]. These are both produced at 
low levels in the non-stimulated cells; however IRF2 is more stable than IRF1 and so 
accumulates in the nucleus and represses the actions of IRF1 [314]. During IFNJ 
signalling the subsequent up-regulation of IRF1 allows competition with IRF2 and 
stimulates transcription of many IFNJ inducible genes [315].     
Caspase 1 is a cysteine protease belonging to a family of caspases which represent the 
common final pathway for a number of apoptotic mechanisms. Caspases tend to act as 
the principle executors in these pathways and produce an amplification cascade between 
individual caspases. Caspases are expressed as inactive pro-enzymes prior to proteolytic 
activation via a number of pro-apoptotic stimuli [316]. Caspase 1 can be triggered by a 
number of mechanisms but is associated with producing IFNJ mediated apoptosis through 
IRF1 [181]. Hence, tumour cell evasion from immunosurveillance through defects in the 
IFNJ pathway may be through inhibition of the pro-apoptotic effects of IFNJ induced 
caspases. Therefore reduced expression of caspase 1 through a defective IFNJ-IRF1-
caspase 1 pathway may result in a poorer prognosis. 
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3.1.5 Regulation of the IFNJ pathway 
 
A number of mechanisms exist which can prevent overstimulation of a cell by IFNJ, which 
is illustrated by the inhibition of STAT1 activation within one hour of IFNJ treatment [298]. 
Following signal transduction the IFNGR1-IFNJ complex is internalised and enters the 
endosomal pathway. Once internalised the ligand is degraded and the receptor is usually 
returned to the cell surface, however, the receptor can also be degraded, thereby 
producing a negative feedback loop [317].  
IRF2 inhibits IRF1, thereby influencing the degree of cell stimulation by IFNJ [314]. Some 
IFNJ inducible targets provide further negative feedback. SOCS1 (suppressor of cytokine 
signalling 1) represents one mechanism which controls IFNJ signalling, and this gene has 
binding sites on its promoter region for STAT1 [318]. SOCS1 binds to and inhibits Jak and 
hence produces a negative feedback loop [319], which occurs through high affinity binding 
to the SH2 region thus preventing STAT1-Jak interaction [320]. SOCS1 is strongly 
induced after IFNJ stimulation [321]. Over expression of SOCS1 inhibits IFNJ signalling 
through inhibition of Jak 1 and 2 [322].  SOCS1 deficient mice die soon after birth from 
excessive IFNJ dependent multi system inflammatory tissue destruction [323]; the effects 
of which are reversed by administration of anti-IFNJ antibodies [324].  
There is a large weight of evidence illustrating that the immune system has considerable 
influence on tumour development and progression, especially the need for tumours to 
develop mechanisms to evade immune attack. These mechanisms are not clear, hence, 
studying the expression of elements within the IFNJ pathway (the pathway which is 
predominantly involved in the anti-tumour activity of the immune system), may provide an 
insight into immune evasion in ovarian cancer. Immunohistochemical assessment of the 
expression of IFNGR1, STAT1, p27 and caspase 1 in relation to clinicopathological 
features, and in particular prognosis, will allow us to test the hypothesis that defects or 
deficiencies within this pathway will lead to a poorer prognosis. 
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3.2 Results 
3.2.1 IFNGR1 
3.2.1.1 Clinicopathological characteristics 
 
Of the 395 patients identified within the series, 339 had archived tissue available. These 
tumours were included in the tissue array. Five of the 339 tumour cores had no tissue 
available for analysis, however, due to its loss during immunohistochemical processing. 
This resulted in the availability of over 98% of cases for analysis, this core loss rate 
compares favourably with previous TMA studies. This subgroup of 334 patients was 
similar to that of the overall group which, as previously discussed, is representative of a 
typical ovarian cancer population (Table 3.1). Of particular importance is the comparability 
of five year survival, which is 24% in the whole series and 25% in those analysed. 
3.2.1.2 IFNGR1 staining 
 
Staining was seen predominantly within the cytoplasm and cell membrane. Complete lack 
of staining was observed in 22% of cores. There was an even distribution of staining 
intensity seen within the remainder with mild, moderate and strong staining occurring in 
23%, 30% and 26% respectively (Table 3.2 and Table 3.3). In those tumours with IFNGR1 
expression the staining tended to be of uniform intensity with the majority of tumour cells 
within the core being positive. Almost half of tumours (45%) displayed immunoreactivity in 
at least 75% of cells, and no staining was seen within the negative controls (Figure 3.4). 
The use of an intensity score allowed the heterogeneity of IFNGR1 expression to be taken 
into account, with the mean intensity score being taken between two cores from each 
tumour. The median intensity score for the tumours was 90, this was used to divide the 
tumours into high and low expression of IFNGR1. Using this system there were 163 low 
intensity and 171 high intensity cores.  
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Table 3.1 Clinicopathological characteristics of the whole series and those analysed for 
IFNGR1 expression. 
Variable Whole series 
n=395 (%) 
IFNGR1 analysed cases 
n=334 (%) 
Age (years) n=394 n=333 
  <30 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 133 (39.9) 
   226 (57.4) 199 (59.8) 
 
  
FIGO Stage n=375 n=326 
  I 99 (22.6) 83 (26.5) 
  II 46 (12.3) 37 (11.3) 
  III 188 (50.1) 167 (51.2) 
  IV 42 (11.2) 39 (12.0) 
 
  
Optimal Debulking n=376 n=322 
  Yes 157 (41.8) 129 (40.1) 
  No 219 (58.2) 193 (59.9) 
 
  
Tumour Grade n=376 n=332 
  1 50 (13.3) 38 (11.4) 
  2 93 (24.7) 72 (21.7) 
  3 233 (62) 222 (66.9) 
 
  
Histological Type n=395 n=334 
  Serous 203 (51.4) 177 (53.0) 
  Endometrioid 46 (11.7) 42 (12.6) 
  Mucinous 50 (12.7) 34 (10.2) 
  Undifferentiated 65 (16.5) 51 (15.3) 
  Clear Cell 26 (6.6) 25 (7.5) 
  Other 5 (1.3) 5 (1.5) 
 
  
Chemotherapy n=388 n=332 
  Platinum 196 (50.5) 166 (50.0) 
  Non-platinum 80 (20.6) 72 (21.7) 
  None 112 (28.9) 94 (28.3) 
 
  
Randomised Treatment 69/395 (17.5) 57/334 (17.1) 
 
  
Five Year Survival n=385 n=329 
  Yes 91 (23.6) 82 (24.9) 
  No 294 (76.4) 247 (75.1) 
 
  
Alive at time of data 
censoring n=388 n=331 
  Yes 60 (15.5) 56 (16.9) 
  No 328 (84.5) 275 (83.1) 
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Figure 3.4 (A) Shows a core from tumour demonstrating negative IFNGR1 staining. B & C 
show cores of tumour demonstrating moderate (B) and strong (C) IFNGR1 staining at x100 
magnification (inserts at x400 magnification). 
 
Table 3.2 Intensity of cytoplasmic staining with IFNGR1. 
Intensity of Staining Number Percentage 
No staining 72 21.6 
Mild 77 23.1 
Moderate 97 29.6 
Strong 87 26.1 
 
Table 3.3 Proportion of viable tumour cells staining with IFNGR1. 
Proportion of tumour 
cells staining Number Percentage 
No cells 72 21.6 
1 - 25% 18 5.4 
26 - 50% 59 17.7 
51 - 75% 35 10.5 
76 - 100% 149 44.7 
 
3.2.1.3 Comparison of IFNGR1 expression and patient tumour 
characteristics including survival 
 
In a univariate analysis, using the F2 test, no significant relationship between IFNGR1 
expression and the standard clinical and pathological variables was apparent. There did, 
however, appear to be a significant difference in the five year survival and the overall 
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survival of patients. Patients with tumours expressing high levels of IFNGR1 had a greater 
overall (p=0.034) and five year survival rate (p=0.006; Table 3.4). Patients in whom 
tumours expressed a high level of IFNGR1 had five year survival and overall survival rates 
of 31% and 21% respectively, compared to 18% and 12% in patients with low expression. 
Correlations between IFNGR1 expression and patient survival were also assessed using 
Kaplan Meier survival curves and log-rank testing (Figure 3.5). There was a statistically 
significant difference in the Disease Specific Survival (DSS) between patients with high 
and low IFNGR1 expression, with high expression predicting an improved outcome (log 
rank= 5.710 (p=0.017)). The mean DSS was 72 months and 46 months for high and low 
receptor expression respectively, which represents a 25 month difference in survival 
between the two groups. The median DSS also supported the favourable survival 
outcome with high receptor expression (27 vs. 16 months; Table 3.5 and Figure 3.5). 
Whilst initial classification into high and low expression using the median intensity score 
was used, a further sub-stratification was analysed in which tumours were divided into 
three groups: those with no expression of IFNGR1 (complete loss), those with low level 
expression and those with high level expression. This illustrated that much of the 
difference in survival rates between the patients appeared to be related to complete loss 
of IFNGR1 (Figure 3.6) (Table 3.6). This is clearly seen in the Kaplan Meier analysis in 
which the survival curves for tumours of high and low expression were very similar; 
tumours with no receptor expression appeared to have a comparatively poorer prognosis 
(p=0.043).  Since the behaviour of the tumours appeared to correlate more closely with 
whether any receptor at all was detected, it seemed intuitive to assess the patients based 
on these criteria, hence, the groups were divided according to the loss or presence of 
IFNGR1 (Figure 3.6). This analysis showed that complete loss was associated with a 
poorer outcome (log rank=6.005, p=0.014); median survival with complete receptor loss 
was 15 months compared with 23 months in tumours expressing any receptor (Table 3.6).
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Table 3.4 IFNGR1 expression in all of the cases included in the final analysis. This includes 
univariate analysis by F2 of IFNGR1 status and clinicopathological criteria. 
Variable Analysed 
cases 
N=334 (%) 
High 
IFNGR1 
expression 
(%) 
Low IFNGR1 
expression 
(%) 
Ȥ 
(p value) 
Age (years) n=333 n=171 n=162 
1.17 
(0.557) 
  <30 1 (0.3) 0 1 (0.6) 
  30-59 133 (39.9) 67 (39.2) 66 (40.7) 
   199 (59.8) 104 (60.8) 95 (58.6) 
 
    
FIGO Stage n=326 n=168 n=158 
1.86 
(0.601) 
  I 83 (26.5) 41 (24.4) 42 (26.6) 
  II 37 (11.3) 18 (10.7) 19 (12.0) 
  III 167 (51.2) 85 (50.6) 82 (51.9) 
  IV 39 (12.0) 24 (14.3) 15 (9.5) 
 
    
Optimal Debulking n=322 n=168 n=157 0.42 
(0.838)   Yes 129 (40.1) 67 (40.6) 62 (39.5) 
  No 193 (59.9) 98 (59.4) 95 (60.5) 
 
    
Tumour Grade n=332 n=165 n=161 
0.31 
(0.856) 
  1 38 (11.4) 20 (11.7) 18 (11.2) 
  2 72 (21.7) 35 (20.5) 37 (23.0) 
  3 222 (66.9) 116 (67.8) 106 (65.8) 
 
    
Histological Type n=334 n=171 n=163 
14.53 
(0.104) 
  Serous 177 (53.0) 92 (53.8) 85 (52.2) 
  Endometrioid 42 (12.6) 22 (12.9) 20 (12.3) 
  Mucinous 34 (10.2) 14 (8.2) 20 (12.3) 
  Undifferentiated 51 (15.3) 33 (19.3) 18 (11.0) 
  Clear Cell 25 (7.5) 8 (4.7) 17 (10.4) 
  Other 5 (1.5) 2 (1.2) 3 (1.8) 
 
    
Chemotherapy n=328 n=169 n=163 
2.43 
(0.487) 
  Platinum 164 (50.0) 88 (52.1) 76 (47.8) 
  Non-platinum 93 (28.4) 46 (27.3) 43 (27.0) 
  No chemotherapy 71 (21.6) 35 (20.7) 36 (22.6) 
Randomised 
Treatment 57/334 (17.1) 29/171 (17.0) 28/163 (17.1) 
0.26 
(0.873) 
 
    
Five Year Survival n=329 n=169 n=160 7.69 
(0.006)   Yes 82 (24.9) 53 (31.4) 29 (18.1) 
  No 247 (75.1) 116 (68.6) 131 (81.9) 
 
   
 
Alive at time of data 
censoring n=331 n=170 n=161 4.508 
(0.034)   Yes 56 (16.9) 36 (21.2) 20 (12.4) 
  No 275 (83.1) 134 (78.8) 141 (87.6) 
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Figure 3.5 Kaplan-Meier plot for disease specific survival. High IFNGR1 expression tumours 
compared with low IFNGR1 expression tumours (n=334). 
 
Table 3.5 Mean and median results for survival time in relation to high and low expression of 
IFNGR1, and Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Low 45.9 5.6 34.9 56.9 16.1 1.3 13.6 18.7 
High 71.9 7.8 56.6 87.1 27.3 3.4 20.6 34.0 
Overall 60.2 5.1 50.2 70.2 19.5 2.1 15.5 23.6 
(a) Estimation is limited to the largest survival time if it is censored. 
 
 Chi-square d.f. p value 
Log Rank (Mantel-
Cox) 5.710 1 0.017 
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Figure 3.6 Kaplan-Meier plots for disease specific survival. IFNGR1 expression: (A) present 
vs. loss and (B) high vs. low vs. loss in tumours (n=334). 
 
Table 3.6 Mean and median results for survival time in relation to complete loss of IFNGR1 
with division into three groups. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
IFNGR1 receptor lost or present 
Lost 36.7 6.6 23.6 49.8 15.2 1.1 13.0 17.3 
Present 65.9 6.0 54.2 77.7 23.4 3.1 17.3 29.4 
Overall 60.2 5.1 50.2 70.2 19.5 2.1 15.5 23.6 
IFNGR1 receptor expression divided into three groups 
Lost 36.7 6.6 23.6 49.8 15.2 1.1 13.0 17.3 
Low 60.1 7.6 45.1 75.1 19.0 3.0 13.1 24.8 
High 68.3 8.3 52.0 84.7 27.8 3.3 21.3 34.3 
Overall 60.2 5.1 50.2 70.2 19.5 2.1 15.5 23.6 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
IFNGR1 receptor lost or present 6.005 1 0.014 
IFNGR1 receptor expression 
(three groups) 6.272 2 0.043 
300.0250.0200.0150.0100.050.00.0
Survival from operation date (months)
Log rank=6.272, p=0.043
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
u
la
tiv
e 
Su
rv
iv
al
Censored
Censored
Censored
Loss of
expression
Low expression
High expression
IGFR1divided into
three groupsA B 
 122 
 
Tumour stage predominantly dictates prognosis in ovarian cancer. Whilst the effects of 
IFNGR1 status on patient survival are independent of stage (see multivariate analysis), an 
analysis of early with late stage tumours was performed to assess if these effects were 
more marked in one subgroup. Tumours were assessed according to high/ low expression 
and loss/ presence of IFNGR1 following division of patients into those with early (stage I 
and II) and advanced disease (stage III and IV) (Figure 3.7). Both classifications of 
IFNGR1 status demonstrated that although the negative effects on patient survival were 
seen in both early and late stages, the effects may be more pronounced in early stage 
disease (p=0.042 vs. p=0.053 and p=0.017 vs. p=0.045). The effects were most marked 
when comparing receptor loss with receptor presence in early stage disease; median 
survival being 30 months and 102 months respectively (Table 3.7 and Table 3.8). 
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Figure 3.7 Kaplan-Meier plots for disease specific survival with early and late stage disease, 
using both loss vs. presence (A) and high vs. low (B) IFNGR1 expression (n=334). 
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Table 3.7 Mean and median results for survival time in relation to complete loss of IFNGR1 
with early and late stage disease. Log Rank test for univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Early stage (I and II) 
IFNGR1 lost 76.5 15.5 46.1 106.9 30.3 14.9 1.05 59.6 
IFNGR1 
present 129.8 12.0 106.2 153.4 102.4 29.1 45.4 159.5 
Overall 120.5 10.6 99.7 141.3 71.0 21.0 30.0 112.2 
Late stage (III and IV) 
IFNGR1 lost 14.7 2.2 10.4 19.1 13.0 3.1 7.0 19.0 
IFNGR1 
present 27.0 3.4 20.2 33.7 11.0 2.0 7.2 14.9 
Overall 24.3 2.8 18.9 30.0 11.3 1.5 8.5 14.2 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
Early stage (I and II) 4.123 1 0.042 
Late stage (III and IV) 3.737 1 0.053 
 
Table 3.8 Mean and median results for survival time in relation to high and low IFNGR1 
expression with early and late stage disease. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Early stage (I and II) 
IFNGR1 low 91.7 12.2 67.8 115.6 42.0 11.8 19.0 65.0 
IFNGR1 high 143.2 15.3 113.2 173.2 137.6 44.4 50.5 224.6 
Overall 120.5 10.6 99.7 141.3 71.1 21.0 30.0 112.5 
Late stage (III and IV) 
IFNGR1 low 18.0 2.4 13.2 22.8 10.2 2.2 6.0 14.4 
IFNGR1 high 30.2 4.7 21.0 39.4 12.5 2.2 8.2 16.7 
Overall 24.3 2.7 18.9 30.0 11.3 1.5 8.5 14.2 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
Early stage (I and II) 5.747 1 0.017 
Late stage (III and IV) 4.010 1 0.045 
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3.2.1.4 Multivariate analysis 
 
In order to assess whether IFNGR1 status was an independent marker of prognosis, the 
relative influence of IFNGR1 expression and other known standard clinicopathological 
prognostic variables were included in a multivariate analysis. Factors shown to predict 
prognosis independently of each other were age, FIGO stage, the absence of 
macroscopic disease after surgery and whether the patient received chemotherapy. 
These factors along with IFNGR1 status were included in the Cox regression analysis. 
IFNGR1 when divided into high and low expression was seen to retain its power to predict 
an improved prognosis in the study population, independent of other prognostic factors, 
HR 0.727 (95% CI 0.570-0.927), p=0.01. This was also seen when patients were divided 
according to complete loss of IFNGR1, HR 0.744 (95% CI 0.558-0.992), p=0.045 (Table 
3.9). 
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Table 3.9 Multivariate analysis using Cox regression model demonstrating IFNGR1 
expression (low vs. high or loss vs. present) predicts a positive survival advantage 
independently of other accepted independent prognostic factors. 
Variable Hazard Ratio 
(95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 1.024 (1.013-1.036) <0.001 
 
 
 
FIGO Stage 
 
 
  I 1  
  II 2.542 (1.469-4.440)  
  III 5.091 (3.109-8.330)  
  IV 6.851 (3.854-12.180) <0.001 
 
 
 
Optimal Debulking 
 
 
  Yes 1  
  No 1.955 (1.389-2.720) <0.001 
 
 
 
Patient received 
Chemotherapy   
  No 1  
  Yes 0.438 (0.312-0.615) <0.001 
 
 
 
IFNGR1 expression 
 
 
  Low 1  
  High 0.727 (0.570-0.927) 0.010 
 
 
 
  Lost 1  
  Present 0.744 (0.558-0.992) 0.045 
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3.2.2 STAT1 
 
Two tumour samples were used from each patient and were represented by two cores on 
the TMA. There were 318 patients in whom the immunohistochemical processing had 
produced cores in which the staining and tissue preservation were possible to evaluate. 
This gave a core loss of 6.2%, which is within recognised standards for TMA work. 
Reasons for cores being lost to analysis included lack of viable tumour cells from 
extensive tumour necrosis and damage to the actual core itself during processing leading 
to detachment or folding of the core. Both of these reasons render it impossible to 
interpret the core.  
3.2.2.1 Clinicopathological characteristics 
 
When compared with the whole study series of 395 cases, the subgroup analysed were 
similar and consistent with recognised clinicopathological patterns from other studies [5, 
10]. Of particular importance was the comparability of the five year survival rates, which 
were 24% in the whole series and 26% in those analysed for STAT1 expression (Table 
3.10). 
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Table 3.10 Clinicopathological characteristics of the whole series and those analysed for 
STAT1 expression. 
Variable Whole series 
n=395 (%) 
STAT1 analysed cases 
n=318 (%) 
Age (years) n=394 n=317 
  <30 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 126 (39.7) 
   226 (57.4) 190 (59.9) 
   
FIGO Stage n=375 n=310 
  I 99 (22.6) 80 (25.8) 
  II 46 (12.3) 34 (11.0) 
  III 188 (50.1) 160 (51.6) 
  IV 42 (11.2) 36 (11.6) 
   
Optimal Debulking n=376 n=318 
  Yes 157 (41.8) 124 (40.5) 
  No 219 (58.2) 182 (59.5) 
   
Tumour Grade n=376 n=318 
  1 50 (13.3) 38 (12.0) 
  2 93 (24.7) 72 (22.7) 
  3 233 (62) 207 (65.3) 
   
Histological Type n=395 n=318 
  Serous 203 (51.4) 169 (53.1) 
  Endometrioid 46 (11.7) 41 (12.9) 
  Mucinous 50 (12.7) 33 (10.4) 
  Undifferentiated 65 (16.5) 48 (15.1) 
  Clear Cell 26 (6.6) 24 (7.5) 
  Other 5 (1.3) 3 (1.0) 
   
Chemotherapy n=388 n=312 
  Platinum 196 (50.5) 159 (51.0) 
  Non-platinum 80 (20.6) 71 (22.7) 
  None 112 (28.9) 82 (26.3) 
Randomised Treatment 69/395 (17.5) 55/312 (17.7) 
   
Five Year Survival n=385 n=318 
  Yes 91 (23.6) 83 (26.3) 
  No 294 (76.4) 232 (73.3) 
Alive at time of data censoring n=388 n=315 
  Yes 60 (15.5) 56 (17.8) 
  No 328 (84.5) 259 (82.2) 
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3.2.2.2 Immunohistochemical expression of STAT1 in ovarian cancer 
 
As expected, STAT1 expression was seen in both the cytoplasm and nucleus. Expression 
in both these locations has been seen previously in ovarian cancer and normal ovarian 
tissue [280]. The antibody used could detect STAT1 in both its inactive and active 
(phosphorylated) form. It was thought that the STAT1 within the nucleus was most likely to 
represent the active form. Analysis of expression looked at both subcellular locations. 
Photomicrographs of the types of staining seen are illustrated (Figure 3.8). There was no 
staining seen within the negative controls. 
 
 
Figure 3.8 A shows a core from tumour demonstrating negative STAT1 staining. B shows a 
core of tumour demonstrating weak cytoplasmic and absent nuclear staining. C illustrates 
strong cytoplasmic and nuclear staining. Tumour cores at x100 magnification (insets at x400 
magnification). 
 
Less than half of tumours (45%) expressed STAT1 within the cytoplasm; the majority were 
of mild and moderate intensity, with only 22 (7%) of tumours having strong STAT1 
cytoplasmic staining. The cytoplasmic staining was heterogeneous between the tumour 
cells, with the majority demonstrating positive staining in less than 50% of cells within 
each core (Table 3.11 and Table 3.12). 
Nuclear STAT1 expression was less prevalent than cytoplasmic; only 20% expressed 
positive nuclear staining, and that tended to be of mild intensity (Table 3.11 and Table 
3.12). In those tumour cores which were negative for any STAT1 staining it was 
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interesting to note that only 3% had evidence of STAT1 expression within the surrounding 
stroma (Table 3.13) implying lack of IFNJ within the tumour micro-environment. 
A previously determined scoring system was used, in which tumours with greater than 5% 
of cells demonstrating cytoplasmic staining were deemed positive and any nuclear 
staining was seen as positive [280]. 39% of tumour cores demonstrated positive 
cytoplasmic staining compared to only 19% with nuclear staining (Table 3.14). As 
expected, there was strong correlation between the expression of nuclear and cytoplasmic 
STAT1 (Ȥ2 94.98, p<0.00001). Whilst 67 (54%) of tumours showing cytoplasmic 
expression had no nuclear expression, there were only four (6%) tumours with positive 
nuclear expression in the absence of cytoplasmic expression. This pattern could be 
predicted by the nature of STAT1 functioning within the cell, namely the production within 
the cytoplasm and translocation to the nucleus (Table 3.14). 
Table 3.11 Intensity of cytoplasmic and nuclear staining with STAT-1. 
Intensity of 
staining 
Cytoplasmic Nuclear 
Number Percentage Number Percentage 
No staining 175 55.0 256 80.5 
Mild 70 22.0 38 12.0 
Moderate 51 16.0 11 3.5 
Strong 22 7.0 13 4.0 
 
Table 3.12 Proportion of viable tumour cells demonstrating cytoplasmic and nuclear staining 
with STAT-1. 
Proportion of 
cells staining 
Cytoplasmic Nuclear 
Number Percentage Number Percentage 
No staining 175 55.0 256 80.5 
1 - 25% 79 24.8 42 13.2 
26 - 50% 36 11.3 10 3.1 
51 - 75% 14 4.4 5 1.6 
76 - 100% 14 4.4 5 1.6 
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Table 3.13 Background STAT1 stromal staining in tumour cores with absent STAT1 
cytoplasmic staining. 
 Present (%) Absent (%) 
Stromal staining 4 (3) 171 (97) 
 
Table 3.14 Expression and correlation of cytoplasmic and nuclear STAT1, using the 
aforementioned scoring system. 
 
Positive (%) Negative (%) 
Cytoplasmic STAT1 125 (39.3) 193 (60.7) 
Nuclear STAT1 62 (19.5) 256 (80.5) 
 
  
Cytoplasmic STAT1 
Nuclear STAT1 (%) Ȥ2 (p value) 
Positive Negative 
Positive 58 (94) 67 (26) 
94.98 (p<0.0001) 
Negative 4 (6) 189 (74) 
3.2.2.3 Comparison of cytoplasmic STAT1 and clinicopathological 
variables 
 
There was a correlation between cytoplasmic STAT1 expression and increasing stage 
and grade of tumour. A correlation also existed with having a lower likelihood of optimal 
tumour debulking, however, this may be due to the associated trend to higher stage at 
presentation. There was a higher proportion of serous tumours with STAT1 positivity and 
less endometriod and clear cell subtypes. Age, types of chemotherapy received and, most 
importantly, five year survival were not related to cytoplasmic STAT1 expression (Table 
3.15). 
3.2.2.4 Comparison of nuclear STAT1 and clinicopathological 
variables 
 
STAT1 nuclear expression was related to a higher grade of tumour with almost all being 
moderately or poorly differentiated (98%). As with cytoplasmic STAT1 a similar trend 
towards higher rate of expression in serous subtype was seen. There was no correlation 
with any of the remaining clinicopathological variables, including five year survival (Table 
3.15). 
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3.2.2.5 STAT1 expression and survival 
 
Using Kaplan-Meier analysis there was no statistically significant difference in survival 
between STAT1 cytoplasmic or nuclear expression, although there was a trend towards 
reduced survival with high cytoplasmic STAT1 expression (Figure 3.9 and Figure 3.10). 
The mean survival time was 66.5 months for cytoplasmic STAT1 positive  tumours and 
52.8 months for negative, the log rank test not reaching significance (p=0.111) 
Table 3.16). The mean survival time for nuclear STAT1 positive tumours was 67.2 months 
compared with 58.5 months in negative tumours. Although there appears to be a 
difference between these groups this was not significant on log rank testing (p=0.887). 
(Table 3.17). 
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Table 3.15 Expression of STAT1 divided according to sub cellular location. Univariate analysis 
by F2 of IFNGR1 status and clinicopathological criteria (>5% cytoplasmic staining = positive, 
any nucleus staining = positive). 
Variable 
STAT1 
Analysed 
Cases  (%) 
Cytoplasmic 
STAT1 
Present (%) 
Cytoplasmic 
STAT1 
Absent (%) 
Ȥ
2
 
(p
 v
alu
e)
 
Nuclear 
STAT1 
Present (%) 
Nuclear 
STAT1 
Absent (%) 
Ȥ
2
 
(p
 v
alu
e)
 
Age (years) n=317 n=125 n=192 
2
.20
 
(p
=0
.334)
 
n=62 n=255 
4
.16
 
(p
=0
.125)
 
<30 1 (0.3) 1 (0.8) 0 1 (1.6) 0 
30-59 126 (39.7) 46 (36.8) 80 (41.7) 25 (40.3) 101 (39.6) 
 190 (59.9) 78 (62.4) 112 (58.3) 36 (58.1) 154 (60.4) 
      
FIGO Stage n=310 n=123 n=187 
18
.82
 
(p
<0
.0001)
 
n=62 n=248 
6
.37
 
(p
=0
.095)
 
I 80 (25.8) 16 (13.0) 64 (34.2) 9 (14.5) 71 (28.6) 
II 34 (11.0) 13 (10.6) 21 (11.2) 9 (14.5) 25 (10.1) 
III 160 (51.6) 78 (63.4) 82 (43.9) 38 (61.3) 122 (49.2) 
IV 36 (11.6) 16 (13.0) 20 (10.7) 6 (9.7) 30 (12.1) 
      
Optimal debulking n=318 n=121 n=185 
5
.71
 
(p
=0
.017)
 
n=60 n=246 
0
.01
 
(p
=0
.927)
 
Yes 124 (40.5) 39 (32.2) 85 (45.9) 24 (40.0) 100 (40.7) 
No 182 (59.5) 82 (67.8) 100 (54.1) 36 (60.0) 146 (59.3) 
      
Tumour Grade n=318 n=125 n=192 
25
.66
 
(p
<0
.0001)
 
n=62 n=255 
9
.53
 
(p
=0
.009)
 
1 38 (12.0) 5 (4.0) 33 (17.2) 1 (1.6) 37 (14.5) 
2 72 (22.7) 18 (14.4) 54 (28.1) 12 (19.4) 60 (23.5) 
3 207 (65.3) 102 (81.6) 105 (54.7) 49 (79.0) 158 (62.0) 
      
Histological Type n=318 n=125 n=193 33
.88
 (p
<0
.0001)
 
n=62 n=256 13
.60
 (p
=0
.018)
 
Serous 169 (53.1) 81 (64.8) 88 (45.6) 41 (66.1) 128 (50.0) 
Endometrioid 41 (12.9) 8 (6.4) 33 (17.1) 5 (8.1) 36 (14.1) 
Mucinous 33 (10.4) 3 (2.4) 30 (15.5) 0 33 (12.9) 
Undifferentiated 48 (15.1) 27 (21.6) 21 (10.9) 12 (19.4) 36 (14.1) 
Clear Cell 24 (7.5) 5 (4.0) 19 (9.8) 4 (6.5) 20 (7.8) 
Other 3 (1.0) 1 (0.8) 2 (1.0) 0 3 (1.2) 
      
Chemotherapy n=312 n=123 n=189 
5
.00
 
(p
=0
.172)
 
n=62 n=250 
2
.92
 
(p
=0
.403)
 
Platinum 159 (51.0) 67 (54.5) 92 (48.7) 37 (59.7) 122 (48.8) 
Non-platinum 71 (22.7) 32 (26.0) 39 (20.6) 11 (17.7) 60 (24) 
None 82 (26.3) 24 (19.5) 58 (30.7) 14 (22.6) 68 (27.2) 
Randomised 
treatment 
55/312 
(17.7) 17/123 (13.8) 38/189 (19.1) 
2
.15
 
(p
=0
.172)
 
8/62 (12.9) 47/248 (19.0) 
1
.24
 
(p
=0
.265)
 
      
Five Year Survival n=318 n=124 n=191 
2
.21
 
(p
=0
.138)
 
n=62 n=253 
0
.05
 
(p
=0
.831)
 
Yes 83 (26.3) 27 (21.8) 56 (29.3) 17 (27.4) 66 (26.1) 
No 232 (73.3) 97 (78.2) 135 (70.7) 45 (72.6) 187 (73.9) 
Alive at time of 
data censoring n=315 n=124 n=191 3
.32
 
(p
=0
.068)
 
n=62 n=253 
0
.13
 
(p
=0
.717)
 
Yes 56 (17.8) 16 (12.9) 40 (20.9) 12 (19.4) 44 (17.4) 
No 259 (82.2) 108 (87.1) 151 (79.1) 50 (80.6) 209 (82.6) 
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Figure 3.9 Kaplan Meier Survival Plots for disease specific survival with positive (>5% of 
tumour cells staining) and negative (<5%) cytoplasmic STAT1 expression. Log rank - 2.5, 
p=0.111. 
 
Table 3.16 Mean and median results for survival time in relation to cytoplasmic STAT1 
expression. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Negative 66.5 6.2 53.4 77.7 22.1 4.4 13.5 30.7 
Positive 52.8 7.4 38.2 67.4 21.1 3.5 14.2 28.1 
Overall 62.9 5.3 52.5 73.4 22.1 2.8 16.7 27.6 
(a) Estimation is limited to the largest survival time if it is censored. 
 
Chi-square d.f. p value 
Log Rank (Mantel-Cox) 2.5 1 0.111 
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Figure 3.10 Kaplan-Meier Survival Plots for disease specific survival with positive (any 
nuclear staining in tumour cells) and negative (no nuclear staining) nuclear STAT1 
expression. Log rank - 0.2, p=0.887. 
 
 
Table 3.17 Mean and median results for survival time in relation to nuclear STAT1 
expression. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Negative 58.5 5.0 48.6 68.3 21.1 2.5 16.2 26.0 
Positive 67.2 12.6 42.6 91.2 27.3 4.0 19.4 35.2 
Overall 62.9 5.3 52.5 73.4 22.1 2.8 16.6 27.6 
(a) Estimation is limited to the largest survival time if it is censored. 
 Chi-square d.f. p value 
Log Rank (Mantel-Cox) 0.2 1 0.887 
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Further analysis of STAT1 functioning within the cell was performed by subgroup analysis, 
according to the relative distribution of STAT1 in the subcellular locations. Cells with no 
STAT1 expression were deemed to not be signalling at that point in time and those with 
STAT1 within the nucleus and cytoplasm, were deemed to be either signalling correctly. 
Both these groups are likely to have intact signalling STAT1 pathways. In contrast, those 
cells with high cytoplasmic expression in the absence of translocation and expression of 
STAT1 in the nucleus may have a defective IFNJ pathway. These groups were assessed 
using Kaplan-Meier analysis. There was a trend towards an improved survival with an 
intact compared with a defective STAT1 pathway, with mean survivals of 69 and 39 
months respectively. This failed to reach statistical significance (p= 0.08). (Figure 3.11 
and Table 3.18). 
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Figure 3.11 Kaplan-Meier Survival Plots for disease specific survival with an intact or 
defective STAT1 pathway (see text for definition). Log rank - 3.063, p=0.080. 
 137 
Table 3.18 Mean and median results for survival time in relation to STAT1 pathway status. 
Log Rank test for univariate survival analysis. 
 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Intact 68.8 6.3 54.4 81.2 23.5 3.5 16.7 30.3 
Defective 39.5 6.4 26.9 52.1 17.3 3.4 10.7 24.0 
Overall 62.9 5.3 52.5 73.4 22.1 2.8 16.6 27.6 
(a) Estimation is limited to the largest survival time if it is censored. 
 
Chi-square d.f. p value 
Log Rank (Mantel-Cox) 3.062 1 0.080 
  
3.2.2.6 STAT1 correlation with IFNGR1 status 
 
As STAT1 is an integral component of the IFNJ pathway, a correlation between IFNGR1 
status and STAT1 expression was performed using the F2 test. Both high/ low and 
present/ absent IFNGR1 expression were compared to cytoplasmic and nuclear STAT1. 
There was a significant association between IFNGR1 status and the expression of both 
nuclear and cytoplasmic STAT1 (Table 3.19). 68% of nuclear (i.e. active) STAT1 occurred 
in high expressers of IFNJ receptors, increasing to 93% in those tumours expressing any 
receptors. 
Table 3.19 Correlation of IFNGR1 expression with cytoplasmic and nuclear STAT1. 
IFNGR1 
expression 
Cytoplasmic STAT1 
(%) Ȥ
2
 
(p value) 
Nuclear STAT1 (%) Ȥ2 
(p value) Present Absent Present Absent 
High 85 (69) 86 (45) 16.4 
(p<0.001) 
42 (68) 129 (51) 5.50 
(p=0.019) Low 39 (31) 104 (55) 20 (32) 123 (49) Total 124 190 62 252 
 
      
Present 115 (93) 146 (77) 13.5 
(p<0.001) 
58 (93) 203 (80) 5.99 
(p=0.014) Absent 9 (7) 44 (23) 4 (7) 49 (20) Total 124 190 62 252 
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3.2.3 p27 
3.2.3.1 Clinicopathological characteristics 
 
Of the 339 tumours that were included in the array, 305 were suitable for the assessment 
of the level of p27 expression. This relatively high loss of tumour cores during 
immunohistochemical processing was due to the buffer required for antigen retrieval. This 
required the use of EDTA buffer which tends to damage the tumour cores. This subgroup 
of 305 patients was similar to that of the overall group, which as previously discussed is 
representative of a typical ovarian cancer population (Table 3.20). Of particular 
importance was the comparability of the five year survival rate, which was 24% in the 
whole series and 26% in those analysed for p27 expression. 
3.2.3.2 p27 staining 
 
In keeping with previous studies, p27 expression was seen in both the cytoplasm and the 
nucleus [325, 326]. This staining was heterogeneous with regard to the number and 
intensity of staining of the cells, in both the nuclear and cytoplasmic sub-cellular locations, 
and as such both aspects were scored in the initial analysis. There was strong p27 
expression in the positive control (tonsil) and no immunoreactivity in the negative control 
section where the primary antibody was omitted (Figure 3.12). 
3.2.3.3 Cytoplasmic staining of p27 
 
There was an even distribution of intensity of p27 immunoreactivity within the cytoplasm 
with 22% having no expression, and 25%, 28% and 26% displaying mild, moderate and 
strong staining respectively. Cytoplasmic p27 expression was not uniform throughout the 
tumour cores, with only 24% having positive staining of the majority of cells (Table 3.21 
and Table 3.22). 
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Figure 3.12 Photomicrographs of p27 immunohistochemical staining of ovarian TMA cores 
using the Avidin-biotin complex protocol. Panel A shows a negative tumour core, with 
positive stromal cells (internal positive controls). Panels B-D show weak, moderate, and 
strong staining respectively. Cores are shown at x100 magnification; insets are x200.   
 
3.2.3.4 Nuclear staining of p27 
 
Nuclear p27 expression was seen in less tumour cores than cytoplasmic, 65% and 78% 
respectively. The tumour cores demonstrating nuclear p27 expression had less variation 
in the intensity of staining when compared to cytoplasmic expression. The majority of 
tumour cells displaying immunoreactivity within the nucleus had moderate or strong 
staining; only 16% of tumours had mild nuclear p27 expression. As was seen with the 
cytoplasmic expression, nuclear p27 expression was not uniform within all the cells in an 
individual core, with the majority of cores expressing immunoreactivity in less than 50% of 
cells (Table 3.21 and Table 3.22). 
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The use of an intensity score allowed the heterogeneity of both cytoplasmic and nuclear 
p27 expression to be taken into account. The mean intensity score was taken between the 
two cores from each tumour. The intensity of staining within the tumour cores varied from 
mild to strong (Table 3.21), as did the proportion of cells staining within each core (Table 
3.22). However, the intensity of staining within the cells of an individual core was relatively 
uniform; therefore, an intensity score provided an accurate representation of the 
immunoreactivity. If the intensity of staining within individual cells had varied significantly 
within an individual core, thH³+VFRULQJV\VWHP´FRXOGKDYHEHHQXWLOLVHGZKLFKDOORZVIRU
scoring of each intensity of staining separately within the core, providing a more accurate 
representation of heterogeneous staining. The median intensity score for the cytoplasmic 
p27 expression in tumours overall was 40 and for nuclear p27 was 25. The median IS was 
used to divide the tumours into high and low expression for cytoplasmic p27. The scoring 
system for nuclear expression was simplified to presence (>5% of cells) or absence (<5% 
of cells) of immunoreactivity as described by previous authors [326]. 
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Table 3.20 Clinicopathological characteristics of whole series and those analysed for p27 
expression. 
Variable Whole series 
n=395 (%) 
p27 analysed cases 
n=305 (%) 
Age (years) n=394 n= 304 
  <30 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 120 (39.5) 
   226 (57.4) 183 (60.2) 
   
FIGO Stage n=375 n= 297 
  I 99 (22.6) 74 (24.9) 
  II 46 (12.3) 33 (11.1) 
  III 188 (50.1) 156 (52.5) 
  IV 42 (11.2) 34 (11.4) 
   
Optimal Debulking n=376 n= 293 
  Yes 157 (41.8) 116 (39.6) 
  No 219 (58.2) 177 (60.4) 
   
Tumour Grade n=376 n= 304 
  1 50 (13.3) 35 (11.5) 
  2 93 (24.7) 67 (22.0) 
  3 233 (62) 202 (66.4) 
   
Histological Type n=395 n= 305 
  Serous 203 (51.4) 161 (52.8) 
  Endometrioid 46 (11.7) 39 (12.8) 
  Mucinous 50 (12.7) 30 (9.8) 
  Undifferentiated 65 (16.5) 48 (15.7) 
  Clear Cell 26 (6.6) 24 (7.9) 
  Other 5 (1.3) 3 (1) 
   
Chemotherapy n=388 n= 299 
  Platinum 196 (50.5) 152 (50.8) 
  Non-platinum 80 (20.6) 68 (22.7) 
  None 112 (28.9) 79 (26.4) 
Randomised treatment 69/395 (17.5) 52/299 
Five Year Survival n=385 n= 300 
  Yes 91 (23.6) 78 (26.0) 
  No 294 (76.4) 222 (74) 
Alive at time of data 
censoring n=388 n= 302 
  Yes 60 (15.5) 54 (17.9) 
  No 328 (84.5) 248 (82.1) 
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Table 3.21 Intensity of cytoplasmic and nuclear staining with p27. 
Intensity of 
Staining 
Cytoplasmic Nuclear 
Number Percentage Number Percentage 
No staining 67 22.0 106 34.8 
Mild 73 24.0 50 16.4 
Moderate 87 28.5 81 26.6 
Strong 78 25.6 68 22.2 
 
 
Table 3.22 Proportion of viable tumour cells with cytoplasmic and nuclear p27 expression. 
Proportion of 
tumour cells 
staining 
Cytoplasmic Nuclear 
Number Percentage Number Percentage 
No cells 67 22.0 106 34.8 
1-25% 87 28.5 69 22.6 
26-50% 77 25.2 66 21.6 
51-75% 37 12.1 32 10.5 
76-100% 37 12.1 32 10.5 
 
3.2.3.5 Comparison of cytoplasmic p27 expression and patient 
tumour characteristics 
 
Dividing the cores into high and low expression of cytoplasmic p27 produced 147 low, and 
157 high, expression tumours. In a univariate analysis, using the F2 test, no significant 
relationship between cytoplasmic p27 expression and age, rates of tumour debulking, 
tumour grade or types of chemotherapy received were apparent. However, there was a 
trend towards earlier stage in tumours with low cytoplasmic p27 expression. 43% of 
tumours with low cytoplasmic p27 expression were stage I and II, compared with 29% of 
those with high p27 expression, although this was not statistically significant (p=0.068). A 
greater proportion of tumours with high p27 expression were of serous subtype and a 
lower proportion were mucinous compared with tumours of low p27 expression (Table 
3.23). There was a clear difference in the prognosis of the two groups with regard to five 
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year survival rates, with high and low cytoplasmic p27 expression being 19% and 35% 
respectively (p=0.002). This is illustrated further in the Kaplan-Meier graphs below. 
3.2.3.6 Comparison of nuclear p27 expression and patient tumour 
characteristics 
 
The tumours cores were divided according to whether or not there was any expression of 
nuclear p27. 199 (65%) of tumour cores expressed some degree of nuclear p27 
expression. As with cytoplasmic p27 there was no significant relationship between nuclear 
p27 positivity and age, rates of tumour debulking, tumour grade or types of chemotherapy 
received. There was a trend towards a higher proportion of early stage tumours (stage I 
and II) in those with absent, compared to those with nuclear p27 expression; 43% and 
32% respectively. This trend was not as clear as with cytoplasmic p27 and was also not 
statistically significant (p=0.261) (Table 3.23). 
As was seen with cytoplasmic expression, there were higher rates of serous and lower 
rates of mucinous subtypes in tumours expressing nuclear p27. There was a clear 
difference in the prognosis of the two groups in terms of five year survival rates, with 
positive and negative nuclear p27 expression being 21% and 36% respectively (p=0.005). 
This is illustrated further in the Kaplan-Meier graphs below. 
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Table 3.23 Expression of p27 divided according to sub cellular location. Univariate analysis 
by F2 p27 status and clinicopathological criteria. 
Variable p27 
analysed 
cases 
n=305(%) 
High 
Cytoplasmic 
p27 
expression 
(%) 
Low 
Cytoplasmic 
p27 
expression 
(%) 
Ȥ
2
 
(p
 v
alu
e)
 
Nuclear 
p27 
present 
(%) 
Nuclear 
p27 
absent 
(%) 
Ȥ
2
 
 
(p
 v
alu
e)
 
Age (years) n= 304 n= 157 n= 147 
3
.912
 
(p
=
 0
.141)
 
n= 199 n= 105 
2
.10
 
(p
=0
.350)
 
<30 1 (0.3) 0 1 (0.7) 0 1 (1) 
30-59 120 (39.5) 55 (35.0) 65 (44.2) 77 (38.7) 43 
(41.0) 
 183 (60.2) 102 (65.0) 81 (55.1) 122 
(61.3) 
61 
(58.0) 
      
FIGO Stage n= 297 n= 156 n= 141 
7
.12
 
(p
=0
.068)
 
n= 198 n= 99 
4
.00
 
(p
=0
.261)
 
I 74 (24.9) 33 (21.2) 41 (29.1) 43 (21.7) 31 
(31.3) 
II 33 (11.1) 13 (8.3) 20 (14.2) 21 (10.6) 12 
(12.1) 
III 156 (52.5) 88 (56.4) 68 (48.2) 111 
(56.1) 
45 
(45.5) 
IV 34 (11.4) 22 (14.1) 12 (8.5) 23 (11.6) 11 
(11.1) 
      
Optimal Debulking n= 293 n= 156 n= 137 
1
.90
 
(p
=
 
0
.168)
 
n= 195 n= 98 
1
.13
 
(p
=
 
0
.287)
 
Yes 116 (39.6) 56 (35.9) 60 (43.8) 73 (37.4) 43 
(43.9) 
No 177 (60.4) 100 (64.1) 77 (56.2) 122 
(62.6) 
55 
(56.1) 
      
Tumour Grade n= 304 n=  157 n= 147 
3
.43
 
(p
=
 0
.180)
 
n= 198 n= 106 
4
.85
 
(p
=
 0
.088)
 
1 35 (11.5) 13 (8.3) 22 (15.0) 17 (8.6) 18 
(17.0) 
2 67 (22.0) 37 (23.6) 30 (20.4) 46 (23.2) 21 
(19.8) 
3 202 (66.4) 107 (68.2) 95 (64.6) 135(68.2) 67(63.2) 
      
Histological Type n= 305 n= 157 n= 148 
13
.71
 
(p
=0
.018)
 
n= 199  n= 106 
16
.8
 
(p
=
 0
.005)
 
Serous 161 (52.8) 94 (59.9) 67 (45.3) 114(57.3) 47(44.3) 
Endometrioid 39 (12.8) 21 (13.4) 18 (12.2) 25 (12.6) 14(13.2) 
Mucinous 30 (9.8) 7 (4.5) 23 (15.5) 10 (5.0) 20(18.9) 
Undifferentiated 48 (15.7) 22 (14.0) 26 (17.6) 30 (15.1) 18(17.0) 
Clear Cell 24 (7.9) 12 (7.6) 12 (8.1) 18 (9.0) 6 (5.7) 
Other 3 (1) 1 (0.6) 2 (1.4) 2 (1.0) 1 (0.9) 
      
Chemotherapy n= 299 n= 157 n= 142 
2
.19
 
(p
=
 
0
.534)
 
n= 199 n= 100 
5
.85
 
(p
=
 
0
.199)
 
Platinum 152 (50.8) 81 (51.6) 71 (50.0) 107(53.8) 45(45.0) 
Non-platinum 68 (22.7) 39 (24.8) 29 (20.4) 48 (24.1) 20(20.0) 
None 79 (26.4) 37 (23.6) 42 (29.6) 44 (22.1) 35(35.0) 
Randomised 
treatment 
52/299 28/157 24/141 0
.034
 
(p
=
 
0
.854)
 
33/199 19/100 0
.251
 
(p
=
 
0
.616)
 
      
Five Year Survival n= 300 n=156 n= 144 
9
.276
 
(p
=
 
0
.002)
 
n= 197 n= 103 
8
.026
 
(p
=
 
0
.005)
 
Yes 78 (26.0) 29 (18.6) 49 (34.0) 41 (20.8) 37 
(35.9) 
No 222 (74) 127 (81.4) 95 (66.0) 156 
(79.2) 
66 
(64.1) 
Alive at time of data 
censoring 
n= 302 n= 157 n= 147 
5
.888
 
(p
=
 0
.015)
 
n= 198 n= 104 
5
.475
 
(p
=
 0
.019)
 
Yes 54 (17.9) 20 (12.7) 34 (23.4) 28 (14.1) 26 
(25.0) 
No 248 (82.1) 137 (87.3) 111 (76.6) 170 
(85.9) 
78 
(75.0) 
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3.2.3.7 Cytoplasmic p27 expression and survival 
 
Correlation between cytoplasmic p27 expression and patient survival was assessed using 
a Kaplan-Meier survival curve and log-rank testing (Figure 3.13). There was a statistically 
significant difference in the DSS between patients with high and low p27 expression; with 
low expression predicting an improved outcome (log rank= 7.849 (p=0.005)). The mean 
DSS was 73 months and 51 months for low and high cytoplasmic p27 expression 
respectively. This relates to a 22 month difference in survival between the two groups. 
The median DSS also supported the favourable survival outcome with low p27 expression 
(28 vs. 17 months) (Table 3.24). 
In an attempt to describe the relationship between cytoplasmic p27 expression and 
prognosis, expression was sub-stratified into three groups; those with absent, low (less 
than median IS) and high (greater than median IS) expression (Figure 3.13). This figure 
illustrates that there is a progressively worsening prognosis with increasing p27 
expression. The mean DSS with absent, low and high expression was 76, 68 and 50 
months respectively (p=0.015) (Table 3.24). 
The Kaplan-Meier survival curve demonstrated that as a group those tumours with high 
cytoplasmic p27 expression behaved particularly poorly. Therefore, the groups were 
reanalysed according to whether there was high expression in comparison with the 
remainder of the tumours (Figure 3.14). This illustrated the profound effect of high p27 
expression on prognosis, with the mean DSS being 50 months in comparison with 72 
months for the remainder of the patients ((p=0.004) (Table 3.25). 
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Figure 3.13 Kaplan-Meier plots for disease-specific survival. A: High cytoplasmic p27 
expression compared with low and (B) high cytoplasmic p27 expression compared with low 
and  absent expression in tumours (n=305). 
 
Table 3.24 Mean and median survival time in relation to high and low cytoplasmic p27 
expression. Division into three groups and Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Cytoplasmic p27 expression 
Low 73.3 7.5 58.5 88.1 28.0 5.5 17.2 38.7 
High 50.6 6.7 37.4 63.8 16.9 2.6 11.8 22.1 
Overall 63.2 5.5 52.3 73.9 21.9 2.8 16.4 27.3 
Cytoplasmic p27 expression in 3 groups 
Nil 76.0 11.3 53.9 98.1 28.4 10.1 8.6 45.2 
Low 67.8 8.9 50.3 85.2 27.6 5.7 16.5 38.8 
High 50.5 7.1 36.5 64.4 16.4 2.7 11.1 21.8 
Overall 63.1 5.5 52.3 73.9 21.9 2.8 16.4 27.3 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
Cytoplasmic p27 high or low expression 7.849 1 0.005 
Cytoplasmic p27 expression (3 groups) 8.386 2 0.015 
A B 
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Figure 3.14 Kaplan-Meier plots for disease specific survival. High cytoplasmic p27 
expression compared with low and absent expression in tumours (n=305). 
 
Table 3.25 Mean and median survival time in relation to high, low and absent expression of 
cytoplasmic p27. Log Rank test for univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Low/Absent 71.9 7.1 57.9 85.8 28.0 5.0 18.1 37.8 
High 50.5 7.1 36.5 64.4 16.4 2.7 11.1 21.8 
Overall 63.1 5.5 52.3 73.9 21.9 2.8 16.4 27.3 
(a) Estimation is limited to the largest survival time if it is censored. 
 Chi-square d.f. p value 
Log Rank (Mantel-Cox) 8.304 1 0.004 
3.2.3.8 Nuclear p27 expression and survival 
 
The initial analysis of nuclear p27 expression included division of tumours into high and 
low expressers according to whether the IS of the tumour was less than or greater than 
the median IS of 25. The results were similar to that of cytoplasmic expression. High 
expression of nuclear p27 correlated with a poorer prognosis, having a mean DSS of 53 
months compared with 72 months for those with low expression (p=0.018) (Figure 3.15) 
(Table 3.26). The patients were then divided into three groups, those with high, low and 
 148 
absent expression of nuclear p27, as was performed for cytoplasmic p27. Kaplan-Meier 
analysis revealed two distinct groups in terms of prognosis. Those patients with low and 
high nuclear p27 expression were seen as having a very similar prognostic outlook, with 
mean DDS of 54 and 53 months respectively, whereas the DSS for those patients with 
absent nuclear p27 expression was 79 months (Figure 3.15) (Table 3.26). Intuitively, 
reanalysis of the groups according to presence (high and low expression) or absence of 
nuclear p27 seemed reasonable (Figure 3.16). This clearly demonstrated that expression 
of nuclear p27 is a poor prognostic marker with a difference in the mean DSS between the 
two groups of 25 months (p=0.0014) (Table 3.27). 
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Figure 3.15 Kaplan-Meier plots for disease-specific survival. A: High nuclear p27 expression 
compared with low and B: high nuclear p27 expression compared with low and absent 
expression in tumours (n=305). 
 
A B 
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Table 3.26 Mean and median survival time in relation to high and low nuclear p27 expression, 
with division into three groups. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Nuclear p27 expression 
Low 72.1 7.5 57.4 86.7 28.9 6.0 17.2 40.6 
High 52.6 7.2 38.6 66.7 19.5 2.8 13.9 25.0 
Overall 64.3 5.7 53.2 75.4 22.4 3.0 16.5 28.4 
Nuclear p27 expression in 3 groups 
Nil 78.7 9.4 60.1 97.1 28.9 5.6 17.8 40.0 
Low 54.3 10.7 33.4 75.3 19.0 10.4 0 39.6 
High 53.0 7.2 38.9 67.1 19.4 2.8 13.9 39.6 
Overall 64.3 5.7 53.2 75.4 22.4 3.0 16.5 28.4 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
Nuclear p27 high or low expression 5.637 1 0.018 
Nuclear p27 expression (3 groups) 6.626 2 0.036 
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Figure 3.16 Kaplan-Meier plots for disease-specific survival. Present nuclear p27 expression 
in comparison with absent expression in tumours (n=305). 
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Table 3.27 Mean and median survival time in relation to present and absent expression of 
nuclear p27. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Absent 78.9 9.4 60.3 97.1 28.9 5.6 17.8 40.0 
Present 54.5 6.3 42.2 66.8 19.4 2.8 14.0 24.8 
Overall 64.3 5.7 53.2 75.4 22.4 3.0 16.5 28.4 
(a) Estimation is limited to the largest survival time if it is censored. 
  Chi-square d.f. p value 
Log Rank (Mantel-Cox) 6.080 1 0.014 
 
3.2.3.9 Multivariate analysis of cytoplasmic and nuclear p27 
expression and survival 
 
In order to assess whether cytoplasmic p27 status was an independent marker of 
prognosis, the relative influence of cytoplasmic p27 expression and other known standard 
clinicopathological prognostic variables were included in a multivariate analysis. Factors 
shown to predict prognosis independently of each other were age, FIGO stage, the 
absence of macroscopic disease after surgery and whether the patient received 
chemotherapy. 
These factors along with p27 status were included in the Cox regression analysis. 
Cytoplasmic p27 expression when divided into high, low and absent expression was seen 
to retain its power to predict a poorer prognosis in the study population. This was 
independent of other prognostic factors (HR 1.313; p=0.042) (Table 3.28). 
Nuclear p27 expression when divided into present compared with absent expression did 
not retain its power to predict a poorer prognosis in the study population (HR 1.304; 
p=0.079) (Table 3.29). 
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Table 3.28 Multivariate analysis using Cox regression model demonstrating that high 
cytoplasmic p27 expression predicts worse survival independently of other accepted 
prognostic factors. 
Variable Hazard Ratios (95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 1.023 (1.012-1.038) <0.001 
   
FIGO Stage   
  I 1  
  II 2.859 (1.569-5.210)  
  III 5.587 (3.238-9.641)  
  IV 6.347 (3.382-11.911) <0.001 
   
Optimal Debulking   
  Yes 1  
  No 2.019 (1.404-2.904) <0.001 
   
Patient received 
Chemotherapy   
  No 1  
  Yes 0.424 (0.290-0.622) <0.001 
   
Cytoplasmic p27 expression   
  Low/ absent 1  
  High 1.313 (1.010-1.707) 0.042 
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Table 3.29 Multivariate analysis using Cox regression model demonstrating that high nuclear 
p27 expression fails to predict improved survival independently of other accepted prognostic 
factors. 
Variable Hazard Ratios (95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 1.025 (1.013-1.037) <0.001 
   
FIGO Stage   
  I 1  
  II 2.865 (1.557-5.273)  
  III 5.203 (2.987-9.064)  
  IV 6.278 (3.315-11.891) <0.001 
   
Optimal Debulking   
  Yes 1  
  No 2.003 (1.382-2.902) <0.001 
   
Patient received 
Chemotherapy   
  No 1  
  Yes 0.455 (0.308-0.671) <0.001 
   
Nuclear p27 expression   
  Absent 1  
  Present 1.304 (0.970- 1.753) 0.079 
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3.2.3.10 Correlation between nuclear and cytoplasmic p27 
 expression 
 
The survival analysis for both cytoplasmic and nuclear p27 demonstrated similar findings, 
with expression of both appearing to confer a survival disadvantage. However, this was 
only independent with cytoplasmic sub-cellular location. As might be predicted there 
appears to be a strong correlation between expression of nuclear and cytoplasmic p27. 
95% of tumours with positive cytoplasmic p27 also had positive nuclear p27, with only 
seven tumours having positive cytoplasmic p27 in the absence of nuclear expression. This 
correlation was also seen in those tumours with negative cytoplasmic p27 expression, 
although not as strongly, as 67% of tumours with negative cytoplasmic expression also 
having negative nuclear expression (Table 3.30). 
Table 3.30 Expression and correlation of cytoplasmic and nuclear p27, using described 
scoring system. 
 Positive (%) Negative (%) 
Cytoplasmic p27 (high/low) 157 (51.5) 148 (48.5) 
Nuclear p27 (present/absent) 199 (65.2) 106 (34.8) 
 
  
Cytoplasmic p27 Nuclear p27 (%) ȤSYDOXH positive negative 
Positive 150 (95.5) 7 (4.5) 130.959 
(p< 0.0001) Negative 49 (33.1) 99 (66.9) 
 
3.2.3.11 Relationship of p27 expression with IFNGR1 and STAT1 
expression 
 
Considering that p27 represents one of the factors induced by IFNJ stimulation there did 
not appear to be a correlation between the presence or absence of either cytoplasmic or 
nuclear p27 expression and IFNJ receptor status (Table 3.31). This included classifying 
receptor positivity according to high/ low expression and presence/ absence of the 
receptor. 
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However, expression of STAT1, the IFNJ transcription factor within the cytoplasm, did 
appear to be related to expression of both cytoplasmic and nuclear p27. Tumours which 
expressed cytoplasmic STAT1 had a high proportion of cytoplasmic p27 positivity (60% 
vs. 44%, p= 0.004). A similar effect was demonstrated, but to a greater extent, with 
nuclear p27 with 75% of tumours being p27-positive in the presence of cytoplasmic 
STAT1 staining compared with only 57% in STAT1-negative tumours (p=0.001). 
Interestingly, a similar relationship was not displayed when comparing nuclear STAT1 with 
p27 expression (Table 3.32). 
Table 3.31 Correlation of IFNGR1 with cytoplasmic and nuclear p27, including high vs. low 
and present vs. absent expression. 
IFNGR1 
expression 
Cytoplasmic p27 (%) Ȥ 
(p value) 
Nuclear p27 (%) Ȥ 
(p value) High Low Present Absent 
IFNGR1 
High 88 (51.8) 82 (48.2) 0.002 
(p= 0.962) 
109 (64.1) 61 (35.9) 0.308 
(p= 0.579) IFNGR1 
Low 69 (51.5) 65 (48.5) 90 (67.2) 44 (32.8) 
 
      
IFNGR1 
Present 132 (51.0) 127 (39.4) 0.323 
(p= 0.570) 
167 (64.1) 92 (35.5) 0.746 
(p= 0.388) IFNGR1 
Absent 25 (55.6) 20 (44.4) 32 (71) 13 (28.9) 
 
Table 3.32 Correlation of nuclear and cytoplasmic STAT1 expression with cytoplasmic and 
nuclear p27. 
 
 
 
STAT1 
expression 
Cytoplasmic p27 (%) Ȥ 
(p value) 
Nuclear p27 (%) Ȥ 
(p value) High Low Present Absent 
Cytoplasmic 
STAT1 Present 86 (60.6) 56 (39.4) 8.192 (p= 
0.004) 
106 (74.6) 36 (25.4) 10.210 
(p= 0.001) Cytoplasmic 
STAT1 Absent 71 (44.1) 90 (55.9) 92 (57.1) 69 (42.9) 
 
      
Nuclear STAT1 
Present 35 (56.5) 27 (43.5) 0.671 (p= 
0.413) 
44 (71.0) 18 (29.0) 1.088 
(p= 0.297) Nuclear STAT1 
Absent 122 (50.6) 119 (49.4) 44 (63.9) 87 (36.1) 
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3.2.4 Caspase1 
3.2.4.1 Clinicopathological characteristics 
 
Of 395 tumours within the study, 301 cases were suitable for immunohistochemical 
analysis for caspase 1 expression. 38 cores were lost during the antigen retrieval process, 
an 11% core loss rate. There was no difference in the clinical or pathological features of 
the tumours assessed when compared with the whole series. Most importantly, survival 
rates were similar, with five year survival in the whole series and in the assessed cores 
being 24% and 25% respectively (Table 3.33). 
3.2.4.2 Caspase 1 staining 
 
Caspase 1 expression was mainly cytoplasmic, with very little expression within the 
nucleus or cell membrane (Figure 3.17). Those tumour cores displaying caspase 1 
immunoreactivity tended to display this in the majority of the tumour cells, with 75% of 
tumours cores expressing caspase 1 in at least half of cells. Caspase 1 expression was 
either moderate or strong (Table 3.34 and Table 3.35). There was strong caspase 1 
expression in the positive control and no immunoreactivity in the negative control. 
Tonsillar tissue was used for both controls, with the negative control having the antibody 
omitted and the positive control exposed to the caspase 1 antibody as per the TMA slides. 
As with previous markers an intensity score which comprised both intensity and proportion 
of tumour cells staining was used, with the median IS dividing tumours into high and low 
expression. The median IS of 150 was relatively high compared with previous markers, 
reflecting the high levels of expression in both intensity and proportion of cells staining. 
Tumours were also assessed according to presence of any caspase 1 expression 
compared with a complete lack of expression, 32 tumours (10%) demonstrated a 
complete lack of caspase 1 expression. 
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Table 3.33 Clinicopathological characteristics of whole series and of those analysed for 
caspase 1 expression. 
Variable Whole series 
n=395 (%) 
Caspase 1 analysed 
cases 
n= 301 (%) 
Age (years) n=394 n=300 
  <30 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 117 (39.0) 
   226 (57.4) 182 (60.7) 
   
FIGO Stage n=375 n= 294 
  I 99 (22.6) 75 (25.5) 
  II 46 (12.3) 30 (10.2) 
  III 188 (50.1) 155 (52.7) 
  IV 42 (11.2) 34 (11.6) 
   
Optimal Debulking n=376 n= 290 
  Yes 157 (41.8) 119 (41.0) 
  No 219 (58.2) 171 (59.0) 
   
Tumour Grade n=376 n=  301 
  1 50 (13.3) 36 (11.9) 
  2 93 (24.7) 69 (22.9) 
  3 233 (62) 196 (65.1) 
   
Histological Type n=395 n=  301 
  Serous 203 (51.4) 159 (52.8) 
  Endometrioid 46 (11.7) 39 (13.0) 
  Mucinous 50 (12.7) 30 (10.0) 
  Undifferentiated 65 (16.5) 47 (15.6) 
  Clear Cell 26 (6.6) 23 (7.6) 
  Other 5 (1.3) 3 (1) 
   
Chemotherapy n=388 n=  296 
  Platinum 196 (50.5) 150 (50.7) 
  Non-platinum 80 (20.6) 67 (22.6) 
  None 112 (28.9) 79 (26.7) 
   
Five Year Survival n=385 n=  299 
  Yes 91 (23.6) 75 (25.1) 
  No 294 (76.4) 224 (74.9) 
Alive at time of data 
censoring n=388 n= 299 
  Yes 60 (15.5) 51 (17.1) 
  No 328 (84.5) 248 (82.9) 
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Figure 3.17 Photomicrographs of caspase 1 immunohistochemical staining of ovarian TMA 
cores using the Avidin-biotin complex protocol. Panel A shows a negative tumour core. 
Panels B - D show weak, moderate, and strong staining respectively. Cores are shown at 
x100 magnification; insets are x200. 
 
Table 3.34 Intensity of cytoplasmic staining with caspase1. 
Intensity of Staining Number Percentage 
No staining 32 10.6 
Mild 57 18.8 
Moderate 120 40.0 
Strong 92 30.6 
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Table 3.35 Proportion of viable tumour cells staining with caspase1. 
Proportion of tumour 
cells staining Number Percentage 
No cells 32 10.6 
1-25% 14 4.7 
26-50% 57 18.9 
51-75% 37 12.3 
76-100% 161 53.5 
 
 
3.2.4.3 Comparison of cytoplasmic caspase 1 expression and patient 
tumour characteristics 
 
Expression of caspase 1 according to both high vs. low and also presence vs. absence, 
was compared to the established clinicopathological features (Table 3.36). When dividing 
the cores according to an absence of staining only 32 (10%) tumours had no caspase 1 
expression, hence comparisons with other factors should be viewed with caution. 
There was preponderance of undifferentiated and endometrioid subtypes and fewer clear 
cell subtypes, in tumours with high expression of caspase 1. Low caspase 1 expression 
appeared to signify a significant survival advantage, with a 30% five year survival 
compared with only 20% in those with high expression (p= 0.036). This relationship is 
further illustrated with Kaplan-Meier survivals curves (Figure 3.18 and Figure 3.19). There 
were no other associations with other clinical parameters. 
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Table 3.36 Expression of caspase 1 divided according to high/ low and presence/ absence. 
Univariate analysis by F2 caspase 1 status and clinicopathological criteria. 
Variable 
Caspase 1 
Analysed 
Cases 
n=301 (%) 
Caspase 1 
high 
expression 
(%) 
Caspase 1 
low 
expression 
(%) 
Ȥ
2
 
(p
 v
alu
e)
 
Caspase 1 
present (%) 
Caspase 
1 absent 
(%) 
Ȥ
2
 
 
(p
 v
alu
e)
 
Age (years) n=300 n=147 n= 153 
 2
.11
 
(p
=0
.348)
 
n= 268 n= 32 9
.85
 
(p
=0
.007)
 
  <30 1 (0.3) 0 1 (0.7) 0 1 (3.1) 
  30-59 117 (39.0) 53 (36.1) 64 (41.8) 108 (40.3) 9 (28.1) 
   182 (60.7) 94 (63.9) 88 (57.5) 160 (59.7) 22 (68.8) 
    
 
  
 
FIGO Stage n= 294 n= 144 n=  150 
5
.64
 
(p
=
 0
.130)
 
n= 262 n= 32 
1
.37
 
(p
=0
.714)
 
  I 75 (25.5) 33 (22.9) 42 (28.0) 65 (24.8) 10 (31.3) 
  II 30 (10.2) 14 (9.7) 16 (10.7) 27 (10.3) 3 (9.4) 
  III 155 (52.7) 74 (51.4) 81 (54.0) 138 (52.7) 17 (53.1) 
  IV 34 (11.6) 23 (16.0) 11 (7.3) 32 (12.2) 2 (6.3) 
    
 
  
 
Optimal Debulking n= 290 n= 143 n= 147 2
.54
 
(p
=
 0
.11)
 
n= 259 n= 31 0
.78
 
(p
=
 
0
.379)
 
  Yes 119 (41.0) 52 (36.4) 67 (45.6) 104 (40.2) 15 (48.4) 
  No 171 (59.0) 91 (63.3) 80 (54.4) 155 (59.8) 16 (51.6) 
    
 
  
 
Tumour Grade n=  301 n=  148 n=  153 1
.65
 
(p
=
 0
.649)
 
n= 269 n= 32 14
.38
 
(p
=0
.002)
 
  1 36 (11.9) 15 (10.1) 21 (13.8) 34 (12.6) 2 (6.2) 
  2 69 (22.9) 35 (23.6) 34 (22.2) 57 (21.2) 12 (37.5) 
  3 196 (65.1) 98 (66.2) 98 (64.1) 178 (66.2) 18 (56.3) 
    
 
  
 
Histological Type n=301 n=148 n= 153 
11
.85
 
(p
=0
.037)
 
n= 269 n= 32 
19
.50
 
(p
=0
.002)
 
  Serous 159 (52.8) 75 (47.2) 84 (54.9) 142 (52.8) 17 (53.1) 
  Endometrioid 39 (13.0) 21 (14.2) 18 (11.8) 37 (13.8) 2 (6.3) 
  Mucinous 30 (10.0) 18 (12.2) 12 (7.8) 28 (10.4) 2 (6.3) 
  Undifferentiated 47 (15.6) 28 (18.9) 19 (12.4) 45 (16.7) 2 (6.3) 
  Clear Cell 23 (7.6) 6 (4.1) 17 (11.1) 15 (5.6) 8 (25.0) 
  Other 3 (1) 0 3 (2.0) 2 (0.7) 1 (3.1) 
    
 
  
 
Chemotherapy n=  296 n= 145 n= 151 3
.05
 
(p
=0
.383)
 
n= 264 n= 32 1
.87
 
(p
=0
.601)
 
  Platinum 150 (50.7) 73 (50.3) 77 (51.0) 133 (50.4) 17 (53.1) 
  Non-platinum 67 (22.6) 33 (22.8) 34 (22.5) 61 (23.0) 6 (18.8) 
  None 79 (26.7) 39 (26.9) 40 (26.5) 70 (26.6) 9 (28.1) 
    
 
  
 
Five Year Survival n=  299 n= 147 n= 152 4
.14
 
(p
=0
.036)
 
n= 267 n= 32 0
.20
 
(p
=
 0
.658)
 
  Yes 75 (25.1) 29 (19.7) 46 (30.3) 68 (25.5) 7 (21.9) 
  No 224 (74.9) 118 (80.3) 106 (69.7) 199 (74.5) 25 (78.1) 
Alive at time of 
data censoring n= 299 n= 147 n= 152 1.57
 
(p
=
 0
.21)
 
n= 267 n= 32 0
.05
 
(p
=0
.820)
 
  Yes 51 (17.1) 21 (14.3) 30 (19.7) 46 (17.2) 5 (15.6) 
  No 248 (82.9) 126 (85.7) 122 (80.3) 221 (82.8) 27 (84.4) 
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3.2.4.4 Caspase 1 and survival 
 
Kaplan-Meier survival curves were used to assess the prognostic significance of caspase 
1 expression, initially using high and low expression according to median IS. This 
demonstrated improved survival with low caspase 1 expression with a mean DSS of 67 
months compared to 46 months with high expression (p=0.025) (Figure 3.18) (Table 
3.37). The relationship between caspase 1 expression and survival was further described 
by dividing tumours into presence or complete absence of caspase 1 (Figure 3.19) (Table 
3.38). This illustrated very similar survival curves, with no significant difference in DSS (p= 
0.15). Dividing the tumours into three groups (absent, low and high expression) failed to 
clarify the relationship. This is because both loss and high expression of caspase 1 
appeared to predict poor prognosis, with mean DSS of 51 and 46 months respectively, 
whereas tumours with low expression had improved prognosis with a mean DSS of 70 
months. 
 
250.0200.0150.0100.050.00.0
Survival in months from operation
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
u
la
tiv
e 
Su
rv
iv
al
Censored
Censored
High expression
Low expression
Caspase 1
Survival Functions
 
Figure 3.18 Kaplan-Meier survival plots for Caspase 1 expression. High expression refers to 
an IS greater than median, whereas low expression is an IS less than median (n=301). 
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Table 3.37 Mean and median survival time in relation to high and low Caspase 1 expression. 
Log Rank test for univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Low 66.7 6.9 53.2 80.3 24.9 3.9 17.3 32.5 
High 46.0 5.6 35.1 56.9 17.3 2.4 12.7 22.0 
Overall 57.4 4.6 48.3 66.5 21.7 2.7 16.4 27.1 
(a) Estimation is limited to the largest survival time if it is censored. 
 Chi-square d.f. p value 
Log Rank (Mantel-Cox) 5.0 1 0.025 
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Figure 3.19 Kaplan-Meier survival plots for Caspase 1 expression. A: Presence of caspase I 
expression compared with absence, and B: high caspase 1 expression compared with low 
and absence, in tumours (n=301)  
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Table 3.38 Mean and median survival time in relation to present and absent Caspase 1 
expression. Log Rank test for univariate survival analysis. 
 Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% 
Confidence 
Interval Estimate (months) 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Caspase 1 present or absent 
Absent 51.5 12.1 27.7 75.3 19.0 6.3 6.5 31.5 
Present 57.8 4.9 48.1 67.4 21.7 3.0 15.9 27.5 
Overall 57.4 4.6 48.3 66.5 21.7 2.8 16.4 27.1 
Caspase 1 expression divided into 3 groups 
Absent 51.5 12.1 27.7 75.3 19.0 6.4 6.5 31.5 
Low 70.2 7.9 54.7 85.8 28.7 7.1 14.8 42.6 
High 46.0 5.6 35.1 56.9 17.3 2.4 12.7 22.0 
Overall 57.4 4.6 48.3 66.5 21.7 2.7 16.4 27.1 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
Caspase 1 present or absent 0.15 1 0.904 
Caspase 1 expression 
(3 groups) 5.8 2 0.056 
3.2.4.5 Multivariate analysis of caspase 1 expression and survival 
 
In order to assess whether caspase 1 status was an independent marker of prognosis, the 
relative influence of caspase 1 expression and the other previously mentioned 
clinicopathological prognostic variables were included in a multivariate analysis. Caspase 
1 when divided into high compared with low expression was seen to lose its power to 
predict prognosis, suggesting dependence on the other prognostic factors (HR 1.180; 
p=0.214) (Table 3.39). 
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Table 3.39 Multivariate analysis using Cox regression model demonstrating that low 
compared with high caspase 1 expression does not predict a survival advantage 
independently of other accepted prognostic factors. 
Variable Hazard Ratios (95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis (years) 1.020 (1.008-1.032) <0.001 
   
FIGO Stage   
  I 1  
  II 3.551 (1.901-6.631)  
  III 5.594 (3.285-9.528)  
  IV 6.257 (3.373-11.608) <0.001 
   
Optimal Debulking   
  Yes 1  
  No 2.261 (1.561-3.277) <0.001 
   
Patient received 
Chemotherapy   
  No 1  
  Yes 0.384 (0.262-0.564) <0.001 
   
Caspase 1 expression   
  Low 1  
  High 1.180 (0.909-1.533) 0.214 
3.2.4.6 Relationship of caspase 1 expression with IFNGR1 and STAT1 
expression 
 
Caspase 1 expression (high vs. low) was seen to correlate with IFNGR1 status. Presence 
of IFNGR1 expression was associated with a higher proportion of caspase 1 positivity 
compared with absent expression; 51% and 34% respectively (p= 0.026). A similar 
relationship was seen with cytoplasmic STAT1, with the presence of STAT1 being 
associated with high caspase 1 expression (58% vs. 42%, p= 0.006). Nuclear STAT1 
expression was also related to high caspase 1 expression, although this did not reach 
statistical significance (Table 3.40). 
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Table 3.40 Correlation of IFNGR1 and STAT1 expression with caspase 1. 
 
Caspase 1 (%) ȤSYDOXH High Low 
IFNGR1 
Present 131 (51.8) 122 (48.2) 4.989 
(p= 0.026) IFNGR1 
Absent 16 (34.0) 31 (66.0) 
 
  
 
Cytoplasmic 
STAT1 Present 80 (58.0) 58 (42.0) 7.680 
(p= 0.006) Cytoplasmic 
STAT1 Absent 67 (41.9) 93 (58.1) 
 
   
Nuclear STAT1 
Present 36 (60.0) 24 (40.0) 3.423 
(p= 0.064) Nuclear STAT1 
Absent 111 (46.6) 127 (53.4) 
3.3 Discussion 
3.3.1 Interferon gamma receptor 
 
Previous authors have established a protective role for IFNJ in ovarian cancer biology 
(reviewed in [206]), although the mechanism through which ovarian cancer is able to 
evade such action is unclear. In this chapter we investigated a potential route by which the 
anti-tumour effects of IFNJ may be avoided, by the down-regulation of IFNJ receptor on 
the tumour cell surface, reduced signalling through STAT1, and effects on two products of 
IFNJ stimulation: caspase 1 and p27.   
The value of TMA technology is highlighted in the analysis of 339 ovarian cancers used in 
the study. With the use of a comprehensive database of clinicopathological variables, this 
provided a powerful tool to examine the components of the IFNJ pathway in an unselected 
cohort of ovarian cancer patients, including the influence IFNJ exerted on survival. As with 
all TMA work, some loss of tissue cores during antigen retrieval occurred. However, this 
amounted to between two and 11%, and so was therefore unlikely to affect the results, 
especially as the core loss, which mainly occurred during antigen retrieval, was random. 
The initial study population included 395 patients; however, archived histopathological 
material was only available for analysis from 334. This, in addition to the aforementioned 
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core loss experienced during each experiment, resulted in less tumours being analysed 
for each marker than the original cohort. To ensure the sample analysed for each marker 
was representative, a chi-squared analysis of the original cohort and the group analysed 
for each specific marker were performed. This illustrated that the group analysed was 
representative for each of the markers (Table 3.1, 3.10, 3.20 and 3.33).  
The IFNJ receptor is made up of two subunits, the first IFNGR1 is responsible for ligand 
binding and signal transduction, and the second IFNGR2 is mainly involved with signal 
transduction. Whilst there is some evidence that IFNGR2 is found in lower concentrations 
and may act as a rate-limiting step during signal transduction in lymphocytes [291], the 
majority of studies relating to receptor function indicate that it is IFNGR1 that is relevant in 
carcinogenesis. Overexpression of defective IFNGR1 in tumours leads to a lack of 
response to IFNJ [173]. In addition, IFNGR1 knockout mice were found to develop 
tumours more frequently when exposed to the chemical carcinogen, methylcholanthrene 
(MCA), than wild type. These tumours when transplanted into naive mice continued to 
grow; however, restoring IFNGR1 expression in these tumours resulted in rapid rejection 
[295]. We decided to look at expression of IFNGR1 as it is most actively involved in IFNJ 
binding and has the most evidence for a role in tumour immunology. 
There was variation in both the intensity of staining and the proportion of tumour cells 
displaying immunoreactivity to IFNGR1 antibody. Using an IS it was possible to 
incorporate both factors when calculating the degree of receptor expression. The median 
IS enabled a statistically valid division into high and low expression of IFNGR1. This 
illustrated a clear relationship between low IFNGR1 expression and reduced survival, a 
difference of 24 months mean survival time (p=0.017) (Figure 3.5). To explore this 
relationship further, the tumours were subdivided into absent, low and high receptor 
expression. This indicated that tumours with any receptor present, regardless of the 
concentration, behaved in a similar manner having very similar survival curves (Figure 
3.6). This might be explained by the fact that IFNGR1 tends to be more abundant in the 
cell membrane than IFNGR2 [291], therefore, it may be that even low levels of IFNGR1 
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are sufficient to combine with the limited supply of IFNGR2 to produce physiologically 
normal levels of the combined receptor. Consequently, the true effects of reduced 
IFNGR1 may only be seen when complete loss occurs. In addition, most of the 
experimental data to date has assessed the potential effects of IFNGR1 loss, as opposed 
to high and low expression, on tumour growth [173, 174]. As such, a reanalysis was 
performed separating those tumours with complete receptor loss from those with any 
receptor expression. This demonstrated that much of the effect on survival was due to 
loss, rather than simple reduction, of IFNGR1 expression (p=0.014). Using complete loss 
of IFNGR1, as opposed to variations in degrees of receptor expression, may be more 
biologically valid and can perhaps more reliably predict which tumours have functioning 
IFNJ pathways. This apparent complete loss of IFNGR1 contrasts with the findings of 
Burke et al who demonstrated 100% expression in ovarian cancers. This was a small set 
of 12 patients, however, and employed RT-PCR to detect mRNA, and is therefore not 
directly comparable with immunohistochemical methods of detection [327]. 
The improved DSS in tumours maintaining IFNGR1 suggests that interruption of the IFNJ 
pathway, and hence evasion of subsequent anti-tumour effects, leads to a tumour being 
more aggressive with a poorer prognosis for the patient. This uncoupling from the immune 
system provides support to the theory of immunoediting in ovarian cancer. 
The lack of correlation with any of the histopathological variables suggests that the effects 
of IFNGR1 on survival are independent of any associated confounding factors. There 
have not been previous studies of IFNGR1 expression in ovarian cancers with which to 
compare these findings. 
In view of the absence of correlation between IFNGR1 and any confounding variables it 
was not surprising to demonstrate that loss of IFNGR1 was an independent prognostic 
marker. This is illustrated by multivariate analysis in which the prognostic value of IFNGR1 
expression maintained significance when all other prognostic markers (tumour stage, 
degree of cytoreductive surgery and chemotherapy) are included (Table 3.9). 
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Interestingly, although the effects of IFNGR1 expression on survival were seen at all 
tumour stages, they may be more pronounced in early stage disease (Figure 3.7). This 
would support the hypothesis that loss of IFNGR1 is an early phenomenon in ovarian 
cancer development, with these effects being diluted by subsequent cellular mutations 
which occur as the tumour escapes from immunological control. 
 The immunoediting theory would suggest that loss of IFNGR1 should confer a survival 
advantage to those cells, which would then become the predominant phenotype leading to 
loss of IFNJ responsiveness. This hypothesis has been supported by animal studies. 
Overexpression of a dominant negative mutant of IFNGR1 produced enhanced 
tumourogenicity and reduced immunogenicity in a mouse model [173]. Furthermore, mice 
lacking IFNGR1 or STAT1 were 10 - 20 times more likely to develop tumours in response 
to the carcinogen (MCA) than their wild type counterparts [174]. To assess if the effects of 
IFNJ insensitivity were related to the lack of expression in the tumour cells or immune 
effector cells, tumours derived from mice lacking IFNGR1 were seen to grow rapidly when 
transplanted into wild type hosts. This suggested that the effects were related to a lack of 
IFNJ function within the tumour cells. Using cell lines from these tumours, IFNGR1 was 
transfected into the cells thereby reneZLQJWKHFHOOV¶,)1J sensitivity. These tumours were 
highly immunogenic and were rejected in a CD4+ and CD8+ T cell dependent manner. 
These findings confirm a key role for IFNJ and IFNGR1 in promoting tumour 
immunogenicity [174] and were independently supported by similar results using C57BL/6 
strain mice lacking the gene for IFNJ itself [328]. These data suggest that the host immune 
system alters the phenotype of the tumours and selects for more aggressive tumour 
variants with less immunogenicity. 
IFNJ upregulates the quantity, quality and diversity of MHC class I. Upregulation of MHC 
class I is important in the host immune response to intracellular pathogens and acts by 
displaying antigens on the cell surface for interaction with CD8+ T cells. Diversity and 
quality of MHC class I products is enhanced by IFNJ inducing changes in the subunits 
within the MHC proteosome. IFNJ also upregulates TAP1 and TAP2, which are the key 
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transport molecules involved in movement of peptides within the MHC pathway. 
3URGXFWLRQ RI 0+& FODVV , KHDY\ FKDLQ DQG ȕ PDFURJOREXOLQ WKH FRQVWLWXHQW SDUWV RI
MHC class I, are increased in response to IFNJ [289]. The increased expression of MHC 
class I has been shown to be important in the immune response to tumours, and in the 
context of tumours evading the immune system. Loss of MHC has been implicated in this 
process [329], thereby preventing activation of CD8+ cytotoxic T cells and subsequent 
apoptotic pathways [330]. HLA class I has been documented to be reduced in a variety of 
tumours including ovarian cancer [331, 332]. Loss of MHC class I has also been shown to 
have a direct effect on tumour behaviour with lack of expression being an independently 
prognostic factor in breast, colorectal and ovarian cancers [333-335]. Clearly, any effects 
on the functioning of the IFNJ pathway may result in disruption of the MHC system with 
potential effects on prognosis. 
Tumour transformation results in an upregulation of stress molecules that are recognised 
E\Ȗį7FHOOVDQG1.FHOOVZLWK WKHVXEVHTXHQW UHOHDVHRIKLJK OHYHOVRI ,)1J. Although 
there is little NK infiltration in ovarian cancer, suggesting that these cells play a limited role 
in immunosurveillance RI WKLV FDQFHU PLFH ODFNLQJ Ȗį 7 FHOOV Kave high levels of 
spontaneous tumours  [176].  IFNJ orchestrates the trafficking of specific immune cells to 
sites of inflammation and stress, through various chemokines and adhesion molecules 
including MIG [336] and ICAM1 [337]. Therefore, disruption in the functioning of the IFNJ 
pathway may result in alterations in the presence of lymphocytes within the tumour milieu. 
There is evidence from a number of cancers, and in particular advanced ovarian cancer, 
that the presence of tumour infiltrating T lymphocytes (TILs) produces an improved clinical 
outcome in terms of disease free and overall survival. The presence of TILs gives a five 
year survival of 38% compared with 4% in those without. There were 39% of tumours with 
no detectable TILs. Interestingly, these findings were even more pronounced in patients 
with complete response to initial first line treatment (surgery and chemotherapy), where 
those with TILs had a 10 fold increase in survival [197]. Since stimulation of cells with IFNJ 
is required to produce signalling for recruitment of further lymphocytes, the loss of the 
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IFNJ receptor demonstrated in our study group may account for the absence of TILs 
witnessed by Zhang et al [197]. There is contrasting data relating to the presence of TILs 
which suggests that excessive accumulation is associated with increased tumour size. 
This may represent immunosuppressive effects from myeloid suppressor cells which 
inhibit the function of the accumulated T cells, and again it is defects in the IFNJ receptor 
that have been implicated in this process [338]. Unfortunately, due to the size of cores 
used in the TMA it was not possible to examine for the presence of TILs within the tumour, 
although this would provide a fascinating avenue for future investigation. 
Evidence from sarcoma cell lines demonstrated reduced levels of IFNJ receptor in lung 
metastases relative to non-metastatic tumours, and this was reflected in reduced levels of 
expression of IFNJ-related genes, in particular, caspase 1 and Fas [339]. This provides 
another potential avenue through which the observed prognostic impact of receptor loss 
demonstrated in our study might be produced, that is through the reduction in apoptotic 
pathways such as Fas and caspase 1. 
In addition to the aforementioned influence IFNJ exerts on stimulating immune effector 
cells, it is also known to exert a number of direct anti-tumour effects in ovarian cancer. A 
number of studies have shown IFNJ to produce negative effects on proliferation [327, 
340]. The anti-proliferative effects are thought to be via the actions of p21 [327, 341] and 
p27 that inhibit cyclin-dependent kinases [341] (see later discussion). In ovarian cancer 
cell lines, IFNJ has been shown to downregulate HER-2/neu, a proto-oncogene 
responsible for inducing proliferation and being a marker of poor prognosis, producing a 
reduction in proliferation rates [342]. Similarly IFNJ was seen to upregulate H-REV 107-1, 
a growth inhibitory gene resulting in apoptosis [343]. 
IFNJ has also been implicated in TRAIL-dependent apoptotic pathways, with IFNJ 
inducing transcription of mRNA for KILLER/DR5 TRAIL receptors mediating p53 
independent apoptosis [344]. 
Whilst the prognostic influence of IFNGR1 has not previously been documented, Marth et 
al did demonstrate, using RT-PCR, that increased expression of IFNJ in ovarian cancer 
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was an independent prognostic factor. This was associated with transcription of known 
IFNJ-associated genes (SOCS-1 and IRF-1) and reduced expression of HER2/neu [345].  
There are now a number of studies supporting a clinical role for IFNJ. The anti-proliferative 
effects of IFNJ were seen to act synergistically when combined with cisplatin in ovarian 
cancer cell lines [340]. Pro-apoptotic effects of IFNJ have been demonstrated via caspase 
pathways in ovarian cancer cells retrieved from ascitic fluid. Yet again, synergistic effects 
were seen with the addition of cisplatin [235], as well as inhibitory effects on anti-apoptotic 
molecules Bcl-2 and Bcl-XL [346]. Wall et al combined in vivo and in vitro methods to 
demonstrate the anti-proliferative effects in eight ovarian cancer cells lines.  However, 
only two of six patients with advanced ovarian cancer demonstrated a clinical 
improvement following administration of intra-peritoneal IFNJ, with reduced ascites 
formation [347]. 
A number of clinical trials have been conducted in an attempt to utilise the potential anti-
tumour effects of IFNJ, in particular, the synergistic effects seen in vitro with cisplatin. 
Early evidence of a potential clinical role came in 1988 when Welander et al [348] 
demonstrated some response to IFNJ in four of 14 patients with relapsed ovarian cancer. 
The intra-peritoneal approach, with the potential advantages of bioavailability via this 
route, was investigated and shown to produce a 31% response rate at second look 
laparotomy in patients with residual disease [349].  
In a randomised phase III study, 148 women with stage Ic-III ovarian cancer were treated 
with cisplatin and cyclophosphamide alone versus chemotherapy plus subcutaneous IFNJ. 
Unfortunately, the trial was terminated early due to changes in the recommended 
standard first line chemotherapy for ovarian cancer. At that point, a significantly improved 
PFS, from 38% in the control group to 51% in the IFNJ treatment group, was seen (RR of 
progression = 0.48, 95% CI 0.28 ± 0.82). Three year overall survival was also improved, 
with 58% and 74% respectively, although this was not statistically significant, possibly due 
to the premature termination of the trial [236]. Recent chemotherapy regimes which tend 
to include paclitaxel appear to be safe with regards to toxicity when combined with IFNJ 
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[237]. In light of this data, a recent large multi-centre phase III trial was conducted similar 
to the Windbichler et al study [236] but using carboplatin and taxol as the standard 
chemotherapeutic regime. This study was stopped early due to a pre-designated stopping 
boundary being reached during the second interim analysis, revealing significantly shorter 
OS time in patients receiving the IFNJ in addition to the standard chemotherapy. 40% of 
patients in the IFNJ group had died in comparison to 30% in the control arm. Higher 
adverse events were also seen in the IFNJ group, primarily due to serious haematological 
toxicities [350]. Explanations postulated as to reasons for treatment failure included direct 
toxicity from IFNJ and alterations in dose regime of chemotherapy, due to toxicity and 
activation of Tregs, resulting in immune suppression. The timing of the deaths tended to 
be after the completion of treatment making direct toxic effects from IFNJ unlikely. There 
was significantly greater incidence of grade 3 (severe) and 4 (life threatening) events with 
IFNJ, especially related to neutropenia. The increase in such toxicities in the IFNJ arm led 
to less patients completing the six cycles of carboplatin/ taxol or there was a requirement 
for dose reductions and delays. This is most likely to account for the reduced survival 
demonstrated, since the administration of sub-therapeutic chemotherapy as a result of 
toxicity occurred in 18% of the IFNJ group compared with only 9% of those receiving 
standard treatment. The third possibility is that IFNJ may have induced Treg cells, which 
have been shown to repress the cancer immune response [249]. The activity of Tregs has 
been linked to reduced survival in ovarian cancer [227, 249]. Hence, there is a possibility 
that exogenous IFNJ may paradoxically suppress the cancer immune response through 
the inhibitory effects of Tregs. Our data illustrates that IFNJ receptor loss occurs in 22% of 
tumours. Hence, a significant proportion of the patients in the study by Albert et al were 
unlikely to have benefited from what was clearly a toxic cocktail of agents, due to a 
defective IFNJ pathway. Therefore, these patients could potentially be receiving the 
additional toxicity from IFNJ without the potential beneficial anti-tumour effects. This might 
partly explain the negative impact IFNJ had on overall survival in this unselected 
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population. Assessment of the IFNGR status of the tumours prior to inclusion in such a 
study would highlight those tumours with an intact IFNJ signalling pathway which may 
benefit from IFNJ treatment. Equally it would exclude those in which a disrupted pathway 
would render the patient insensitive to such treatment.  
In summary, the expression of IFNGR1 in a typical ovarian cancer population is variable, 
with 22% showing complete loss of the receptor. Reduced receptor expression appears to 
have a negative effect on survival and is unrelated to other clinicopathological variables. 
The low expression of IFNGR1 is an independent prognostic marker in ovarian cancer. 
These data suggest that evasion of the IFNJ effects, through reduced receptor expression, 
results in more aggressive tumours, and supports the theory of immunoediting. Future 
work focusing on the targeting of susceptible tumours (those with functioning receptors) to 
IFNJ therapy may provide improved outcomes. 
3.3.2 STAT1 
 
The antibody used in this work detects STAT1 in both its inactive and active 
(phosphorylated) form. The process of activation of STAT1 via phosphorylation with 
subsequent translocation to the nucleus is well established [351]. Therefore, STAT1 within 
the nucleus is most likely to represent the active form with STAT1 in the cytoplasm being 
a combination of both forms. Similarly, deactivation and subsequent removal of STAT1 
from the nucleus through the action of nuclear tyrosine phosphatases has also been 
demonstrated [352]. Therefore, the assumption that the appearance of STAT1 within the 
nucleus represents active STAT1 seems reasonable. 
The distribution of STAT1 expression within the nucleus and cytoplasm (Figure 3.1), has 
previously been described [280]. The nuclear STAT1 is likely to represent the functioning 
component, however, high levels of phospho-STAT1 (i.e. activated) have been shown to 
predominantly reside within the cytoplasm, with weaker nuclear expression [280]. In 
addition, Meyer et al have demonstrated some level of functioning of unphosphorylated 
STAT1 within the nucleus, independent of the IFNJ activation [353]. This further 
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complicates the analysis of STAT1 expression as a component of the IFNJ pathway. We 
found a similar pattern of STAT1 expression to Chen et al [280] with cytoplasmic and 
nuclear immunoreactivity of 45% and 20% respectively (Table 3.11). There are a number 
of potential explanations for higher cytoplasmic, compared with nuclear, expression. 
Firstly, as was previously alluded to, the antibody which we used targeted both 
phosphorylated and non-phosphorylated STAT1. Therefore, we may be demonstrating a 
predominantly inactive reserve of STAT1 which does not correlate with cell signalling. 
However, as Chen et al [280] described similar findings, when only detecting activated 
STAT1, this seems unlikely. The use of an antibody for phospo-STAT1 may have 
removed this potential dilemma, but when this was used on the current TMA it produced 
non-specific staining and therefore the current antibody was preferred. Secondly, it has 
been suggested that a defective STAT1 transport system could occur in cancer cells, 
resulting in an accumulation of STAT1 within the cytoplasm [353]. 
When assessing the distribution of STAT1 expression, it was interesting to note that in the 
majority (97%) of cores in which there was an absence of STAT1 within the tumour cells, 
there was also loss of expression within the stromal cells. This suggests a generalised 
lack of IFNJ production within the tumour milieu (Table 3.13) 
There was a strong correlation between the expression of cytoplasmic and nuclear STAT1 
(Table 3.14). The vast majority (94%) of nuclear STAT1 was seen in tumours expressing 
cytoplasmic STAT1, which is to be expected since STAT1 translocates from the 
cytoplasm to the nucleus [351]. Interestingly, just fewer than half of the tumours 
expressing cytoplasmic STAT1 also displayed nuclear STAT1 expression . 
A correlation was seen between nuclear and cytoplasmic STAT1 and increasing tumour 
grade (Table 3.15). This had been previously demonstrated [354] and is thought to reflect 
an increasing stress response of the cell to dedifferentiation. A similar explanation may 
attribute the association with advanced stage and cytoplasmic STAT1 status, although 
this was not seen in nuclear STAT1. 
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Since STAT1 is the key signal transducer for IFNJ, it would be expected that IFNGR1 
status and STAT1 expression would be closely correlated, and this is indeed what is seen. 
In those tumours expressing high levels of STAT1 (both nuclear and cytoplasmic) the 
majority (93%) had expression of the IFNJ receptor (p<0.001) (Table 3.19). This 
relationship suggests that most of the demonstrated STAT1 expression is in the activated 
form. 
The survival analysis did not demonstrate a significant correlation between STAT1 
expression and prognosis, although there was a trend towards reduced survival with 
positive cytoplasmic STAT1 (Figure 3.9 and Figure 3.10). This suggests the possibility of 
an accumulation of STAT1 in the cytoplasm, resulting from defects in the upstream 
signalling pathway or defective translocation of STAT1 to the nucleus. To further 
investigate this possibility the tumours were regrouped according to this hypothesis, that is 
tumours in which there was positive cytoplasmic and negative nuclear STAT1 expression 
were grouped together and were deemed to have a potentially defective pathway. These 
were assessed against the remainder of the group (Figure 3.11). This demonstrated 
UHGXFHG VXUYLYDO LQ WXPRXUVZLWK WKH ³GHIHFWLYH67$7SDWKZD\´DOWKRXJK WKLV IDLOed to 
reach statistical significance. Clearly, this hypothesis can not be proven by 
immunohistochemical methods, and would require other techniques to investigate it 
further. There is early evidence that mutations in the nuclear import protein importin E p97, 
normally responsible for translocation of activated STAT1, could result in inhibition of this 
function with accumulation of STAT1 within the cytoplasm and a lack STAT1 within the 
nucleus [353]. This effective inhibition of IFNJ signalling might explain the trend towards 
reduced survival with high cytoplasmic and low nuclear STAT1. 
There is little data regarding the prognostic significance of STAT1 in ovarian cancer; 
however, contrasting findings have been illustrated in breast cancer where a positive 
correlation with STAT1 expression and prognosis was seen by one group [279], although 
others were unable to reproduce these findings [355]. In addition, activation of STAT1 in 
melanoma patients was seen to be a predictor of poor prognosis [356]. 
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Interestingly, although there was a correlation between IFNGR1 status and STAT1 
expression, STAT1 failed to produce similar prognostic features seen with the IFNGR1. 
There are a number of explanations for this; firstly, the IFNJ receptor represents a more 
stable protein. Only small fluctuations are produced with the ubiquitination and loss of 
some of the receptor molecules following signalling, the majority returning to the cell 
membrane [317]. Conversely, STAT1 is more unstable, with rapid deactivation through 
dephosphorylation and ubiquitin proteosome degradation pathways. This is possibly via 
the STAT-interacting ubiquitin ligase enzyme [357] and so may be producing a snapshot 
RI WKH FHOOV¶ DFWLYLW\ ZKLFK PD\ QRW EH HQWLUHO\ UHSUHVHQWDWLYH 6HFRQGO\ ZKLOVW 67$7
represents the main signal transducer for IFNJ, it can also be associated with other 
signalling pathways, for example, type I IFN.  Heterodimers and heterotrimers are 
produced with other STATs and IRFs, such as the STAT1:STAT2:IRF9 complex, which 
produces differing cellular effects [294]. Therefore, STAT1 expression will not exclusively 
represent IFNJ signalling, which may distort the perceived correlation of STAT1 with the 
IFNJ signalling pathway. 
3.3.3 p27 
 
p27 represents a prognostic marker in ovarian cancer which has sparked much 
controversy and debate. Various studies conducted on breast [358], gastric [359], 
colorectal [307], bladder [360], endometrial [311] and ovarian cancers [308, 361-365] have 
demonstrated seemingly contrasting results regarding the influence of p27 on tumour 
behaviour. 
Many studies in ovarian cancer have focused on the expression of nuclear p27, since this 
is its site of action as a CDKI [362, 366]. Some authors have demonstrated expression of 
p27 in both cytoplasmic and nuclear locations [325, 326, 367]. In the current study we 
support these findings with clear expression of nuclear and cytoplasmic p27 (Figure 3.12). 
The distribution of p27 expression was patchy in both sub-cellular locations with less then 
25% of tumour cores displaying positivity in the majority of the cells (Table 3.21). This 
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correlates with previous work in which the variation in nuclear staining was between eight 
and 99% of tumour cells [366]. This heterogeneity of staining is not ideal in TMA analysis, 
since only a relatively small area of the tumour is represented; the staining pattern could 
result in inaccurate assessment of protein expression if a non-representative area has 
been sampled. It was for this reason that two cores were assessed from each tumour, in 
an attempt to improve the likelihood of samples being representative. However, it is clear 
that this could not be as robust as using whole sections of tissue. This is one of the 
sacrifices made in the use of such high throughput immunohistochemical techniques. 
There has been huge variation as to whether nuclear or cytoplasmic p27 expression is 
relevant, with some authors suggesting the importance of nuclear [366] and others 
cytoplasmic [325, 367], whilst some do not distinguish [362]. To fully assess the potential 
influence of p27, we felt it necessary to assess both sub-cellular locations. 
With cytoplasmic p27 expression there was very limited data regarding a scoring system. 
Some studies showing limited cytoplasmic expression, which was not recorded or 
analysed [362], whilst others documented any immunoreactivity as positive [326]. Using 
an IS provided the maximum semi-quantitative assessment, using a well-recognised 
scoring system [368].  
Many studies have failed to describe any association between p27 and clinicopathological 
parameters [325, 362, 367]. We have demonstrated a trend towards early stage, with low 
compared to high cytoplasmic p27 expression, with 42% and 29% being early stage 
respectively (p=0.068). This relationship has previously been described [326]. Both high 
nuclear and cytoplasmic p27 expression was seen more predominantly in serous 
subtypes and less frequently in mucinous, which has also been reported previously [367]. 
High tumour grade has been associated with low p27 expression [366, 369, 370], but this 
was not seen in our study (Table 3.23). 
The initial survival analysis for cytoplasmic p27 showed a clear association between high 
expression and reduced survival (Figure 3.13), which supports the findings of Rosen et al 
[326]. The current analysis elaborates on this relationship, when the group is sub-
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stratified. It appears that there is a progressive impact on prognosis from no expression 
through to high expression, with increasing levels of cytoplasmic p27 resulting in 
increasingly poorer prognosis (Figure 3.13). Comparing those tumours with high 
expression with the remainder highlights these tumours as a particularly poor prognostic 
group (Figure 3.14).  
The analysis of nuclear p27 expression was also initially recorded as an IS. This 
demonstrated a reduced survival with high expression, and the subgroup analysis 
revealed that tumours with absent expression (<5% of cells positive), appeared to behave 
differently to those with low or high expression (Figure 3.15). Since most previous studies 
have divided tumours according to <5% as being negative, this method was favoured 
(Figure 3.15) [326, 366]. This clearly demonstrated that tumours with nuclear p27 
expression had a poorer prognosis (Figure 3.16). Using the previously mentioned 
established prognostic factors in a Cox regression model demonstrated that high 
cytoplasmic p27 expression was an independent prognostic factor (p=0.042), but nuclear 
expression was not (p=0.079) (Table 3.28 and Table 3.29). 
The nucleus is clearly the primary site of p27 action, however, a number of studies have 
demonstrated high levels of cytoplasmic expression in colorectal [371] and ovarian 
cancers [326]. This sequestering of p27 to the cytoplasm has been suggested as a 
mechanism for inactivation, by removal from its site of action [372]. This process is 
thought to occur as a result of PKB/Akt phosphorylation of p27, which itself may be related 
to the hyperactivation of Ras signalling [373]. Hence, activation of the Ras pathway results 
in the sequestration and inactivation of p27, which leads to increased levels of function 
CDK2 with subsequent triggering of the G1 phase of the cell cycle.   
There is increasing evidence that cytoplasmic expression of p27 does not simply reflect a 
method of inactivation, and that it has specific functions within the cytoplasm. p27 is 
associated with the formation of cyclin D and E-CDK complexes within the cytoplasm and 
the subsequent translocation to the nucleus [374]. Hence, high levels of cytoplasmic p27 
may result in increased formation and translocation of cyclin-CDK complexes to the 
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nucleus with subsequent stimulation of cell proliferation. Cytoplasmic p27 may have an 
anti-apoptotic effect through inhibition of cytochrome c release [375] and regulation of 
expression of the anti-apoptotic protein mcl-1 [375, 376]. The stimulation of cyclin-CDK 
complexes and the anti-apoptotic effects of p27 within the cytoplasm may explain the 
negative prognostic influence of high cytoplasmic p27 demonstrated in our study 
population. Recent evidence suggests that cytoplasmic p27 may have an influence on 
cellular motility as it has been shown to bind to and inhibit RhoA. The increased motility of 
tumour cells may effect their ability to invade and metastasise, which intuitively may 
influence tumour behaviour and hence prognosis [377]. The prognostic significance of the 
subcellular location of p27 again provides contrasting results with Watson et al 
demonstrating improved survival with high expression of cytoplasmic p27 in colorectal 
cancers [378]. Rosen et al, however, suggest the opposite effect in a series of ovarian 
cancers [326]. 
The novel role suggested for cytoplasmic p27 fails to explain our findings that increased 
nuclear p27 also predicts an unfavourable prognosis. This result seems paradoxical when 
considering that the role of p27 within the nucleus as a cell cycle inhibitor is well 
established [303]. However, whilst a number of studies have shown the expected effect of 
a correlation between reduced nuclear p27 and poor survival in ovarian cancer [363, 379], 
overexpression of nuclear p27 has also been proposed as a mechanism for inactivation. 
Two other studies failed to demonstrate these effects [361, 380], whilst the findings of 
Psryrri et al concurred with our results [325]. 
Nuclear p27 overexpression has been demonstrated in a number of tumours, including 
endometrial [311, 381], pancreatic [310] and breast [382]. Paradoxically, increased 
nuclear p27 has been linked to an increased cellular proliferation rate in endometrial [311], 
colorectal [383] and lung cancer [384].  This upregulation of p27 has been proposed to 
induce, as opposed to inhibit, cyclinE-CDK2 signalling and hence promote cell division 
[374, 383]. 
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Since mutation in the p27 gene is very rare [385], the explanation of the seeming 
dysregulation of p27 in malignant tissue relates to post-translational effects. The tumour 
cells may become resistant to inhibition by p27, resulting in its amplification of p27 in an 
attempt to overcome this resistance [386]. Secondly, alterations in the level of associated 
factors such as cyclin D and E may influence p27 effects [281]. Thirdly, there may be 
alterations in the ubiquitin-related p27 degradation pathway, leading to elevation of p27 
levels within the nucleus resulting in disruption of normal functioning [387]. 
3.3.4 Caspase 1 
 
Caspase 1 is a protease, which cleaves inactive pro-interleukin-1E (IL1E) to produce the 
active 17 kDa mature form, which is a key mediator of inflammation [388, 389]. Hence, the 
alternative name for caspase 1, IL1E converting enzyme (ICE). In addition to its role in 
triggering inflammation, caspase 1 is also associated with apoptosis [390]. The inactive 
precursor of caspase 1 is the 45 kDa protein, p45. Activation occurs through the cleaving 
of the terminal subunit to create two active components p20 and p10. The active caspase 
1 complex consists of two p10 and two p20 monomers [391, 392]. The caspase 1 
antibody used in this study (06-503 Upstate Biotechnology) recognises both the inactive 
pro-caspase (p45) and one of the active subunits (p20), hence any immunoreactivity 
demonstrated may have represented either inactive or active caspase 1. 
In normal cells caspase 1 predominantly exists within the cytoplasm as the p45 proform 
[393] which is converted via upstream initiator caspases such as caspase 8 and 9 [316]. 
Yang et al, working with the same antibody used in our study showed immunoreactivity in 
71% of tumour cells compared to 90% in our population [283] (
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Table 3.35), and demonstrated overexpression of caspase 1 in pancreatic carcinomas 
and in chronic pancreatitis. Feng et al reported opposite effects, with reduced levels of 
caspase 1 in ovarian cancer cell lines compared with surface epithelium of normal 
ovaries. This was associated with reduced caspase 1 mRNA, suggesting reduced 
production as opposed to increased utilisation of the enzyme, which was also linked to 
reduced apoptosis [394].  Caspase 1 has a predominantly cytoplasmic location [393], and 
this was clearly seen in the pattern of staining within the TMA (Figure 3.17).The 
preponderance to high caspase 1 expression in undifferentiated and endometrioid cell 
types has not previously been reported (Table 3.36). 
An alternative route of activation of caspase 1 is via IRF1 to produce IFNJ-mediated 
apoptosis [181]. This process was illustrated in the loss of IFNJ-induced caspase 1 
apoptosis in IRF1-deficient mice [395]. Induced caspase 1 activates downstream 
caspases such as caspase 3, a highly active apoptotic target which destroys the 
homeostatic functions within a cell, to produce a final common caspase mediated 
apoptotic pathway [316]. Therefore, one of the principle effects of IFNJ on tumour cells, 
apoptosis, is thought to be via activation of IRF1 with subsequent triggering of the 
caspase cascade via caspase 1. This pathway has been illustrated using pancreatic [182] 
and ovarian cell lines [396]. Consequently, tumour cell evasion from immunosurveillance 
through defects in the IFNJ pathway may be through inhibition of the pro-apoptotic effects 
of IFNJ induced caspases. Therefore, reduced expression of active caspase 1 through a 
defective IFNJ-IRF1-caspase 1 pathway may result in a poorer prognosis. 
In our population, tumours with reduced caspase 1 expression had significantly improved 
overall survival, with mean survival time 20 months greater than tumours with high 
caspase 1 expression (p=0.025) (Figure 3.18) (Table 3.37) although this was not 
independently significant (Table 3.39). This effect was not reproduced when looking at 
absence vs. presence of caspase 1, which may be due to the small number of patients 
within the absent caspase 1 group (10% of total). This would require a bigger difference in 
survival to produce a significant association with survival (Figure 3.19) (Table 3.38). 
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Since the antibody recognises both active and inactive caspase 1, the interpretation of 
these results is difficult. Caspase 1 is known to exist mainly in the inactive form within 
cells. A cell which is actively converting pro-caspase would therefore produce a reduction 
in the total amount of caspase 1 within the cell. Hence, the low expression of total 
caspase 1 within tumour cells may represent a cell with increased utilisation of the 
caspase 1 pathway, which in turn triggers higher levels of apoptosis. This theory could 
explain why reduced levels of caspase 1, as a marker of increased apoptosis, would 
produce a more favourable prognosis since greater tumour killing is occurring. 
Whilst caspase 1 has a clear role in apoptosis, overexpression has been associated with 
elevated levels of cyclin D1 [283], which has been demonstrated to lead to increased cell 
proliferation and contribute to aggressive tumour behaviour in lung [397] and ovarian 
cancers [341]. Overexpression of caspase 1 has also been linked to increased levels of 
epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) [283] which 
have also been linked to poor prognosis in ovarian cancer [256]. 
Interestingly, of the six ovarian cancer cell lines used by Feng et al, one had very high 
levels of caspase 1 expression in the absence of any caspase-dependent apoptosis [394]. 
This suggests a defect in the downstream caspase pathway which could result in 
increasing levels of caspase 1 without subsequent apoptosis. This may be an alternative 
explanation for the association between poor prognosis and the high levels of caspase 1 
in the current study. 
The positive correlation displayed between high caspase 1 expression, IFNGR1 and 
STAT1 status (Table 3.40) suggests that the signalling pathway in tumours with a 
functioning IFNJ pathway, that is STAT1 and IFNGR1 positive, produces elevated levels 
of caspase 1. The correlation between STAT1 activation, through IFNJ stimulation, and 
subsequent caspase 1-induced apoptosis has been demonstrated in cancer cell lines 
[181]. This association would contradict the hypothesis that low caspase 1 levels were a 
result of excessive signalling leading to reduced reserves of pro-caspase 1. This 
association would instead suggest that the elevated caspase 1 expression seen was a 
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result of increased levels of the activated isoforms. This could possibly lead to increased 
levels of EFG, EGFR and cyclin D1, or reflect a defective downstream pathway, both of 
which would produce the observed reduction in survival seen. Further work investigating 
the influence of these factors and IRF1 may elucidate the relationship between high 
caspase 1 expression and reduced survival. 
3.4 Conclusion 
 
Loss of IFNGR1 was demonstrated to be an independent marker of poor prognosis. This 
effect was seen in both early and late stage tumours, suggesting that this was an early 
phenomenon in tumourigenesis. The loss of IFNGR1 in a significant number of tumours 
might explain the negative findings of previous clinical trials using IFNJ [350]. 
STAT1, the main intracellular signalling molecule for the IFNJ pathway, failed to show the 
same strong correlation with prognosis as IFNGR1. There was a non-significant 
association between a defective STAT1 pathway and prognosis.  
p27 showed a clear association between high cytoplasmic and nuclear p27 expression 
and reduced survival; however, only cytoplasmic expression was an independent 
prognostic factor. This result seems paradoxical when considering that the role of p27 
within the nucleus as a cell cycle inhibitor is well established, although increased nuclear 
p27 has been linked paradoxically to an increased cellular proliferation rate [311, 374, 
384].  This upregulation has been proposed to induce, as opposed to inhibit, cyclinE-
CDK2 signalling and hence promote cell division [374, 383]. 
Tumours with reduced caspase 1 expression demonstrated significantly improved overall 
survival, although this was not independent of other prognostic factors. Reduced levels of 
caspase 1, as a marker of increased apoptosis, would produce a more favourable 
prognosis since greater tumour killing is occurring. Alternatively, overexpression of 
caspase 1 has been associated with elevated levels of cyclin D1 [283], with increased cell 
proliferation and aggressive tumour behaviour [341]. 
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4 TRAIL Pathway 
4.1 Introduction 
 
Dysregulated apoptosis plays a key role in carcinogenesis producing an increased tumour 
cell life span as well as contributing to the development of chemoresistance. The tumour 
necrosis factor D (TNFD) super-family represents a significant apoptotic pathway. The 
death receptor ligands for this pathway include Fas ligand, TNFD, TL1A and TNF- related 
apoptosis inducing ligand (TRAIL). These ligands can signal following release into the 
extracellular matrix or whilst bound to the cell membrane during cell-cell contact [260]. 
TRAIL has attracted recent attention as a potential anticancer agent due to its apoptotic 
activity against cancer cells in vitro [398]. Unlike other TNF family members, soluble 
TRAIL seems inactive against normal cells [399]. 
Thus far, there have been five TRAIL receptors identified, two agonistic receptors DR4 (or 
TRAIL-R1) and DR5 (TRAIL-R2), and three antagonistic TRAIL-R3, TRAIL-R4 and 
osteoprotegerin [16]. For the reminder of this work DR4 and DR5 will be used as opposed 
to TRAIL-R1/-R2, although these terms are interchangeable. 
Both DR4 and DR5 are transmembrane proteins which contain an extracellular receptor 
with an intracellular tail containing a death domain (DD), which engages downstream 
apoptotic pathways after ligand binding [398]. TRAIL-R4 has a non-functioning cytosolic 
tail and TRAIL-R3 lacks a cytosolic tail entirely, hence they fail to transmit ligand 
signalling. Since all the TRAIL receptors have similar extracellular domains they all bind to 
the same ligand, therefore TRAIL-3 and -4 have the effect of acting as decoy receptors 
[16]. 
TRAIL forms homotrimers that bind three receptor molecules resulting in trimerisation of 
receptors with clustering of the intracellular DDs. The clustering of the DDs leads to the 
recruitment of the adaptor molecule Fas-associated protein with death domain (FADD), 
which in turn activates caspase 8 and caspase 10. The activation of caspase 8 and 10 
leads to direct and indirect (through mitochondrial cytochrome c) conversion of pro-
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caspase 3 and 7 to the active forms, both of which lead to cellular disassembly (Figure 
4.1) [16]. 
The evidence of dysregulation of TRAIL in the development of tumours and their 
resistance to chemotherapy, as well as its potential therapeutic role, provides an 
interesting avenue of investigation using the ovarian cancer TMA. The hypothesis follows 
that tumours with low expression of DR4 and DR5 would be less prone to TRAIL-
mediated attack and therefore apoptosis. This would be reflected in reduced patient 
survival. 
 
Figure 4.1 TRAIL apoptosis pathway. Trimerisation of death receptors (R1 and R2) by TRAIL 
triggers activation of caspase 8 and caspase 10. This subsequently activates caspase 3 and 
caspase 7 leading to apoptosis. Adapted from Carlo-Stella et al [16]. 
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4.2 Results 
4.2.1 Clinicopathological characteristics 
 
Of the 339 tumour cores on the TMA, 40 were lost with DR4 and 39 with DR5 
immunohistochemical processing. This left approximately 88% of cases available for 
analysis. The subgroups analysed were similar to that of the overall group, which as 
previously discussed, is representative of a typical ovarian cancer population (Table 4.1). 
Of particular importance was the comparability of five year survival, being 24% in the 
whole series and 25% in those analysed for DR4 and DR5 expression. 
4.2.2 DR4 and DR5 staining 
 
The subcellular distribution of both DR4 and DR5 expression was mainly seen within the 
cytoplasm. There was very occasional membrane staining and some nuclear staining 
seen with DR4 and DR5, although this was most prominent with DR4 (Figure 4.2 and 
Figure 4.3). In line with previous studies, expression within the cytoplasm was assessed 
[286, 400-402]. DR4 expression, when present, was of predominantly mild to moderate 
intensity (67%), with only 14% of cores showing strong staining and 19% showing no 
immunoreactivity (Table 4.2). DR4 expression tended to be homogeneous within the 
positive cores and was demonstrated in at least 75% of cells (Table 4.3). 
DR5 expression was also mainly mild to moderate in intensity, although a greater 
proportion of cores were negative (36%) compared with DR4 (Table 4.2). The staining 
was more heterogeneous than DR4, with less than 50% of cells demonstrating 
immunoreactivity within each positive core cells (Table 4.3). For the purposes of analysis, 
and in line with previous work [286], a core was deemed positive if there was the 
presence of staining and negative if there was a complete absence of immunoreactivity. 
This system was decided upon prior to analysis in order to avoid potential bias. When 
classifying tumour cores, according to these criteria, 81% and 65% were positive for DR4 
and DR5 respectively. 
 186 
Table 4.1 Clinicopathological characteristics of whole series and those analysed from the 
TMA. 
Variable Whole series 
n=395 (%) 
DR4 Analysed 
Cases n=299 (%) 
DR5 Analysed 
Cases n=300 (%) 
Age (years) n=394 n=298 n=299 
  <30 1 (0.3) 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 118 (39.6) 117 (39.1) 
   226 (57.4) 179 (60.1) 181 (60.5) 
    
FIGO Stage n=375 n=292 n=292 
  I 99 (22.6) 74 (25.3) 74 (25.3) 
  II 46 (12.3) 32 (11.0) 31 (10.6) 
  III 188 (50.1) 153 (54.4) 153 (52.4) 
  IV 42 (11.2) 33 (11.3) 34 (11.6) 
    
Optimal Debulking n=376 n= 288 n=289 
  Yes 157 (41.8) 117 (40.6) 118 (40.8) 
  No 219 (58.2) 135 (59.4) 171 (59.2) 
    
Tumour Grade n=376 n=298 n=299 
  1 50 (13.3) 34 (11.4) 33 (11.0) 
  2 93 (24.7) 67 (22.5) 67 (22.4) 
  3 233 (62) 197 (66.1) 199 (66.6) 
    
Histological Type n=395 n=299 n=300 
  Serous 203 (51.4) 160 (53.5) 160 (53.3) 
  Endometrioid 46 (11.7) 39 (13.0) 40 (13.3) 
  Mucinous 50 (12.7) 30 (10.0) 28 (9.3) 
  Undifferentiated 65 (16.5) 14 (15.7) 46 (15.3) 
  Clear Cell 26 (6.6) 20 (6.7) 23 (7.7) 
  Other 5 (1.3) 3 (1.0) 3 (1.0) 
    
Chemotherapy n=388 n=294 n=294 
  Platinum 196 (50.5) 150 (51.0) 150 (51.0) 
  Non-platinum 80 (20.6) 69 (23.5) 70 (23.8) 
  None 112 (28.9) 75 (25.5) 74 (25.2) 
Randomised treatment 69/395 (17.5) 53/299 (17.7) 52/300 (17.3) 
    
Five Year Survival n=385 n=294 n=295 
  Yes 91 (23.6) 74 (25.2) 76 (25.8) 
  No 294 (76.4) 226 (74.8) 219 (74.2) 
Alive at time of censoring n=388 n=296 n=297 
  Yes 60 (15.5) 50 (16.9) 52 (17.5) 
  No 328 (84.5) 246 (83.1) 245 (82.5) 
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Figure 4.2 Photomicrographs of ovarian TMA cores immunohistochemically stained for DR4. 
The level of expression ranged from none (A), weak (B), moderate (C) through strong (D). 
Expression was mainly cytoplasmic but nuclear staining was also seen. Magnification: x100, 
inset x400. 
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Figure 4.3 Photomicrographs of ovarian TMA cores immunohistochemically stained for DR5. 
The level of expression ranged from none (A), weak (B), moderate (C) through strong (D). 
Expression is mainly cytoplasmic, although occasional nuclear staining is seen. 
Magnification: x100, inset x400. 
 
Table 4.2 Intensity of cytoplasmic staining with DR4 and DR5. 
 
Intensity of 
Staining 
DR4 DR5 
Number Percentage Number Percentage 
No staining 56 18.7 106 35.5 
Mild 91 30.4 72 24.0 
Moderate 101 37.2 100 33.3 
Strong 41 13.7 22 7.4 
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Table 4.3 Proportion of viable tumour cells staining with DR4 and DR5. 
Proportion of 
tumour cells 
staining 
DR4 DR5 
Number Percentage Number Percentage 
No cells 56 18.7 106 35.5 
1 - 25% 13 4.3 25 8.3 
26 - 50% 39 13.0 57 19.0 
51 - 75% 30 10.0 29 9.7 
76 - 100% 161 54.0 83 27.7 
 
4.2.3 Comparison of DR4 and DR5 expression 
clinicopathological characteristics including survival 
 
In a univariate analysis, using the F2 test, no significant relationship between DR4 
expression and the standard clinical and pathological variables was apparent. This 
included five year survival and overall patient survival. There was a higher proportion of 
endometrioid and mucinous subtypes with DR4 positive tumours, although this was not 
statistically significant. 
There was a trend towards improved prognosis with positive DR4 expression, with 27% 
vs. 18%, five year survival. However, this also failed to reach statistical significance 
(p=0.107), which may be due to the relatively small proportion of tumours with negative 
DR4 status (Table 4.4). 
Further analysis of the prognostic significance of DR4 status is provided by Kaplan-Meier 
survival curves and log rank testing (Figure 4.4). There is a suggestion that loss of DR4 
expression leads to a poorer prognosis, with mean and median survival times of 39 and 
16 months respectively. This prognosis compares unfavourably with tumours which 
express DR4, as these have mean and median survival times of 64 and 23 months 
respectively. This difference between the two groups failed to reach statistical significance 
(p=0.153), and is possibly due to the small group of patients with no DR4 expression, 
leading to wide confidence intervals (Table 4.6). 
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Table 4.4 DR4 expression in all cases included in final analysis including univariate analysis 
by F2 of DR4 status and clinicopathological criteria. 
Variable Analysed DR4 
cases n= 299 
Positive DR4 
expression 
Negative DR4 
expression  
Ȥ 
(p value) 
Age (years) n=298 n=193 n=56 
4.65 
(0.098) 
  <30 1 (0.3) 0 1 (1.8) 
  30-59 118 (39.6) 98 (40.5) 20 (35.7) 
   179 (60.1) 144 (59.5) 35 (62.5) 
     
FIGO Stage n=292 n=237 n=55 
1.93 
(0.588) 
  I 74 (25.3) 64 (27.0) 10 (18.2) 
  II 32 (11.0) 26 (11.0) 6 (10.9) 
  III 153 (54.4) 121 (51.1) 32 (58.2) 
  IV 33 (11.3) 26 (10.9) 7 (12.7) 
    
 
Optimal Debulking n= 288 n=233 n=55 
1.04 
(0.307)   Yes 117 (40.6) 98 (42.1) 19 (34.5) 
  No 135 (59.4) 135 (57.9) 36 (65.5) 
    
 
Tumour Grade n=298 n=242 n=56 
4.20 
(0.122) 
  1 34 (11.4) 32 (13.2) 2 (3.6) 
  2 67 (22.5) 53 (21.9) 14 (25.0) 
  3 197 (66.1) 157 (64.9) 40 (71.4) 
    
 
Histological Type n=299 n=243 n=56 
9.25 
(0.099) 
  Serous 160 (53.5) 127 (52.3) 33 (58.9) 
  Endometrioid 39 (13.0) 35 (14.4) 4 (7.1) 
  Mucinous 30 (10.0) 29 (11.9) 1 (1.8) 
  Undifferentiated 14 (15.7) 35 (14.4) 12 (21.4) 
  Clear Cell 20 (6.7) 15 (6.2) 5 (8.9) 
  Other 3 (1.0) 2 (0.8) 1 (1.8) 
    
 
Chemotherapy n=294 n=238 n=56 
2.09 
(0.554) 
  Platinum 150 (51.0) 125 (52.5) 16 (28.6) 
  Non-platinum 69 (23.5) 54 (22.7) 25 (44.6) 
  None 75 (25.5) 59 (24.8) 15 (26.8) 
Randomised treatment 53/299 (17.7) 40/171 (17.6) 10/56 (17.8) 0.26 (0.87) 
    
 
Five Year Survival n=294 n=238 n=56 
1.96 
(0.107)   Yes 74 (25.2) 64 (26.9) 10 (17.9) 
  No 226 (74.8) 174 (73.1) 46 (82.1) 
Alive at time of censoring n=296 n=240 n=56 
0.33 
(0.563)   Yes 50 (16.9) 42 (17.5) 8 (14.3) 
  No 246 (83.1) 198 (82.5) 48 (85.7) 
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DR5 expression did demonstrate some associations with a number of clinicopathological 
features. There did appear to be an increased likelihood of optimal debulking surgery in 
DR5 negative tumours (49% vs. 37%, p=0.047). There was also a propensity for clear cell 
tumours to have a DR5 negative status. In addition, more patients with DR5 positive 
tumours received platinum-based chemotherapy (55% vs. 43%, p=0.039). In spite of 
these differences, however, this failed to translate into an alteration in prognosis, with DR5 
positive patients having a 27% five year and a 19% overall survival respectively, 
compared with 23% and 15% in DR5 negative patients (p=0.487 and p=0.415) (Table 
4.5). Unsurprisingly, using a Kaplan-Meier survival curve and log rank testing confirmed 
that there was no prognostic value to DR5 status (p=0.538) (Figure 4.4 and Table 4.6). 
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Table 4.5 DR5 expression in all cases included in final analysis including univariate analysis 
by F2 of DR5 status and clinicopathological criteria. 
Variable Analysed DR5 cases 
Positive DR5 
expression 
Negative DR5 
expression 
Ȥ 
(p value) 
Age (years) n=299 n=193 N=106 
2.30 
(0.317) 
  <30 1 (0.3) 0 1 (0.9) 
  30-59 117 (39.1) 73 (37.8) 44 (41.5) 
   181 (60.5) 120 (62.2) 61 (57.6) 
     
FIGO Stage n=292 n=189 n=103 
1.58 
(0.663) 
  I 74 (25.3) 44 (23.3) 30 (29.1) 
  II 31 (10.6) 22 (11.6) 9 (8.7) 
  III 153 (52.4) 100 (52.9) 53 (51.5) 
  IV 34 (11.6) 23 (12.2) 11 (10.7) 
     
Optimal Debulking n=289 n=186 n=103 
3.94 
(0.047)   Yes 118 (40.8) 68 (36.6) 50 (48.5) 
  No 171 (59.2) 118 (63.4) 53 (51.5) 
     
Tumour Grade n=299 n=194 n=105 
3.64 
(0.161) 
  1 33 (11.0) 18 (9.3) 15 (14.3) 
  2 67 (22.4) 49 (25.3) 18 (17.1) 
  3 199 (66.6) 127 (65.5) 72 (86.6) 
     
Histological Type n=300 n=194 n=106 
13.32 
(0.021) 
  Serous 160 (53.3) 108 (55.7) 52 (49.1) 
  Endometrioid 40 (13.3) 27 (13.9) 13 (12.3) 
  Mucinous 28 (9.3) 20 (10.3) 8 (7.3) 
  Undifferentiated 46 (15.3) 30 (15.5) 16 (15.1) 
  Clear Cell 23 (7.7) 9 (4.6) 14 (13.2) 
  Other 3 (1.0) 0 3 (2.8) 
     
Chemotherapy n=294 n=190 n=104 
8.34 
(0.039) 
  Platinum 150 (51.0) 105 (55.3) 45 (43.3) 
  Non-platinum 70 (23.8) 36 (19.0) 34 (32.7) 
  Other 74 (25.2) 49 (25.8) 25 (24.0) 
Randomised treatment 52/300 (17.3) 34/194 (17.5) 18/106 (17.0) 0.26 (0.87) 
     
Five Year Survival n=295 n=190 n=105 
0.720 
(0.487)   Yes 76 (25.8) 52 (27.4) 24 (22.9) 
  No 219 (74.2) 138 (72.6) 81 (77.1) 
Alive at time of censoring n=297 n=191 n=106 
0.665 
(0.415)   Yes 52 (17.5) 36 (18.8) 16 (15.1) 
  No 245 (82.5) 155 (81.2) 90 (84.9) 
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Figure 4.4 Kaplan-Meier plot for disease-specific survival. A: Absent compared with present 
DR4 expression in tumours (n=299). No association between DR4 status and survival shown. 
Log rank= 2.045, p=0.153. B: Absent compared with present DR5 expression in tumours 
(n=300). No association between DR5 status and survival shown. Log rank= 0.379, p=0.538. 
 
Table 4.6 Mean and median survival time in relation to DR4 and DR5 expression. Log Rank 
test for univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
DR4 
DR4 lost 39.2 7.1 25.3 53.1 15.9 2.5 11.0 20.7 
DR4 present 63.8 6.0 52.0 75.5 23.1 3.3 16.9 29.5 
Overall 60.6 5.3 50.2 71.1 21.6 2.6 16.4 26.8 
DR5 
DR5 lost 55.3 7.6 40.5 70.2 21.1 5.1 11.2 31.1 
DR5 present 65.0 7.0 51.3 78.7 23.1 3.7 15.8 30.4 
Overall 62.3 5.4 51.6 73.0 22.1 2.9 16.4 27.8 
(a) Estimation is limited to the largest survival time if it is censored. 
Log Rank (Mantel-Cox) Chi-square d.f. p value 
DR4 2.0451 1 0.153 
DR5 0.379 1 0.538 
 
Since DR4 and DR5 have similar functions (they both act as agonist receptors for TRAIL) 
an analysis of the combined receptor status was performed (Table 4.7 and Figure 4.5). As 
illustrated in the Kaplan-Meier curves there was no clear relationship when assessing 
receptor status in combination. The absence or presence of both receptors resulted in 
similar median survival times of 22 and 24 months respectively. Prognosis did appear to 
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be worse in those patients expressing only a single receptor, but overall the relationship 
failed to reach significance (p=0.078). 
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Figure 4.5 Kaplan-Meier plot for disease-specific survival according to combined DR4 and 
DR5 receptor status (n=299) 
 
Table 4.7 Mean and median survival time in relation to combined DR4 and DR5 expression. 
Log Rank test for univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Both DR4 
and DR5 
absent 
57.0 14.4 28.7 85.3 21.6 16.6 0.0 54.2 
One receptor 
lost 44.8 6.6 31.9 57.6 16.9 3.5 10.0 23.9 
Both DR4 
and DR5 
present 
68.8 7.8 53.4 84.1 24.2 4.2 16.0 32.6 
Overall 60.2 5.3 49.7 70.7 21.7 2.9 16.1 27.3 
(a) Estimation is limited to the largest survival time if it is censored. 
 Chi-square d.f. p value 
Log Rank (Mantel-Cox) 5.112 2 0.078 
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4.3 Discussion 
 
This chapter focused on the theoretical possibility that changes in the expression of TRAIL 
receptors DR4 and DR5 may occur in ovarian cancer cells, and that these differences 
might produce differences in tumour behaviour. The loss of death receptor expression, 
thereby enabling evasion of immune attack, would be in keeping with the theory of 
immunoediting [206]. 
The expression of DR4 and DR5 within the tumour cores was mainly seen in the 
cytoplasm with occasional nuclear and membrane staining. These patterns are similar to 
those of a previous study of ovarian cancers [286], suggesting that the staining distribution 
was representative. Previous work has demonstrated that loss of DR4 and DR5 
expression in ovarian cancer is associated with increasing tumour grade and stage [286]. 
This was not seen in the current cohort, although other workers also failed to demonstrate 
this association [403]. 
Since TRAIL is an important pathway in apoptosis, intuitively a role in tumour behaviour 
seems likely. Evidence exists for a role in tumourogenesis and immune response to 
tumours. In a mouse model, it was shown that TRAIL is important in the surveillance of 
tumour metastases by NK cells [404].  
There are a number of studies suggesting that dysregulation of the TRAIL pathway, 
through alteration in the expression of receptors, leads to effects on patient survival [286, 
400-402]. The results are varied and may be dependent on the type of cancer. Renal cell 
cancers were seen to have poorer prognosis with high DR5 and low TRAIL-R4 (a decoy 
receptor) expression, which seems counterintuitive [401]. However, this has been 
reproduced in breast [402] and lung cancers [405]. The opposite finding of an improved 
prognosis with high expression of DR4 and DR5 has been seen in colorectal and 
glioblastomas respectively [406, 407]. It has been postulated that the association between 
high death receptor expression and poor prognosis is due to a proliferative response to 
TRAIL from DR4 and DR5 receptors in cells with TRAIL resistance. This mechanism has 
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also been suggested to promote invasion and metastasis in some tumour types [401]. In 
ovarian cancer there has been an association between high DR5 expression and poor 
survival; however, as was found with the current cohort no association was seen with DR4 
[286]. 
Most chemotherapy and radiotherapy produce cellular damage which triggers apoptosis 
through the tumour suppressor p53 pathway. Due to the survival advantage conferred, 
continued treatment eventually results in selection of tumour cells with inactivated p53 
pathways. This renders the tumours resistant to treatment. Activation of the TRAIL death 
receptors represents an extrinsic, p53-independent, pathway for apoptosis. This 
mechanism may potentially resensitise tumours to chemotherapy through the use of 
TRAIL in combination with conventional treatment [16]. There is also evidence to suggest 
that TRAIL-related apoptosis may be highly selective for tumour cells, since low levels of 
death receptors are seen in normal cells, and there seems to be a limited effect on normal 
cells from exposure to TRAIL [399]. 
A number of TRAIL-related complexes have been developed including recombinant 
TRAIL and agonist monoclonal antibodies to DR4 and DR5. These monoclonal antibodies 
have the theoretical advantage of only stimulating the death receptors and not the decoys 
[16]. These therapies are currently at the phase I stage in solid tumours in conjunction 
with carboplatin and paclitaxel chemotherapy [408]. These DNA-damaging agents may 
act synergistically with TRAIL by upregulating the death receptors [409]. There is some 
evidence that mutations and defects in the receptors (DR4 and DR5) and downstream 
components may lead to resistance to TRAIL-mediated therapy [410]. TRAIL targeting 
therapeutics are highly specific for TRAIL death receptors. Therefore, the level of receptor 
expression should be examined as a prerequisite IRUSDWLHQWV¶LQFOXVLRQLQFOLQLFDOVWXGLHV
of such agents. In the current cohort of ovarian cancers contained within the TMA it 
seems that both agonist receptors are expressed in the majority of cases (72% DR4, 65% 
DR5). Hence, most patients would be eligible for such studies. However, the influence of 
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prior exposure of tumours to chemotherapy to the levels of death receptor expression is 
not yet known.  
This current work does not appear to demonstrate any prognostic significance from either 
DR4 or DR5, but since both receptors can respond independently to TRAIL, a combined 
analysis was performed. This failed to show any effect from either complete loss, or 
presence, of both receptors. There are a number of reasons why no prognostic 
significance was seen in the ovarian TMA compared with previous studies [286, 400-402]. 
Firstly, there do appear to be varying effects dependent on tumour type. Therefore, 
ovarian cancer may not have a prominent TRAIL-dependent component of apoptosis 
relative to other tumour sites. In addition to alterations in the levels of expression of the 
receptor, there may also be changes in the downstream pathway, such as the caspase 
cascade, which would alter the responsiveness to TRAIL. This was not assessed in the 
current work, but could be a focus of future work. DR4 and DR5 are both agonist 
receptors whose effects are balanced by decoy receptors (TRAIL R3, R4 and OPG); 
alterations in their expression may contribute to the response of the cell to TRAIL. 
Previous work has suggested that high levels of decoy receptors may produce resistance 
to TRAIL-mediated apoptosis [411], although other authors suggest that the ratio of death 
receptors and decoys does not correlate with TRAIL resistance [412]. Finally, as with all 
immunohistochemical studies there may also be variations in antibody and antigen 
preparation and inter-observer variations between the current work and previous studies.  
4.4 Conclusion 
 
Of the patients included in the ovarian TMA neither DR4 nor DR5 expression was 
SURJQRVWLF 7KLV PD\ QRW UHIOHFW WKH FHOOV¶ UHVSRQVLYHQHss to TRAIL, since analysis of 
decoy receptors was not included and could be the focus of future work. The death 
receptors are expressed in the majority of tumours, making ovarian cancer an ideal 
candidate for clinical studies of TRAIL and TRAIL monoclonal antibodies. 
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5 Vascular Endothelial Growth Factor 
5.1 Introduction 
 
Angiogenesis has been established as a vital component among the mechanisms 
involved in tumour growth and metastasis [261, 262]. The angiogenic potential of tumours 
can be assessed by measuring microvessel density (MVD). Earlier studies illustrated the 
importance of angiogenesis in tumour development, with MVD directly correlating with a 
poor prognosis in ovarian [413] and other tumours [414, 415]. The mounting evidence of a 
pivotal role for neovascularisation in carcinogenesis has lead to the development of drugs 
targeting these mechanisms and hence the degree of vascular activity within a specific 
tumour may be vital when planning treatment. 
Angiogenesis is the process of new vessel formation, which can be either physiological or 
pathological. For the purposes of clarification angiogenesis refers to the formation of small 
vessels, as opposed to arteriogenesis and lymphangiogenesis which are the development 
of arteries and lymphatics respectively. There are some common agents, however, which 
are involved in all these processes, an example being VEGF [416]. 
Physiological angiogenesis occurs in the foetus and developing adult, as well as during 
wound healing, leading to a well ordered hierarchy of vessels from arterioles to capillaries 
and finally post-capillary venules and veins. In contrast, pathological angiogenesis which 
occurs in tumours leads to a disordered, chaotic vascular pattern with irregular branches 
and arterio-venous shunts [417]. These vessels are functionally heterogeneous with 
variable fenestrations which are often highly permeable to plasma and plasma proteins. 
This is of significance when considering the potential for metastasis in tumour-associated 
vessels. 
The VEGF group of proteins are multifunctional cytokines that stimulate angiogenesis and 
increase microvascular permeability through binding to specific receptors expressed on 
vascular endothelial cells [418, 419]. Although VEGF is produced by a number of tumours 
and hypoxic tissues [420] its receptors are expressed primarily by endothelial cells. VEGF 
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has been shown to have a crucial role in neovascular formation in tumours, providing 
nourishment for the highly metabolic tumour cells as well as providing access to the host 
vasculature [317]. 
The VEGF family of proteins is thought to represent the most important of all angiogenic 
factors. Of these, VEGF-A is the most extensively researched and seemingly the most 
important. VEGF-B is linked with coronary artery development, and VEGF-C and -D are 
primarily associated with lymphangiogenesis [421, 422]. There are numerous other factors 
and cytokines which have angiogenic activity, for example, fibroblast growth factors 1 and 
2 SODWHOHW GHULYHG JURZWK IDFWRU 3'*) WXPRXU QHFURVLV IDFWRU DOSKD 71)Į DQG
angiopoietins 1 and 2. These factors are of secondary importance when considering 
angiogenesis, and indeed many exert their effects through modification of VEGF 
expression. 
VEGF-A is a glycoprotein which is encoded for on a single gene. Although alternative 
splicing leads to a number of isoforms, these are thought to have similar but not identical 
activities. VEGF-A is produced by most tissues, often during physiological angiogenesis; 
however, the pathway of recent interest is that of tumour-associated VEGF production. 
Expression of VEGF-A is influenced by a number of cytokines, as well as hypoxic 
inducible factor 1Į +,)Į ZKLFK LV H[SUHVVHG LQ K\SR[LF HQYLURQPHQWV [423]. Hypoxia 
SURPRWLQJ 9(*) SURGXFWLRQ YLD +,)Į LV WKRXJKW WR EH FUXFLDO LQ VROLG WXPRXU
angiogenesis since such tumours have a high metabolic turnover and rapidly expanding 
mass and frequently become hypoxic because of their increasing distance from the 
nearest blood supply. Various oncogenes (src, ras) and tumour suppressor genes (p53, 
p73 and von Hippel-Laudau (vHL)) also influence VEGF-A expression. For example, vHL 
JHQH SURGXFW IRUPV SDUW RI WKH SURWHLQ FRPSOH[ ZKLFK WDUJHWV +,)Į IRU SURWHRO\VLV
Hence, if vHL is inactivated during tumour development this leads to an accumulation of 
+,)ĮZKLFKVXEVHTXHQWO\OHDGVWRXSUHJXODWLRQRI9(*)-A even in normoxic conditions 
[424]. 
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The VEGF family members bind to three high affinity tyrosine kinase receptors (VEGFR1-
3). VEGFR1 and 2 are expressed on normal vascular endothelium and are regulated 
mainly by interaction with VEGF-A [425]. VEGF-A is thought to exert most if its actions via 
VEGFR2. Upon binding of VEGF-A, receptor dimerisation and autophosphorylation occurs 
with subsequent activation of downstream targets such as nitric oxide synthase leading to 
increased vascular permeability [416]. This increase in vascular permeability causes 
extravasation of fibrinogen and other clotting proteins to produce a fibrin gel. This increase 
in vascular permeability is also thought to lead to ascites formation in ovarian cancer 
[426]. Following the formation of the pro-angiogenic gel, VEGF-A stimulates endothelial 
cell division, migration and prolonged cell survival. This leads to new vessel buds forming 
and it is thought that VEGF also provides guidance for the direction of endothelial cell 
migration and hence the direction of subsequent new vessel growth.   
Studies have suggested a specific role for VEGF in various phases of ovarian 
carcinogenesis, with effects on tumour growth and neovascularisation seen in animal 
models and in humans [427, 428]. Higher levels of VEGF are demonstrated in ovarian 
carcinomas when compared to normal ovaries [429, 430]. Recent interest has focused on 
the use of anti-angiogenic drugs in an attempt to inhibit the pro-tumour effects of VEGF 
and other such cytokines. These studies have demonstrated some anti-tumour effects but 
have shown significant side effects. The future role of such therapies is yet to be 
established [431-433]. 
Previous research has produced inconsistent evidence regarding the importance of VEGF 
in ovarian cancer and its relation to prognosis. These studies often suffered from low 
patient numbers and the use of subset analysis[434-436]. The aim of our work was two 
fold. Firstly, to determine the distribution of VEGF expression and its relation to prognosis, 
and secondly, to elucidate the prognostic role of VEGF in patients with ovarian cancer. 
This might enable the development of more individualised adjuvant treatments using 
emergent novel therapies to inhibit tumour angiogenesis. 
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5.2 Results 
5.2.1 Clinicopathological characteristics 
 
Of the 395 patients identified with ovarian cancer, 339 had archived tissue available, and 
these tumours were included in the tissue array. Nineteen of the 339 tumour cores had no 
tissue available for analysis due to loss during immunohistochemical processing, which 
left 94% of cases available for analysis. This core loss rate compares favourably with 
previous TMA studies. This subgroup of 320 patients was similar to that of the overall 
group, which as previously discussed is representative of a typical ovarian cancer 
population (Table 5.1). Of particular importance was the comparability of five year 
survival, which was 24% in the whole series and 27% in those analysed for VEGF 
expression. 
5.2.2 VEGF staining 
 
The intensity of the staining was estimated on a 4-tiered scale; encoded as 0 (absent), 1 
(weak), 2 (moderate), and 3 (strong). When staining was positive, it was primarily of 
cytoplasmic location and its pattern was uniform among the cancer cells within each core. 
Only 22 tumours (6.9%) were strongly positive, whilst the remaining tumours (298/ 320) 
exhibited either weak (42.2%) or moderate (39.4%) staining. Thirty seven tumour cores 
(11.6%) failed to show any noteworthy staining. A summary of the results is shown in  
Table 5.2, with photomicrographs of each category in Figure 5.1. For survival analysis 
purposes, cases were categorised as eLWKHU³KLJK´H[SUHVVHUVUHSUHVHQWHGE\WKH
strongly-VWDLQHGJURXSRU³ORZ´H[SUHVVHUVFRPSULVHGRIWKHQHJDWive, weak and 
moderate groups). 
 
 202 
(d) Strong
 
Figure 5.1 Photomicrographs of ovarian TMA cores immunohistochemically stained for 
VEGF. The level of expression ranged from none (A), weak (B), moderate (C) through strong 
(D). Magnification: x100, inset x400. 
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Table 5.1 Clinicopathological characteristics of whole series and those analysed for VEGF 
expression. 
Variable Whole series 
n=395 (%) 
VEGF Analysed 
Cases 
n=320 (%) 
Age (years) n=394 n=319 
  <30 1 (0.3) 1 (0.3) 
  30-59 167 (42.4) 126 (39.7) 
   226 (57.4) 192 (60.2) 
   
FIGO Stage n=375 n=312 
  I 99 (22.6) 84 (26.9) 
  II 46 (12.3) 32 (10.3) 
  III 188 (50.1) 162 (51.9) 
  IV 42 (11.2) 34 (10.9) 
   
Optimal Debulking n=376 n=308 
  Yes 157 (41.8) 132 (42.9) 
  No 219 (58.2) 176 (57.1) 
   
Tumour Grade n=376 n=302 
  1 50 (13.3) 36 (11.8) 
  2 93 (24.7) 69 (22.7) 
  3 233 (62) 199 (65.5) 
   
Histological Type n=395 n=320 
  Serous 203 (51.4) 168 (52.5) 
  Endometrioid 46 (11.7) 42 (13.1) 
  Mucinous 50 (12.7) 33 (10.3) 
  Undifferentiated 65 (16.5) 49 (15.3) 
  Clear Cell 26 (6.6) 25 (7.8) 
  Other 5 (1.3) 3 (1.0) 
   
Chemotherapy n=388 n=314 
  Platinum 196 (50.5) 156 (49.7) 
  Non-platinum 80 (20.6) 75 (23.9) 
  None 112 (28.9) 83 (26.4) 
Randomised treatment 69/395 (17.5) 54/320 (16.8) 
Five Year Survival n=385 n=315 
  Yes 91 (23.6) 87 (27.6) 
  No 294 (76.4) 228 (72.4) 
Alive at time of data 
censoring n=388 n=317 
  Yes 60 (15.5) 58 (18.3) 
  No 328 (84.5) 259 (81.7) 
 204 
 
Table 5.2 Intensity of cytoplasmic staining with VEGF. 
Intensity of Staining Number Percentage 
No staining 37 11.6 
Mild 135 42.2 
Moderate 126 39.4 
Strong 22 6.9 
5.2.3 Comparison of VEGF expression and patient tumour 
characteristics including survival 
 
Using Chi-squared test, VEGF expression did not correlate with the age of the patient, 
tumour grade, stage, or histological type, nor was it associated with the presence or 
absence of residual disease or with the administration of adjuvant chemotherapy (Table 
5.3). 
Survival analysis revealed that patients who had tumours with low levels of VEGF had a 
median survival time of 24 months while that of high VEGF expression was 14 months 
(Table 5.4). The difference in mean survival time was 40 months (67 and 27 months for 
low VEGF and high VEGF groups, respectively). This difference in survival was shown to 
be statistically significant with the Log rank test (p value= 0.04) (Table 5.4). A Kaplan-
Meier survival plot is shown in Figure 5.2. 
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Table 5.3 VEGF expression in all cases included in the final analysis including univariate 
analysis by F2 of VEGF status and clinicopathological criteria. 
Variable Analysed Cases 
n=320 (%) 
High VEGF 
expression (%) 
Low VEGF 
expression (%) 
Ȥ 
(p value) 
Age (years) n=319 n=22 n=297 
0.24 
(0.886) 
  <30 1 (0.3) 0 1 (0.3) 
  30-59 126 (39.7) 8 (36.4) 118 (39.8) 
   192 (60.2) 14 (63.6) 178 (59.9) 
     
FIGO Stage n=312 n=20 n=292 
0.76 
(0.860) 
  I 84 (26.9) 6 (30) 78 (26.7) 
  II 32 (10.3) 3 (15) 29 (9.9) 
  III 162 (51.9) 9 (45) 153 (52.4) 
  IV 34 (10.9) 2 (10) 32 (11.0) 
     
Optimal Debulking n=308 n=18 n=290 
0.40 
(0.528)   Yes 132 (42.9) 9 (50) 123 (42.4) 
  No 176 (57.1) 9 (50) 167 (57.6) 
     
Tumour Grade n=302 n=22 n=282 
5.77 
(0.056) 
  1 36 (11.8) 6 (27.3) 30 (10.6) 
  2 69 (22.7) 3 (13.6) 66 (23.4) 
  3 199 (65.5) 13 (59.1) 186 (66.0) 
     
Histological Type n=320 n=22 n=298 
9.20 
(0.162) 
  Serous 168 (52.5) 10 (45.5) 158 (53.0) 
  Endometrioid 42 (13.1) 7 (31.8) 35 (11.7) 
  Mucinous 33 (10.3) 2 (9.1) 31 (10.4) 
  Undifferentiated 49 (15.3) 2 (9.1) 47 (15.8) 
  Clear Cell 25 (7.8) 1 (4.5) 24 (8.0) 
  Other 3 (1.0) 0 3 (1.0) 
     
Chemotherapy n=314 n=21 n=293 
2.07 
(0.559) 
  Platinum 156 (49.7) 8 (38.1) 148 (50.5) 
  Non-platinum 75 (23.9) 5 (23.8) 70 (23.9) 
  None 83 (26.4) 8 (38.1) 75 (25.6) 
Randomised 
treatment 54/320 (16.8) 3/21 (14.3) 49/293 (16.7) 
0.26 
(0.873) 
Five Year Survival n=315 n=22 n=293 
4.06 
(0.031)   Yes 87 (27.6) 2 (9.1) 85 (29.0) 
  No 228 (72.4) 20 (90.9) 208 (71.0) 
Alive at time of data 
censoring n=317 n=22 n=295 
2.99 
(0.063)   Yes 58 (18.3) 1 (4.5) 57 (19.3) 
   No 259 (81.7) 21 (95.5) 238 (80.7) 
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Figure 5.2 Kaplan-Meier plot for disease-specific survival, High compared with low VEGF 
expression tumours (n=319). 
 
Table 5.4 Mean and median survival time in relation to VEGF expression. Log Rank test for 
univariate survival analysis. 
 
Mean(a) Median 
Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval Estimate 
(months) 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Low  67.4 5.6 56.3 78.3 24.1 2.7 18.9 29.4 
High 27.4 7.6 12.5 42.2 13.8 6.2 1.5 26.0 
Overall 64.8 5.3 54.4 75.3 23.5 2.4 18.7 28.3 
(a) Estimation is limited to the largest survival time if it is censored 
  Chi square d.f. p value 
Log Rank (Mantel-Cox) 4.2 1 0.04 
5.2.4 Multivariate analysis 
 
VEGF did not correlate with any of the established clinicopathological prognostic 
parameters, for example, age, stage or grade. This limited the possibility of any 
³FRQIRXQGHU´ HIIHFW RQ VXUYLYDO SUHGLFWLRQV +RZHYHU WR HQVXUH WKH ILQGLQJV ZHUH WUXO\
independent, a multi-variant Cox proportional hazards model was constructed 
incorporating age, residual disease, grade and the receipt of adjuvant therapy. A hazard 
ratio for high VEGF expression was obtained (HR = 1.75, p value= 0.02) (Table 5.5). 
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Table 5.5 Multivariate analysis using Cox regression model demonstrating that high VEGF 
expression predicts a poor prognosis independently of other accepted independent 
prognostic factors. 
Variable Hazard Ratios (95% Confidence intervals) 
Significance 
(p) 
Age at diagnosis 
(years) 
1.025 (1.013-1.036) 
<0.001 
 
   
FIGO Stage  
<0.001 
I 1 
II 1.779 (1.041-3.040) 
III 3.081 (1.997-4.753) 
IV 4.233 (2.431-7.371) 
   
Optimal Debulking  
<0.001 Yes 1 
No 2.173 
   
Patient received 
Chemotherapy  
<0.001 No 1 
Yes 0.462 (0.320-0.666) 
   
VEGF expression  
0.02 Low 1 
High 1.752 (1.062-2.899) 
5.3 Discussion 
 
In spite of the assumed importance of VEGF in the progression of cancer, relatively few 
studies of the expression of this protein in ovarian cancer have been linked to 
comprehensive clinical data, and in particular data on survival. In addition, the low 
numbers in previous studies may have contributed to inconsistency in findings. Using 
TMA technology allowed 320 primary ovarian cancers to be immunohistochemically 
assessed under identical experimental conditions, and this coupled with the robust 
clinicopathological database allowed for a more confident assessment of VEGF 
expression and its role as a prognostic marker. 
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The expression of VEGF in patients exhibited a similar pattern to that of Goodheart et al 
[434] with a strong expression seen in 6.9% of the tumours. Lesser expression ranged 
from moderate (39.4%) through weak (42.2%) to no expression in 11.6% of the patients 
(Table 5.2). Other groups reported varying levels of VEGF. They used different antibodies 
to stain the tissue, different scoring systems and different cut-off points. Although this 
highlights the need for inter-laboratory standardisation of immunohistochemical 
techniques, it does not detract from the results as the differences observed in each study 
represent comparisons among different tumours treated uniformly following a standard 
protocol. 
Our results indicate that patients with tumours which express high levels of VEGF have 
worse survival rates compared with those with medium, low or no VEGF expression. A 
median survival advantage of almost ten months is seen among the latter group when 
compared to the former. This was confirmed statistically using the log rank test (p= 0.04) 
and shown graphically using Kaplan-Meier curves (Table 5.4 and Figure 5.2). This result 
is further substantiated when a multivariate Cox regression model was constructed in 
which factors such as stage, microscopic residual disease, tumour grade, and the use of 
adjuvant therapy were accounted for. VEGF maintained statistical significance with regard 
to patient survival (p=0.02) (Table 5.5). The HR indicates that patients with high VEGF 
have an approximately 75% higher risk of dying than their low VEGF counterparts. 
The role of angiogenesis in ovarian carcinoma development remains unclear, with 
contradictory studies existing regarding the influence of MVD in ovarian cancer prognosis 
[413, 437, 438]. Immunohistochemical assessment of VEGF within a tumour offers further 
information regarding the potential for angiogenic activity and its effects on tumour 
behaviour and subsequent prognosis for the patient. The literature has been equally 
controversial concerning VEGF expression within ovarian tumours; some authors 
demonstrate no independent relationship with prognosis[439, 440] whereas others have 
shown a significant independent prognostic influence. Patients with early stage disease 
(FIGO I and II) had a poorer prognosis with increased VEGF expression within the tumour 
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[441]. Shen et al demonstrated elevated expression of VEGF (using mRNA) to be 
predictive of a poor prognosis [430]. Interestingly, there was no correlation with MVD 
which is in contradiction to previous work [439]. Raspollini et al illustrated that VEGF and 
MVD were both independent predictors of survival in advanced disease (FIGO III) and this 
also correlated with the likelihood of response to chemotherapy [436]. Similar findings 
were also seen when including early stage disease [435]. Since we have such a large 
number of cases in our study we can clearly demonstrate that the prognostic effects of 
VEGF are seen at all disease stages and that these effects are independent of 
confounding variables such as stage, grade and residual disease. 
The results illustrate no clear association between VEGF and any of the 
clinicopathological variables, including stage and grade of tumour. This is in agreement 
with some studies, most of which had a typical distribution of disease according to stage 
[413, 435, 439, 442, 443]. Some studies have suggested that stage and grade are 
associated with VEGF, although these studies tended to have an unusually high 
proportion of early stage disease (up to 58%) [430, 444, 445]. 
Studies investigating serum VEGF levels in ovarian cancer offer further evidence of a role 
for VEGF, with elevated levels being independently predictive of a poor prognosis [446, 
447]. Rudlowski et al demonstrated similar elevations in VEGF level in ascites from 
malignant tumours compared with borderline and benign disease, which correlated with 
advanced stage and patient survival. Interestingly, there was no difference in serum 
VEGF levels between benign and malignant tumours in this study [445]. 
Zhang et al in a study of infiltrating T cells in ovarian cancer showed that the absence of 
intratumoral T cells was associated with higher levels of VEGF [197]. This group of 
patients had early recurrence rates and short survival. It is therefore thought that VEGF 
further affects the behaviour of ovarian tumours by reducing the number of T cells in the 
WXPRXUPLOLHX VXSSUHVVLQJ WKH LPPXQHV\VWHP¶VGHIHQFHV DJDLQVWRYDULDQFDQFHU7he 
potential mechanism through which VEFG might inhibit migration of T cells into tumours is 
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not clear; especially considering the increase in vascular permeability associated with 
VEFG which promotes extravasation of intravascular contents. 
There is early evidence that VEGF-mediated angiogenesis may be utilised as a novel 
pathway in the treatment of ovarian cancer as has been witnessed in colon [448], breast 
[449] and lung [450] carcinomas. Monk et al have demonstrated some clinical benefit from 
using a monoclonal antibody against VEGF (bevacizumab) in recurrent ovarian cancer 
[432]. This has also been used successfully in the palliative treatment of ascites in 
refractory disease [451].  The Gynecologic Oncology Group are completing a phase III 
trial (GOG 218), using bevacizumab in combination with standard chemotherapeutic 
agents, the results of which are eagerly awaited. Another strategy devised to suppress 
angiogenesis in ovarian cancer is the interception of VEGF with receptor decoys, such as 
VEGF-Trap, which has shown encouraging results in early phase trials. Studies performed 
on mouse cancer models have demonstrated that, combined with paclitaxel, VEGF-Trap 
inhibits tumour growth and prolongs survival [431]. Early results from a randomised, multi-
centre, double-blind, phase 2 study suggest that VEGF-Trap may represent an important 
new option for patients who have received three or four prior chemotherapy regimens and 
have become resistant to platinum-based agents [452]. 
It should be noted that the subgroup of high VEGF expressing tumours accounts for less 
than 10% of patients and hence we are identifying a small group who appear to have a 
much worse prognosis. The small proportion of tumours expressing high levels of VEGF 
may explain why smaller studies failed to find significant prognostic associations [439, 
440]. The clinical value of identifying these patients and adapting treatment will therefore 
have a limited effect on overall population survival; however, we may have identified a 
specific group of patients who are highly sensitive to anti-angiogenic drugs. VEGF status 
is independent of stage in chemotherapy-naïve patients suggesting that there may be a 
role for bevacizumab as first line treatment in addition to standard chemotherapy in 
selected patients. This would represent a significant new role for such agents, as most 
studies have looked at use in recurrent platinum-resistant disease [433, 453].  As 
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illustrated in this set of experiments, VEGF expression in tumours can be demonstrated 
using standard immunohistochemical techniques and therefore could be undertaken in 
most histopathology departments to aid the clinician in tailoring treatment to an individual 
patient. For example, the use of bevacizumab alone in those tumours expressing high 
levels of VEGF.   
5.4 Conclusion 
 
The expression of VEGF is an independent prognostic indicator in a large series of 
patients with early and late stage ovarian cancer. High VEGF expression only occurs in a 
small proportion of ovarian cancers but may denote a specific group in which anti-
angiogenic therapy is more effective. 
 212 
6 General Discussion 
 
Ovarian cancer is an uncommon disease, however, due to the vagueness of symptoms 
patients often present at an advanced stage. This results in ovarian cancer being the 
fourth most common cause of cancer-related death in women in the UK [1]. Over the last 
30 years there have been improvements in the surgical and postoperative care received 
by women with ovarian cancer. In addition, refinements in chemotherapeutic agents have 
been introduced, in particular the use of platinum-based compounds and more recently 
paclitaxel. Unfortunately, these changes have had little, if any, impact on prognosis with 
the typical five year survival rate of 30% [113].  Novel targeted therapy combined with a 
better prognostic index, which stratifies patients for the optimal therapy to cure their 
cancer, based upon its molecular background could significantly change the outcome from 
this disease as has been proved for breast cancer. 
Established prognostic markers in ovarian cancer include age, stage of disease and 
extent of residual disease following surgery [5]. Patients with a curative resection that has 
not metastasised (stage Ia) can be considered cured and will not require adjuvant therapy 
but will be closely monitored for recurrent disease. All other patients will be considered for 
further therapy. The current work demonstrated that tumours which expressed high levels 
of VEGF had worse survival rates compared with those with medium, low or no VEGF 
expression. The literature is controversial with regard to VEGF expression and ovarian 
cancer prognosis. Some authors demonstrate no independent relationship with prognosis 
whereas other studies have shown a significant independent prognostic influence; 
however, the number of cases in these studies was often limited [439, 440]. These smaller 
studies may prove less robust when it is considered that less than 10% of tumours in the 
current series had high VEGF. Due to the large number of cases analysed in this thesis, 
we can clearly demonstrate that the prognostic effects of VEGF are seen at all stages of 
disease. These effects are independent of confounding variables such as stage, grade 
and residual disease. 
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The clinical value of identifying these patients and adapting treatment will therefore have a 
limited effect on overall population survival; however, we may have identified a specific 
group of patients who are highly sensitive to anti-angiogenic drugs. The prognostic 
influence of VEGF status is independent of stage in chemotherapy-naïve patients. 
Therefore, there may be a role for bevacizumab as first line treatment in addition to 
standard chemotherapy in selected patients. This would represent a significant new role 
for such agents, as most studies have looked at use in recurrent platinum-resistant 
disease [433, 453]. The prognostic value of high VEGF-A expression in these and future 
trials involving anti-VEGF therapy must be considered. 
There is increasing evidence that the immune system plays a pivotal role in ovarian 
cancer, controlling its growth until a phenotypic variant that is resistant to immune attack 
arises [158, 197, 224]. Animal studies have identified IFNJ as a critical cytokine involved in 
recognition of stressed or transformed cells [167, 173-175]. In this thesis we provide the 
first evidence of immunoediting of the IFNJ  pathway in ovarian cancer. Loss of IFNGR1 
was demonstrated to be an independent marker of poor prognosis. This effect was seen 
in both early and late stage tumours, suggesting that this was an early phenomenon in 
tumourogenesis. Interestingly, later molecules involved in the IFNJ  signalling pathway 
(STAT-1, p27, caspase 1) did not have such strong prognostic value. This may be 
because these other molecules can also be associated with other signalling pathways 
[294]. Tumours lacking the IFNGR1 receptor are unlikely to respond to IFNJ therapy. This 
may explain the lack of response to this cytokine in a recent phase III clinical trial [350]. If 
30% of patients could not respond to the therapy, but had to have a reduction in the dose 
of platinum due to increased toxicity, then these patients would do worse and thus 
confound any positive benefit in the responsive group. This trial should be reassessed for 
response based upon expression of the IFNGR1. If this proves to be of prognostic value 
then there may be a role for IFNJ as first line treatment in addition to standard 
chemotherapy in selected patients. It follows that those patients with tumours that have 
low VEGF-A expression and absent IFNGR1 should avoid anti-angiogenic and IFNJ 
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therapies and be treated with standard chemotherapy alone or be considered for trials 
involving other targeted treatments [454-458]. 
The evidence of dysregulation of TRAIL in the development of tumours and their 
resistance to chemotherapy, as well as its potential therapeutic role, provides an 
interesting avenue of investigation. The hypothesis followed that tumours with low 
expression of DR4 and DR5 (TRAIL receptors) would be less prone to TRAIL-mediated 
attack and therefore apoptosis. This would be reflected in reduced patient survival. This 
current work does not appear to demonstrate any prognostic significance from either DR4 
or DR5. However, there was high expression of both receptors, hence patients may 
benefit from TRAIL ligand or anti-TRAIL mab therapy [408]. 
Our studies would suggest that patients with stage II - IV disease who express high levels 
of VEGF-A should be stratified to first line therapy of bevacizumab plus chemotherapy. In 
contrast, stage II - IV patients with low levels of VEGF-A, but who still express IFNGR, 
should receive first line IFNJ plus chemotherapy. Only patients who have low VEGF-A and 
IFNGR negative expression should receive chemotherapy alone (Figure 6.1). 
 
Figure 6.1 1RYHOWUHDWPHQWVWUDWHJ\IRURYDULDQFDUFLQRPDUHIOHFWLQJWKHWXPRXU¶VPROHFXODU
profile. 
 
The need for an extensive array of targeted therapies is highlighted by the poor prognosis 
seen in patients whose tumours are platinum-resistant VEGF-A low expressers and 
IFNGR1 negative. New therapies as they arise should be trialed and targeted to tumours 
expressing the appropriate molecular marker. These include PDGF receptor inhibitor 
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(imatinib) [456], PDGF tyrosine kinase inhibitor (gefitinib) [457], alpha folate receptor 
inhibitors (farletuzumab) [454], DNA repair inhibitors (PARP) [458] and P13K-Akt inhibitors 
[455]. All these novel treatments have pathways in which components can be identified 
through IHC techniques and hence a prediction of response is possible. 
This thesis addresses three areas of tumour biology: immunoediting, angiogenesis and 
apoptosis, through the use of TMA immunohistochemical techniques. The work illustrates 
that ovarian cancers can be extremely heterogeneous and that variations in expression of 
protein markers between individual tumours can be used to predict tumour behavior. Due 
WRWKHKHWHURJHQHRXVQDWXUHRIRYDULDQFDQFHULWLVQRWVXUSULVLQJWKDWD³RQHVL]HILWVDOO´
approach to treatment with standard chemotherapeutic agents has met with limited 
success. Future ovarian cancer treatment will be individualised and based on the 
molecular characteristics of the tumour assessed through immunohistochemistry and 
genomic hybridisation [458]. This assessment will need to be performed at each relapse 
as potential therapeutic pathways may change. Of equal importance is the design of 
clinical trials of novel treatments. These will need to include predictive biomarkers of the 
particular pathway being targeted. This will ensure that only patients likely to benefit from 
a particular treatment will be exposed to the potentially toxic compound. 
The markers used in this thesis have direct links to potential targeted therapies, and 
variations in the functionality of these pathways may exist between individual tumours. In 
the future targeted therapies may be selected on the basis of an IHC panel of markers 
which predict which pathways are still functioning and hence which therapy should be 
employed for each individual tumour. 
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7 Appendices 
7.1 Appendix 1 
Table 7.1 Staging of ovarian cancer by the FIGO classification [84]. 
Stage 0 No evidence of primary tumour 
Stage I Tumour confined to the ovaries 
IA 
Tumour limited to one ovary, capsule 
intact 
No tumour on ovarian surface 
No malignant cells in ascites or 
peritoneal washings 
IIB 
Tumour limited to both ovaries, capsules 
intact 
No tumour on ovarian surface 
No malignant cells in ascites or 
peritoneal washings 
IC 
Tumour limited to one or both ovaries 
With any of the following:- 
Capsule ruptured, tumour on ovarian 
surface, positive malignant cells in the 
ascites or positive peritoneal washings 
Stage II Tumour involves one or both ovaries with 
pelvic extension 
IIA 
Extension and/ or implants in uterus 
and/ or tubes 
No malignant cells in the ascites or 
peritoneal washings 
IIB 
Extension to other pelvic organs 
No malignant cells in the ascites or 
peritoneal washings 
IIC IIA/B with positive malignant cells in the 
ascites or positive peritoneal washings 
Stage III Tumour involves one or both ovaries with 
microscopically confirmed peritoneal 
metastasis outside the pelvis and/ or 
regional lymph node metastasis 
IIIA Microscopic peritoneal metastasis beyond the pelvis 
IIIB 
Macroscopic peritoneal metastasis 
beyond the pelvis 2cm or less in 
dimension 
IIIC 
Peritoneal metastases beyond the pelvis 
more than 2cm in greatest dimension 
and/ or regional lymph node metastasis 
Stage IV Distant metastasis beyond the peritoneal 
cavity 
(including parenchymal liver metastasis and 
pleural effusion with positive cytology) 
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